Mechanisms of Stem Cell Regulation in Medulloblastoma

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11169777">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11169777</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Mechanisms of Stem Cell Regulation in Medulloblastoma

A dissertation presented

by

Ronnie Yoo

to

The Division of Medical Sciences

in partial fulfillment of the requirements

for the degree of

Doctor of Philosophy

in the subject of

Biological and Biomedical Sciences

Harvard University

Cambridge, Massachusetts

April 2013
Abstract

Medulloblastoma, the most common pediatric malignant brain tumor, is comprised of a heterogeneous group of tumors with distinct molecular subtypes and clinical outcomes. In particular, tumors with a cancer stem cell (CSC) population have been observed to be more resistant to conventional therapies, necessitating the elucidation of pathways important in this population. Work in our lab has shown that neurosphere culture-enriched cells from $Ptch1^{LacZ/+};Trp53^{-/-}$ mouse medulloblastomas exhibit properties of self-renewal, expression of neural stem cell (NSC) markers and potent tumor-initiation. The pathway dependencies and mechanisms of self-renewal in these medulloblastoma neurospheres (MBNS) have not yet been characterized.

Reprogramming and dedifferentiation of tumor cells have been proposed as a mechanism for the establishment and maintenance of CSC. To test this, we asked if the endogenous genetic program of the $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS was sufficient for the reprogramming of tumor cells into a pluripotent-like state in vitro. We observed that MBNS, unlike normal cerebellar stem cells (CbSC), were able to form embryonic stem (ES) cell-like colonies upon growth in ES culture conditions. $Klf4$, a reprogramming factor, was identified to be functionally important in maintaining both MBNS plasticity upon transfer to ES culture conditions and clonal self-renewal as neurospheres. Further, $Klf4$ expression compensated for Stat3 inhibition in a Stat3-
independent manner for the maintenance of survival gene expression, thus identifying a novel compensatory transcriptional mechanism enhancing the survival of CSC.

We further characterized Sox2, a NSC marker highly expressed in the MBNS, as a definitive marker for the isolation of self-renewing CbSC from postnatal day 7 wild-type (WT) animals. Moreover, Sox2 expression was maintained in the cerebella of 3-week-old $Ptch1^{LacZ/+};Trp53^{-/-}$ animals and the prospective isolation of the Sox2-positive cells enriched for the aberrantly persisting, self-renewing cells, which are absent in by 3 weeks in WT animals. Thus, we have validated an endogenous Sox2-GFP reporter system that allows for the prospective isolation of the aberrant tissue stem cells from $Ptch1^{LacZ/+};Trp53^{-/-}$ animals, which will be valuable for furthering our understanding of stem cell regulation during medulloblastoma tumorigenesis.
Table of Contents

Abstract ........................................................................................................................................... iii

Table of Contents .......................................................................................................................... v

List of Abbreviations ...................................................................................................................... vii

List of Figures .................................................................................................................................. ix

List of Tables .................................................................................................................................... xi

Acknowledgements ........................................................................................................................ xii

Chapter 1: Introduction .................................................................................................................. 1

Medulloblastoma Overview ......................................................................................................... 2

Clinical features of human medulloblastoma .............................................................................. 2

Cerebellar development ................................................................................................................ 4

Cerebellar Stem Cells .................................................................................................................. 7

Molecular classification of human medulloblastoma .................................................................. 7

Four subtypes of human medulloblastoma ................................................................................. 9

Cancer Stem Cells ....................................................................................................................... 15

Background .................................................................................................................................... 15

Isolation of cancer stem cells in solid tumors .............................................................................. 17

Tracking cancer stem cells in vivo .............................................................................................. 19

Treatment resistance of cancer stem cells ................................................................................ 20

Significance and Controversy ...................................................................................................... 22

Brain tumor stem cells .............................................................................................................. 24

Ptch1LacZ/+; Trp53−/− mouse model of disseminated medulloblastoma with self-renewing, tumor-initiating cells ................................................................................................................ 25

Research Objectives ................................................................................................................... 29

Chapter 2: Klf4 maintains the plasticity and self-renewal of medulloblastoma neurospheres in a Stat3-independent manner ................................................................................................. 31

Introduction .................................................................................................................................... 32

Results ............................................................................................................................................ 34

Neurosphere culture-enriched Ptch1LacZ/+; Trp53−/− medulloblastoma line exhibits characteristics of self-renewal and tumor-propagation ........................................................................... 34

Phenotypic conversion of Ptch1LacZ/+; Trp53−/− MBNS grown in ES cell culture conditions 37

Klf4 mediates MBNS plasticity during conversion into ES culture conditions .......................... 43

Klf4 is important for the self-renewal of MBNS ..................................................................... 48

Stat3 signaling is endogenously activated in MBNS ................................................................. 51

Combination Jak and Mek inhibition leads to the reduction of MBNS survival ....................... 55

MBNS self-renewal is, in part, mediated by Stat3, but less significant than the role of Klf4 ........................................................................................................................................... 57

Klf4 levels rebound in a Stat3-independent manner in clonally derived shStat3 MBNS .... 59
Stat3 and Klf4 independently regulate the expression of Stat3-target survival genes .......... 61
BCL-X and CD133 expression in human medulloblastoma is associated with poor survival
................................................................................................................................. 65
Discussion.................................................................................................................................................. 67
Methods..................................................................................................................................................... 78

Chapter 3 : Mechanisms of aberrant persistence of cerebellar stem cells during
medulloblastoma development ............................................................................................................... 86

Introduction............................................................................................................................................. 87
Results..................................................................................................................................................... 91
Sox2-expression marks the self-renewing stem cells in the postnatal day 7 cerebella .......... 91
Enrichment of stem cell gene expression in Sox2-GFP positive CbSC ................................. 93
Characterization of Sox2-GFP positive cells in Pch1^LacZ/+;Trp53^+/− chimeras ............... 94
Sox2-expression isolates the self-renewing cells in 3 week Pch1^LacZ/+;Trp53^+/− cerebella .. 99
Differential gene expression between P7 WT and 3 week Pch1^LacZ/+;Trp53^+/− Sox2-GFP
positive cells............................................................................................................................................. 100
Discussion............................................................................................................................................... 103
Methods.................................................................................................................................................. 107

Chapter 4 : Conclusions and Future Directions.............................................................................. 110

Chapter 5 : References ....................................................................................................................... 123
### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myeloid leukemia</td>
<td>AML</td>
</tr>
<tr>
<td>Adenomatous polyposis coli</td>
<td>APC</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>AP</td>
</tr>
<tr>
<td>Basic fibroblast growth factor</td>
<td>bFGF</td>
</tr>
<tr>
<td>Beta-catenin</td>
<td>CTNNB1</td>
</tr>
<tr>
<td>Beta-galactosidase</td>
<td>LacZ</td>
</tr>
<tr>
<td>Cancer stem cells</td>
<td>CSC</td>
</tr>
<tr>
<td>Cerebella</td>
<td>Cb</td>
</tr>
<tr>
<td>Cerebellar stem cells</td>
<td>CbSC</td>
</tr>
<tr>
<td>Cre-recombinase</td>
<td>Cre</td>
</tr>
<tr>
<td>Embryonic stem</td>
<td>ES</td>
</tr>
<tr>
<td>Epidermal growth factor</td>
<td>EGF</td>
</tr>
<tr>
<td>External granule layer</td>
<td>EGL</td>
</tr>
<tr>
<td>Extreme limiting dilution assay</td>
<td>ELDA</td>
</tr>
<tr>
<td>Fetal bovine serum</td>
<td>FBS</td>
</tr>
<tr>
<td>Fluorescence-activated cell sorting</td>
<td>FACS</td>
</tr>
<tr>
<td>Glial fibrillary acidic protein</td>
<td>GFAP</td>
</tr>
<tr>
<td>GLI-Krüppel family member</td>
<td>GLI</td>
</tr>
<tr>
<td>Granule cell progenitor</td>
<td>GCP</td>
</tr>
<tr>
<td>Green fluorescent protein</td>
<td>GFP</td>
</tr>
<tr>
<td>Hairy and enhancer of split-1</td>
<td>Hes1</td>
</tr>
<tr>
<td>Hematopoietic stem cells</td>
<td>HSC</td>
</tr>
<tr>
<td>Hematoxylin and eosin</td>
<td>H&amp;E</td>
</tr>
<tr>
<td>Induced pluripotent cells</td>
<td>iPS</td>
</tr>
<tr>
<td>Janus kinase</td>
<td>Jak</td>
</tr>
<tr>
<td>Knockdown</td>
<td>kd</td>
</tr>
<tr>
<td>Krüppel-like factor 4</td>
<td>Klf4</td>
</tr>
<tr>
<td>Large cell anaplastic</td>
<td>LCA</td>
</tr>
<tr>
<td>Term</td>
<td>Abbreviation</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Leukemia inhibitory factor</td>
<td>LIF</td>
</tr>
<tr>
<td>Mammalian target of rapamycin</td>
<td>mTOR</td>
</tr>
<tr>
<td>Medulloblastoma neurosphere</td>
<td>MBNS</td>
</tr>
<tr>
<td>Mitogen-activated protein kinase</td>
<td>MAPK/Erk</td>
</tr>
<tr>
<td>Mitogen-activated protein kinase kinase</td>
<td>Mek</td>
</tr>
<tr>
<td>Mouse embryonic fibroblast</td>
<td>MEF</td>
</tr>
<tr>
<td>Myelocytomatosis oncogene</td>
<td>MYC</td>
</tr>
<tr>
<td>Myeloid/lymphoid leukemia</td>
<td>MML</td>
</tr>
<tr>
<td>Neural stem cell</td>
<td>NSC</td>
</tr>
<tr>
<td>Neurosphere</td>
<td>NS</td>
</tr>
<tr>
<td>Non-obese diabetic/severe combined immunodeficiency</td>
<td>NOD/SCID</td>
</tr>
<tr>
<td>Octamer-binding transcription factor 4</td>
<td>Oct4</td>
</tr>
<tr>
<td>Oligodendrocyte transcription factor 2</td>
<td>Olig2</td>
</tr>
<tr>
<td>Patched-1</td>
<td>PTCH1</td>
</tr>
<tr>
<td>Phosphoinositide 3-kinase</td>
<td>PI3K</td>
</tr>
<tr>
<td>Retinoblastoma protein</td>
<td>Rb</td>
</tr>
<tr>
<td>Short hairpin RNA</td>
<td>shRNA</td>
</tr>
<tr>
<td>Smoothened</td>
<td>SMO</td>
</tr>
<tr>
<td>Sonic hedgehog</td>
<td>SHH</td>
</tr>
<tr>
<td>Suppressor of cytokine signaling 3</td>
<td>Socs3</td>
</tr>
<tr>
<td>Suppressor of fused</td>
<td>SUFU</td>
</tr>
<tr>
<td>Transcriptional start site</td>
<td>TSS</td>
</tr>
<tr>
<td>Transformation related protein 53</td>
<td>Trp53</td>
</tr>
<tr>
<td>Wild-type</td>
<td>WT</td>
</tr>
<tr>
<td>Wingless</td>
<td>WNT</td>
</tr>
</tbody>
</table>
List of Figures

Figure 1-1 Overview of mouse cerebellar development through embryonic and postnatal development ................................................................. 6
Figure 1-2 Developmental pathways implicated in medulloblastoma tumorigenesis .. 9
Figure 1-3 The four molecular subtypes of human medulloblastoma.......................................................... 11
Figure 2-1 A Ptc1lacZ/+/Trp53−/− medulloblastoma-derived neurosphere line is enriched for NSC cell marker expression in comparison to the primary tumor .................................................. 35
Figure 2-2 A neurosphere line derived from a primary Ptc1lacZ/+/Trp53−/− medulloblastoma is able to propagate secondary tumors recapitulating the primary tumor .......... 37
Figure 2-3 MBNS exhibit growth as alkaline phosphatase-positive colonies in ES cell culture conditions .................................................. 38
Figure 2-4 AP+ MBNS subclones maintain ES-like morphology and exhibit stochastic expression of pluripotency genes ................................................................. 40
Figure 2-5 AP+ MBNS cells do not form teratomas as robustly as ES cells .................................................. 41
Figure 2-6 AP+ MBNS-derived teratomas are histologically distinct from the parental MBNS-derived tumors .................................................. 42
Figure 2-7 CpGs in the 5′ regulatory regions of Klf4 and Sox2 are differentially methylated between the MBNS and AP+ MBNS .................................................. 44
Figure 2-8 Quantitative methylation analyses of individual CpGs in the 5′ regulatory regions and promoters of pluripotency genes in MBNS and AP+ MBNS show differential methylation in Klf4 and Sox2 .................................................. 45
Figure 2-9 Klf4 mediates MBNS plasticity for conversion into ES culture conditions .................................................. 46
Figure 2-10 Exogenous LIF is not required for the conversion or maintenance of MBNS in ES cell conditions .................................................. 47
Figure 2-11 Klf4 kd leads to a reduction in MBNS self-renewal .................................................. 49
Figure 2-12 Stat3 is endogenously activated in MBNS .................................................. 52
Figure 2-13 Pathways of Stat3 activation and kinase inhibitors used for the treatment of MBNS .................................................. 54
Figure 2-14 pTyr705 and pSer727 Stat3 are differentially regulated by Jak and Mek signaling in the MBNS .................................................. 55
Figure 2-15 Combinatory treatment of Jak and Mek inhibitors leads to a synergistic reduction in MBNS self-renewal and size .................................................. 56
Figure 2-16 Stat3 kd leads to a reduction in MBNS self-renewal .................................................. 58
Figure 2-17 Klf4 expression rebounds in Stat3-independent manner in clonal density .................................................. 60
Figure 2-18 Binding site motifs of Stat3 and Klf4 and overview of binding sites in the Stat3-target survival gene promoters as determined by Genomatix .................................................. 61
Figure 2-19 Mcl1 and survivin promoter analyses identify predicted Klf4 binding sites in close proximity to predicted Stat3-binding sites .................................................. 62
Figure 2-20 Bcl-x promoter analysis identifies predicted Klf4-binding sites in close proximity to predicted Stat3 binding sites .................................................. 63
Figure 2-21 Stat3 or Klf4 expression is sufficient for the maintenance of Stat3-target survival gene expression .................................................. 64
Figure 2-22 BCL-X and PROM1 expression is associated with human medulloblastomas with the poorest prognosis .................................................. 65
Figure 2-23 BCL-X and CD133 are elevated in Group 3 human tumors .................................................. 66
Figure 3-1 The frequency of Sox2-GFP positive cells is significantly reduced during cerebellar development in wild-type animals ................................................................. 92
Figure 3-2 Sox2 expression fractionates the self-renewal activity of CbSC in wild-type P7 animals ............................................................................................................. 93
Figure 3-3 Expression of stem cell genes are enriched in WT P7 Sox2-GFP positive cells ...... 94
Figure 3-4 An identifiable population of Sox2-GFP expressing cells is maintained at 3 weeks in Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} animals ........................................................................................................ 96
Figure 3-5 Backgating analyses of Sox2-GFP positive cells in WT and Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} P7 and 3 week animals suggest that the Sox2-positive cell population in the 3 week Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} is a developmentally persistent population ........................................ 97
Figure 3-6 Sox2-expressing cells mark the self-renewing cells in the 3 week Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} cerebella ......................................................................................................................... 99
Figure 3-7 Summary of the frequency of GFP-expressing cells in P7 and 3 week WT Sox2-GFP and Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} Sox2-GFP animals ................................................................. 100
Figure 3-8 Sox2-GFP negative and positive cells were re-sorted to increase purity for RNA isolation for gene expression analysis ........................................................................ 101
Figure 3-9 Differential gene expression of granule cell progenitor markers in the 3 week Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-}; Sox2-GFP positive cerebellar cells ........................................................................... 102
Figure 4-1 Tentative hypothesis for the aberrant persistence of Sox2-expressing cerebellar stem cell in the 3 week Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} animals ........................................................................ 122
List of Tables

Table 1. Hairpin sequences of shKlf4 ........................................................................................................ 48
Table 2. Hairpin sequences of shStat3 .................................................................................................... 59
Table 3. Statistical analyses of extreme limiting dilution analyses (ELDA) of Stat3 and Klf4 kd
MBNS self-renewal ................................................................................................................................ 59
Acknowledgements

My graduate studies would not have been possible without the support of many people. Words cannot describe my gratitude for everyone who has encouraged and helped me along the way. Firstly, I would like to thank Dr. Laurie Jackson-Grusby, my thesis advisor, for allowing me the opportunity to work in her lab. I am greatly appreciative for her guidance, patience and mentorship throughout my time in the lab. I am grateful for my DAC members, Drs. Ramesh Shivdasani, David Frank and Richard Mass, for being insightful, supportive, encouraging throughout the years. I would also like to extend my appreciation to the Examination Committee members, Drs. David Langenau, David Breault, and Charlotte Kuperwasser. Thank you to all past and present members of the Jackson-Grusby lab. My project would not have been possible without the efforts of Chewie Lin, Juliana Brown, and Chris Kanner in establishing the Ptc;p53 tumor system. I am greatly appreciative for their teaching, training, and advice. I thank Bernd Zetsche and Ann Ran for their company and all the laughter. I also greatly appreciate all the help provided by Guangwen Wang, Leah Liu, Daniel Park, David Dai and the guidance provided by my collaborator Suhu Liu (Frank lab). I would also like to extend my gratitude to Giri Buruzula and Joyce Lavecchio at the Joslin Flow Core and Ronald Mathieu at the CHB Flow Core for technical support and expertise; Konrad Hochedlinger lab for the collaboration (Sox2-GFP mice and construct); David Sabatini lab for reagent support (Rapamycin, Torin). Thank you to all of the members of the Pathology Department on Enders 11, the BBS office (including Tucker), friends and colleagues in BBS/DMS. I am deeply grateful to my lifelong support network of friends, both near and far. Thank you Harrison for just everything. And lastly my family- Mom, Luther, and Dad, whom I miss very, very much. Thank you for your endless love, support and encouragement. I would not have made it without you.
Chapter 1: Introduction
Medulloblastoma Overview

Medulloblastoma, a primitive neuroectodermal tumor arising in the cerebellum, is the most common malignant childhood brain cancer and accounts for about 20% of pediatric brain tumors (Ellison et al., 2003). Peak incidences occur in children from ages 3-4 and ages 8-9 and about 10% of cases occur in infants (Crawford et al., 2007). While overall survival rates of medulloblastoma patients are about 80%, aggressive and non-specific conventional treatment strategies usually result in long-term cognitive deficits and neuroendocrinial abnormalities (Ellison et al., 2003). Furthermore, aggressive tumor subtypes with a disseminated phenotype are associated with a higher frequency of relapse and have poor prognoses (Zeltzer et al., 1999; Northcott et al., 2011b). Such relapse mechanisms have been attributed to a subset of cancer stem cells (CSC) in the bulk tumor (Clarke et al., 2006), which have, in fact, been identified in human medulloblastomas (Singh et al., 2004). In the recent decade, immense advances have been made in the elucidation of the molecular underpinnings of medulloblastoma tumorigenesis (Taylor et al., 2012), while the understanding of the tumor-initiating cells remains relatively sparse. As such, the identification of molecular pathways involved in CSC homeostasis could have potential ramifications for better risk-stratification and allow for the development of targeted therapeutic strategies to increase efficacy and reduce long-term sequelae in patients.

Clinical features of human medulloblastoma

The World Health Organization (WHO) classifies all medulloblastomas as malignant and invasive grade IV tumors. Based on the WHO classification, there are five histological variants of human medulloblastoma: classic, desmoplastic/nodular, extensive nodularity, large cell, and
anaplastic (Louis et al., 2007). Classic medulloblastomas, which make up about ~70% of all cases (Ellison et al., 2011) are characterized by sheets of undifferentiated cells with high nuclei to cytoplasm ratios. Desmoplastic/nodular and extensive nodularity tumors are closely related variants, both characterized by nodules (pale islands) of tumor cells undergoing neuronal differentiation, interspersed with stroma composed of reticulin (type III collagen) fibers. The internodular, reticulin regions are reduced in the extensive nodularity tumors compared to the desmoplastic tumors. The last two variants, the anaplastic and large cell medulloblastomas, which are cytologically similar, are marked with high mitotic activity and atypical nuclear pleomorphisms and are the most aggressive and treatment-resistant tumors.

Current risk stratification of patients is based on age, extent of surgical resection, and metastatic status. Standard risk patients include those greater than 3 years of age, with complete or near complete surgical resection of the tumor (<1.5cm² residual tumor) and absence of leptomeningeal dissemination; all other patients are classified as high risk (Zeltzer et al., 1999). Long-term survival rates of standard risk patients are 60-80%, but surviving patients are often subject to a variety of long-term sequelae such as cognitive decline and neuroendocrinal defects, due to the non-specific and aggressive nature of standard treatment modalities, which entail post-operative radiation and chemotherapy (Dennis et al., 1996; Crawford et al., 2007). While efforts have been made to reduce the doses of irradiation, this has been associated with a subsequent increase in the risk of relapse (Thomas et al., 2000). Furthermore, in the most recently published study of long-term effects of patients treated for standard-risk medulloblastoma, lower doses of radiospinal therapy than the standard dose (24Gy vs. 36Gy), nevertheless resulted in progressive decline in intellectual and academic scores (Ris et al., 2013). Currently, young age at diagnosis is consistently the most important risk factor in determining if neurocognitive defects will follow a
standard treatment regime (Ris et al., 2013). Given the non-specific modalities of the current therapies and their significant developmental impact, especially in young patients, a better understanding of specific molecular pathways involved in medulloblastoma tumorigenesis is crucial for the development of targeted therapies and improved risk stratification.

**Cerebellar development**

The cerebellum has been referred to as the “coordination center” of the brain, playing a role in balance and the fine tuning of motor movements (Wang and Zoghbi, 2001). In addition to the well-established role of the cerebellum in motor control, it has also been implicated in higher cognitive functions including spatial memory, speech and sensory motor learning (Hatten and Roussel, 2011; Marino, 2005). In humans and mice, the formation of the mature cerebellum is a protracted developmental process that continues postnatally for months after birth in humans and weeks in mice. Abnormalities during cerebellar development lead to developmental defects affecting balance and coordination such as Chiari malformations and Dandy-Walker syndrome or may lead to malignant transformation, resulting in medulloblastoma (Wang et al., 2003). Therefore, an understanding of the genetic pathways regulating cerebellar development and the cell types present during the process is crucial in studying the mechanisms of tumorigenesis.

During mouse embryogenesis, the cerebellum arises from two embryonic germinal zones, the ventricular zone (VZ) and the rhombic lip (RL) (Figure 1-1a). In mice, by embryonic day 14 (E14), early progenitors in the ventricular zone, marked by Ptf1 expression (Hoshino et al., 2005), cease proliferation and begin to differentiate to give rise to calbindin-positive Purkinje neurons. Between E14-E17, the postmitotic Purkinje neurons subsequently migrate radially along glial fibers to establish the cerebellar field (Hatten and Heintz, 1995), by secreting Sonic
Hedgehog (SHH), a factor important for the proliferation and differentiation of granule neurons (Wechsler-Reya and Scott, 1999). In addition to Purkinje neuron fate determination, the Ptf1-expressing cells from the ventricular zone are also thought to give rise to other GABAergic neurons in the cerebella including the Golgi, basket, and stellate cells (Hoshino et al., 2005).

The granule neurons of the cerebella are derived from another germinal epithelium, known as the rhombic lip (Figure 1-1a), located in between the neural tube and the fourth ventricle. Around E13, Math1-positive cells migrate out of the rhombic lip and coat the surface of the developing cerebellar field to form the external granule layer (EGL) (Hatten and Heintz, 1995; Ben-Arie et al., 1997), which by postnatal day 0 (P0) is composed of a single layer of undifferentiated cells (Figure 1-1b). Beginning around postnatal day 7 (P7), the majority of the Math1-positive cells in the EGL form a zone of proliferating granule cell progenitors (GCP) that are driven by SHH secreted by the Purkinje neurons (Figure 1-1b, c) (Wechsler-Reya and Scott, 1999). This large clonal expansion continues until P15, after which the post-mitotic granule cells exit the cell cycle, downregulate Math1 expression and move inwards from the EGL along the radial fibers of Bergmann glia cells to form the internal granule layer (IGL) (Hatten and Heintz, 1995; Hatten et al., 1997). In normal development, cerebellar development is largely complete by P21, when the EGL diminishes as the mature granule neurons migrate into the IGL, leaving the trailing processes in the molecular layer (Wechsler-Reya and Scott, 2001). Dysregulated granule cell proliferation during cerebellar development results in the formation of an abnormally thickened EGL, containing aberrantly proliferative “rests”, which may subsequently lead to tumorigenesis upon acquisition of additional mutations (Kim et al., 2003).
Figure 1-1 Overview of mouse cerebellar development through embryonic and postnatal development

(a) Around E13, Math1-expressing cells from the rhombic lip migrate rostrally over the surface of the cerebellum to form the external granule layer (EGL). Purkinje cells are derived from the Ptf1-expressing progenitors from the ventricular zone around E14 and migrate radially. (b) Histology of sagittal sections of mouse cerebella corresponding to the different stages during cerebellar development: postnatal day 0 (P0), day 7 (P7), and adult. “P” denotes the Purkinje cell layer. Images are taken from Goldowitz and Hambre, 1998. (c) During the large clonal expansion and differentiation of the granule cell progenitors that occur during the first 2-3 weeks, postmitotic granule neurons migrate inwards to form the internal granule layer (IGL). They move past the Purkinje layer, which secrete SHH to regulate the proliferation of the progenitors, leaving behind processes in the molecular layer. Non-neuronal cell types in the cerebellum include the Bergmann glia and oligodendrocytes (not shown). Figures are modified from Marino 2005 and Ruiz y Altaba et al., Nat Neuroscience 2002.
Cerebellar Stem Cells

In addition to the granule neurons and Purkinje cells, which are the two major neuronal cells in the cerebellum, other cell types of the cerebellum include the Golgi, stellate and basket interneurons, the Bergmann glia (located at the border of Purkinje cell layer and the IGL) and oligodendrocytes (found in the white matter). Unlike the granule neurons and the Purkinje cells, whose cells of origin have been well characterized as the GCP of the EGL and the progenitor cells of the ventricular zone, respectively, the developmental origins of the interneurons, glial cells and the oligodendrocytes are much less clear.

A multipotent cerebellar stem cell population with the ability to give rise to neurons, astrocytes, and oligodendrocytes in vitro and in vivo has, in fact, been isolated from the postnatal day 7 (P7) mouse cerebella (Lee et al., 2005). Prospective isolation of prominin 1 (Prom1)-positive (also known as CD133) cells leads to the enrichment of these multipotent stem cells, which also exhibit self-renewal and high expression of NSC genes, SRY-box containing gene 2 (Sox2) and nestin. This suggests that the different cell types of the cerebellum can arise from a common multipotent stem cell population, revealing another potential cell population for transformation during medulloblastoma tumorigenesis.

Molecular classification of human medulloblastoma

Early insights into the molecular basis of medulloblastomas were drawn from the identification of developmental pathways altered in hereditary tumor syndromes and the examination of their roles in cerebellar development (Wechsler-Reya and Scott, 2001). The role
of the SHH signaling pathway in medulloblastoma was first appreciated when individuals with Gorlin’s syndrome, which is characterized by heterozygous \textit{PTCH1} mutations, were observed to display a predisposition to develop medulloblastomas (Hahn et al, 1996). \textit{PTCH1}, a receptor for SHH, functions as a negative regulator of SHH signaling by inhibiting smoothened (SMO), which activates the downstream GLI transcriptional factors. Upon SHH binding to the \textit{PTCH1} receptor, SMO inhibition is relieved and the downstream GLI transcription factors are released from inhibitory complexes, which include the protein SUFU, to activate target gene expression (Figure 1-2) (Huse and Holland, 2010). Sporadic mutations in components of the SHH-\textit{PTCH1} signaling pathway, including \textit{PTCH1}, \textit{SUFU} and \textit{SMO} have been reported in 25% of medulloblastomas (Ellison et al., 2003). Similarly, the role of the WNT signaling pathway, known to be crucial during the embryonic development of the cerebellum and the midbrain (McMahon and Bradley, 1990; Thomas and Capecchi, 1990), was recognized by studying patients with Turcot’s syndrome. Turcot’s syndrome is characterized by the concomitant occurrence of multiple colorectal adenomas and a primary brain tumor, in particular medulloblastoma (Hamilton et al., 1995). These patients were identified to harbor germline mutations in the adenomatous polyposis coli (\textit{APC}) gene, a tumor suppressor that regulates the activity of the transcriptional co-activator beta-catenin (\textit{CTNNB1}), a key regulator of the WNT pathway (Figure 1-2). Mutations in the \textit{CTNNB1}, \textit{APC}, and \textit{AXIN}, another component of the APC complex, have also been observed to occur in about 20% of sporadic medulloblastomas (Huse and Holland, 2010).
Figure 1-2 Developmental pathways implicated in medulloblastoma tumorigenesis

Both germline and sporadic mutations in components of the SHH and WNT signaling pathways have been identified to occur in human medulloblastomas. Figure taken from Huse and Holland (2010).

Four subtypes of human medulloblastoma

While candidate gene approaches have been crucial to our early understanding of the molecular basis of medulloblastoma and the development of early mouse models, genome-wide expression analyses are critical for further identification of potential prognostic markers and elucidation of other pathways important in tumorigenesis. An early expression profiling study established that different tumor types and histological variants within the same tumor (ie. classic vs. desmoplastic medulloblastoma) are molecularly distinct and furthermore, gene expression signatures can serve as predictors of patient outcome (Pomeroy et al., 2002). Following this study, multiple transcriptional profiling studies have identified four to six subclasses of human medulloblastoma, highlighting medulloblastoma as a collection of tumors with distinct clinical features and outcomes, molecular underpinnings, and demographics and not a single-entity
disease (Kool et al., 2008; Northcott et al., 2011b; Cho et al., 2010). The current consensus as determined by the multiple groups that conducted the genome-wide analyses of the human tumors, identifies four distinct molecular subtypes; WNT, SHH, Group 3 (MYC), and Group 4 tumors (Taylor et al., 2012) (Figure 1-3). Meta-analyses of the expression profiling data from seven independent studies show consistency in the tumor grouping, further validating the four consensus classes (Kool et al., 2012).

The WNT and SHH subtypes show clear activation of the corresponding signaling pathways by target gene expression and make up the two groups that have the most favorable clinical outcomes, with survival rates of 80-90%. Group 3 and Group 4 have lower survival rates and while they have overlapping gene signatures, Group 3 tumors have an increased proportion of metastases and the worst prognosis (Northcott et al., 2011b). Given the molecular variation and differences in clinical outcomes, recent efforts have focused on developing and validating tumor subtype-specific mouse models of human medulloblastoma (Figure 1-3). As reviewed in the following sections, subtype-specific medulloblastoma models have also identified different putative subtype-specific tumor-initiating cells and cell of origins.

**WNT subtype:**

WNT tumors, which are characterized by the expression of genes present during activated WNT signaling (WIF1, DKK1, DKK2, etc.), constitute the subtype with the most favorable clinical outcome, with survival rates of over 95% in children and up to 100% in adults (Kool et al., 2012). The WNT tumors are a well-defined subclass characterized by distinct features, including mutations in beta-catenin (CTNNB1), loss of chromosome 6, and
<table>
<thead>
<tr>
<th>Subtypes</th>
<th>WNT</th>
<th>SHH</th>
<th>Group 3</th>
<th>Group 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prognosis/Survival</strong></td>
<td>Very good/95%</td>
<td>Infants good, others intermediate/75%</td>
<td>Poor/50%</td>
<td>Intermediate/75%</td>
</tr>
<tr>
<td><strong>Gene expression profile</strong></td>
<td>Wnt signaling</td>
<td>Shh signaling</td>
<td>Myc signature</td>
<td>Neuronal signature</td>
</tr>
<tr>
<td><strong>Histology</strong></td>
<td>Classic; rarely LCA</td>
<td>Classic; Desmoplastic; LCA</td>
<td>Classic; LCA</td>
<td>Classic LCA</td>
</tr>
<tr>
<td><strong>Metastases (at diagnosis)</strong></td>
<td>5-10%</td>
<td>15-20%</td>
<td>40-50%</td>
<td>35-40%</td>
</tr>
<tr>
<td><strong>Mutations</strong></td>
<td>CTNNB1/APC</td>
<td>PTCH1/Smo/SUFU; Gli2; TP53</td>
<td>MYC amplification</td>
<td>MYCN amplification</td>
</tr>
<tr>
<td><strong>Mouse Models</strong></td>
<td>Beta-catenin overexpression</td>
<td>Pth inactivation, Smo activation, Sufu deletion</td>
<td>cmyc overexpression</td>
<td>Mycn overexpression</td>
</tr>
<tr>
<td><strong>Proposed cell of origin</strong></td>
<td>Lower rhombic lip</td>
<td>Granule neuron progenitors, SVZ neural stem cells</td>
<td>Cerebellar stem cells; GNP</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Figure 1-3 The four molecular subtypes of human medulloblastoma**

Each subtype displays distinct clinical, genetic, and histological features. Subtype-specific mouse models have identified differences in the putative cell of origin. LCA=large cell anaplastic; SVZ=subventricular zone; GNP=granule neuron progenitors. Figure adapted from Northcott et al., 2012 and Lau et al. 2012.
immunopositivity for beta-catenin (Clifford et al., 2006). Metastases are rare in the WNT tumors and given the favorable clinical outcome of these tumors, efforts have begun to stratify patients with WNT tumors for consideration in reducing treatment intensities (Northcott et al., 2012).

The WNT subtype was recently established in a mouse model with a stabilizing mutation of beta-catenin (Ctnnb1) (Gibson et al., 2010), which led to the abnormal accumulation of cells from the embryonic dorsal brainstem persisting into adulthood. However, tumors did not form without the inactivation of Trp53. Ctnnb1;Trp53 mutant tumors recapitulated the characteristics and gene expression of human WNT tumors. In this model, the cell of origin of the WNT subtype has been suggested to be the dorsal brainstem progenitor cell (Gibson et al., 2010).

**SHH subtype:**

SHH tumors exhibit activation of the SHH signaling pathway, a pathway critical for the proliferation and differentiation of the granule cell neurons, and are marked by expression of genes such as HHIP, ATOH1 (MATH1), and SFR1 as well as the SHH pathway-dependent transcription factors GLI1, GLI2, and GLI3 (Northcott et al., 2011b). Mutations associated with the SHH subtype include PTCH1 and SUFU, both negative regulators of SHH signaling. Overall survival rates are good, with 5 or 10 year survival rates of ~80%. However, further stratification of the group by age indicates that the overall survival of children and adults are worse (10 year survival of 51% and 34%, respectively) than infants, suggesting the need for further subcategorization.

The SHH subtype has the most well-established mouse models of medulloblastoma. Various models with activating mutations or overexpression of Smo (Hatton et al., 2008) or
inactivating mutations (Goodrich et al., 1997; Wetmore et al., 2001) or deletion (Yang et al., 2008b; Schüller et al., 2008) of Ptch1 have been validated to recapitulate SHH human tumors. From the study of SHH subtype mouse models, it has been shown that both granule cell progenitors (GCP) and multipotent neural stem cells (NSC) can initiate medulloblastoma tumorigenesis following the inactivation of Ptch1. Cre-mediated deletion of Ptch1 in the granule lineage-committed Math1-expressing cells in E14.5 to postnatal day 10 (P10) mice result in tumor formation, indicating that both embryonic and postnatal GCP can function as tumor-initiating cells (Yang et al., 2008b). Ptch1 deletion in GFAP-expressing multipotent NSC at E14.5 led to an expansion of the NSC in the embryonic cerebella, resulting in an abnormally thick EGL at birth and was soon followed by rapid tumor formation. However, no abnormalities were observed in astrocytes, oligodendrocytes and other non-granule neurons, suggesting that the oncogenic effects of the Ptch1 deletion are only evident in cells that have committed to the granule cell lineage (Yang et al., 2008b). Similarly, Schuller et al. (2008) showed that activation of Smo in Math1-expressing lineage-restricted progenitors, as well as early multipotent hGFAP+ and Olig2+ progenitors led to GCP-activated medulloblastomas. No other tumor types were observed, despite the multipotency of the progenitors, consistent with the observation that acquisition of the granule cell lineage is critical for the development of SHH-induced tumors (Schüller et al., 2008).

As a result of the well-characterized nature of the SHH pathway and its role in tumorigenesis, various mouse models have been used in preclinical studies to test inhibitors of the SHH pathway for potential therapeutics (Lau et al., 2012). In particular, SMO antagonists, such as Cyclopamine and HhAntag, have shown promise in Ptch1 models (Berman et al., 2002; Romer et al., 2004). Notably, a SMO antagonist (GDC-0449) resulted in rapid, albeit transient,
tumor regression in a patient with a SHH-activated tumor displaying widespread dissemination (Rudin et al., 2009). Nevertheless, further understanding of disease relapse and drug resistance mechanisms will be necessary for the development of effective treatments against SHH tumors.

**Group 3**

Group 3 human tumors, molecularly characterized by MYC overexpression or amplification, are more likely to exhibit metastases at time of diagnosis and have the poorest prognoses, with overall survival rates of 30-50% (Northcott et al., 2011b; Kool et al., 2012). Recently, two independent studies have validated the functional role of MYC overexpression in medulloblastoma tumorigenesis. Transformation of the postnatal cerebellar stem cells (CbSC) at P5-P7 with a stabilizing mutant of c-myc and dominant-negative Trp53 leads to highly aggressive tumor formation (Pei et al., 2012). While overexpression of c-myc and Trp53 in Math1-GFP GCP can also lead to tumor formation with lower penetrance and longer latency, the tumors that develop no longer express GFP, indicating that the expression of Math1, a key marker for granule lineage commitment is lost during tumorigenesis. Tumors arising from this model exhibit gene expression profiles that overlap with NSC, suggesting that the c-myc and Trp53-induced transformation may, in fact, be leading to the dedifferentiation to more primitive cell types during tumorigenesis (Pei et al., 2012; Kawauchi et al., 2012). While these recent studies have been significant in providing the first validated models for the Group 3 tumors, one must keep in mind that these models are generated by the ex vivo transformation of CbSC by retroviral overexpression. Establishment of an endogenous system for targeting CbSC will be important to further examine the potential role for CbSC in medulloblastoma tumorigenesis.
Group 4

While Group 4 tumors are the most common subtype, it is by far the least characterized subtype of medulloblastoma (Kool et al., 2012). Group 4 tumors display overlapping gene expression profiles with Group 3 tumors, but are distinguished by the amplification of proto-oncogene MYCN (Kool et al., 2012) and have better overall survival rates (~75%) (Northcott et al., 2012). In one model, the overexpression of Mycn in the postnatal day 0 cerebella led to the formation of SHH-independent tumors with LCA and classic histology, as typically observed in Group 4 tumors. Furthermore, these tumors, although infrequently, displayed leptomeningeal metastases and contain transplantable tumor-propagating cells (Swartling et al., 2010). However, this model still remains to be validated for recapitulation of the human Group 4 subtype tumors.

Cancer Stem Cells

Background

A cancer stem cell is defined as a cell present in a tumor that possesses 1) the capability for self-renewal and 2) the ability to differentiate and give rise to the variety of heterogeneous progeny that make up the bulk of the tumor (Reya et al., 2001; Clarke et al., 2006). A self-renewing cell must be able to generate a daughter cell that retains its ability for self-renewal and differentiation and occurs either by symmetrical (generating two stem cells) or asymmetrical cell division (generating one stem cell and one differentiated cell) (Clarke et al., 2006). The cancer stem cell hypothesis states that it is this rare population of cells with stem-like properties that drive the initiation and progression of the tumor and establish hierarchically organized,
differentiated tumor progeny. Therefore, akin to normal development, tumor heterogeneity is a result of the multipotent differentiation of the stem-like cell. By contrast, in the clonal, or stochastic model of tumorigenesis, any cell within the tumor that acquires the appropriate genetic and/or epigenetic alterations can gain the potential for tumor initiation (Shackleton et al., 2009; Dick, 2009).

Cancer stem cells were first identified and characterized in human acute myeloid leukemia (AML). Drawing from the well-established markers of hematopoietic stem cells (HSC), Dick et al. (1994) observed that human AML cells with cell surface profiles (CD34+CD38−) typical of immature cells in the bone marrow were also able to regenerate leukemia and recapitulate the original tumor when serially transplanted into irradiated NOD/SCID mice. In contrast, the CD34+CD38+ or CD34− cells failed to initiate leukemia (Lapidot et al., 1994; Bonnet and Dick, 1997). However, a CSC population is not necessarily derived from the transformation of the corresponding tissue stem cell. Increasing evidence has supported the notion that differentiated tissue progenitors, through oncogenic mutations, can dedifferentiate and acquire characteristics of CSC to initiate tumorigenesis (Passegué et al., 2003). For example, the expression of the MLL-ENL and MLL-AF9 fusion oncogenes can bestow properties of self-renewal in committed progenitors in myeloid/lymphoid leukemia (Cozzio et al., 2003; Krivtsov et al., 2006). The extensive lineage maps and validated cell surface markers for each distinct cell lineage have made it feasible to study the role of each cell population during hematopoietic tumorigenesis. The challenge remains in solid tumors, as the surface markers of stem cells and their progeny or even the developmental cellular hierarchies are not well defined in solid organs. However, mounting evidence has shown that CSC are, in fact, present in solid tumors, as will be discussed in the following section.
**Isolation of cancer stem cells in solid tumors**

The first demonstration that a specific, identifiable population of cells within a solid human tumor was able to isolate the tumor-initiating activity in a xenograft transplantation assay occurred in breast cancers (Al-Hajj *et al.*, 2003). In this study, FACS sorting based on the expression of cell surface markers CD44 and CD24 demonstrated that only the CD44$^+$/CD24$^{-/low}$ population of cells possessed the capability for self-renewal and tumor-initiation by serial transplantation. The transplanted tumors initiated by the CD44$^+$/CD24$^{-/low}$ population further exhibited differentiation into heterogeneous cell types to regenerate the phenotypic complexity observed in the primary tumor. Following this study, CSC have been further identified in other solid tumors of the brain (Singh *et al.*, 2004), colon (O’Brien *et al.*, 2007; Ricci-Vitiani *et al.*, 2007) and pancreas (Li *et al.*, 2007; Hermann *et al.*, 2007) by the prospective isolation with cell surface markers. Cell surface markers utilized for isolation of the tumor-initiating, stem-like cells in the variety of solid tumors include CD133 (also known as prominin 1) for brain, colon and pancreatic cancers, CD44/CD24/ESA (epithelial-specific antigen) for pancreatic cancer, and ALDH1 (aldehyde dehydrogenase) as an additional marker for breast cancers (Ginestier *et al.*, 2007). As observed in AML, the CSC surface markers in solid tumors include those that have also been characterized as markers for tissue stem cells present in the corresponding disease organ, such as CD133, a marker for NSC (Uchida *et al.*, 2000) and ALDH1 for mammary stem cells (Ginestier *et al.*, 2007).

The gold standard assay for determining CSC activity is the *in vivo* transplantation assay, in which the putative CSC population is orthotopically injected into immunocompromised mice (Clarke *et al.*, 2006). Animals are monitored for tumor formation and secondary tumors are
analyzed for differentiation capacity and recapitulation of the primary tumor. Serial transplantation further validates the self-renewal capability of the CSC present in the tumor (Clarke et al., 2006). Limiting dilution transplantation assays can also be carried out to determine the number of fractionated cells required for cancer-initiation in vivo (Ginestier et al., 2007; O’Brien et al., 2007). Nonetheless, the xenograft assay is not without caveats and limitations. Importantly, there are major concerns about the separation of the tumor cells from the endogenous stroma, which may prevent engraftment in a foreign microenvironment (Clarke et al., 2006). While this issue may be circumvented if the CSC population is niche-independent, the frequency of tumor-initiation has been shown to vary greatly depending on the genetic background of the recipient mouse (Quintana et al., 2008). The role of the niche is further highlighted in cancers that may be induced by an endogenous tumorigenic niche itself (Walkley et al., 2007). In addition, the xenograft assays have the technical disadvantage of being slow and may take months for tumors develop in vivo following transplantation.

The prospective isolation of CSC has largely been dependent on cell surface markers using markers of normal stem cells, mainly CD133 and CD44/CD24 (Visvader and Lindeman, 2008), but concerns about the purity of FACS isolated cell populations due to subjective factors such as gating or variability in reagents such as antibodies must be considered and marker expression may also not be a stable characteristic of the CSC. One possible method for circumventing these issues is by increasing specificity by using a combination of markers (Medema, 2013).

Non-adherent sphere formation assays, developed for the isolation of NSC (Reynolds and Weiss, 1996), have been a standard assay in isolating and maintaining the growth of brain tumor cell stems in vitro (Dirks, 2008). Tumors maintained in serum-free sphere cultures have been
shown to represent the characteristics of the original tumor more accurately than serum cultured lines (Lee et al., 2006). It has also been reported that neurospheres are not necessarily derived from stem cells (Pastrana et al., 2011) and intra-clonal heterogeneity is observed within a neurosphere, that may contain stem cells, as well as, more differentiated progenitors (Suslov et al., 2002). One must consider the caveats of utilizing a culture-based isolation method, as tissue culture-induced alterations may also occur. Nonetheless, *in vitro* propagation and expansion of stem-like cells by sphere formation assays prove to be a valuable method for rapid examination of pathways and amenable for genetic manipulation.

**Tracking cancer stem cells in vivo**

An ideal method to avoid the concerns of separating CSC from its endogenous niche, which may lead to culture-induced changes or loss of activity, is by tracking cells *in vivo* in an unperturbed system with viral tagging strategies or knock-in reporter models. (Clevers, 2011). While this is not feasible in humans for obvious ethical reasons, *in vivo* lineage tracing of genetically marked cells allows for the observation of progeny derived from a single cell in mouse models. Recently, three independent studies demonstrated the presence of endogenous tumor-initiating cells by marking a putative stem cell population and tracking the tumor growth *in vivo*, in colon, skin, and brain cancers (Schepers et al., 2012; Driessens et al., 2012; Chen et al., 2012). Particularly, in the brain tumor study, *Nestin-ATK-IRE5-GFP* expressing stem cells in a mouse model of glioblastoma (*hGFAP-Cre;Nf1^{fl/+};P53^{fl/+};Pten^{fl/+}*), which mark the adult NSC in the subventricular zone, were also demonstrated to identify the glioma-initiating stem cells *in vivo* (Chen et al., 2012). Furthermore, ablation of this cell population by treatment with ganciclovir led to arrested tumor growth, showing that the *hGFAP*-expressing stem cells
maintained tumor growth. Importantly, following the regression of the tumor with chemotherapeutic agent temozolmide (TMZ), tumor regrowth was observed to be initiated by the Nestin-ΔTK-IRES-GFP cells. Together, the results from the three independent lineage tracing studies provide a convincing demonstration of an endogenous CSC population in solid tumors, as the CSC were identified in an unperturbed system in which cells are not removed from endogenous niche and transplanted to another species. A question that remains is whether the cells being tracked in vivo with the lineage tracing methods are, in fact, the same populations being functionally assayed in the xenograft transplantation assays. This will be important in determining the validity of transplantation assays that have been being utilized as the gold-standard method.

Treatment resistance of cancer stem cells

Chemo- and radiotherapy preferentially kill rapidly dividing, cycling cells. If a CSC is derived from a rare cell that infrequently enters the cell cycle, such therapies would be relatively inefficient or unable to target these cells (Clarke et al., 2006). In fact, normal stem cells exhibit properties such as quiescence, expression of ABC (ATP-binding cassette) transporters, active DNA-repair, and resistance to apoptosis, rendering them resistant to radiation and toxins (Dean et al., 2005). In particularly, high expression of ABC transporters, known for their role in multi-drug resistance, results in a “side-population” phenotype characterized by efflux of the Hoechst dye. In bone marrow, the “side population” contains HSC that are able to reconstitute the hematopoietic system. Utilization of the Hoechst dye has also allowed for the early isolation of cells with stem-like characteristics from tumor samples (Dean et al., 2005). However, this
method isolates a heterogeneous population and subsequent studies have focused on the characterization of specific cell-surface markers for the prospective isolation of CSC.

Both chemo- and radioresistance mechanisms have been observed in the cancer stem-like population in hematopoietic cancers and solid tumors. In human AML, the CD34⁺CD38⁻ leukemia stem cells were more resistant to the chemotherapeutic Ara-C and a greater fraction of these cells were found to be quiescent in G0 compared to the CD34⁺CD38⁺ or CD34⁻ cells. Secondary transplantation of the Ara-C-surviving CD34⁺CD38⁻ cells suggests that these chemoresistant cells can be responsible for tumor relapse (Ishikawa et al., 2007). In breast tumors, standard chemotherapy treatment led to an increase in the fraction of CD44⁺CD24⁻/low breast CSC and a concurrent increase in mammosphere formation (Li et al., 2008; Yu et al., 2007) and this was mediated by the reduction of miRNA let7 expression by the breast CSC.

Several mechanisms have been implicated in the resistance of CSC to ionizing radiation. In human glioblastoma primary and xenograft tumors, CD133⁺ glioma stem cells displayed increased resistance to ionizing radiation compared to CD133⁻ cells and the CD133⁺ cells that survived the radiation were able to initiate tumors with similar potency as untreated cells. This survival was mediated by enhanced DNA damage checkpoint activation by the CD133⁺ cells (Bao et al., 2006). CD133⁺ cells in medulloblastoma cell lines exhibited greater radioresistance than the CD133⁻ counterparts and displayed an increase in CD133 expression in hypoxic conditions (Blazek et al., 2007). In a breast cancer model, CSC-enriched populations also exhibited less DNA damage after radiation and this was be attributed to lower levels of reactive oxygen species (ROS), mediated by the increased expression of antioxidant or anti-ROS genes (Diehn et al., 2009).
In several mouse models of medulloblastomas, a population of radioresistant CSC was identified to be present in the perivascular niche (Hambardzumyan et al., 2008). Upon radiation treatment, the bulk of the tumor underwent Trp53-dependent apoptosis. However, a subset of nestin-positive cells in the vascular niche was able to survive radiation and undergo cell cycle arrest, until they re-entered the cell cycle 72 hours post-treatment and proceeded to proliferate and cause tumor recurrence (Hambardzumyan et al., 2008).

Significance and Controversy

The CSC hypothesis emerged in part from observations that tumors with stem cell-like properties have greater resistance to conventional chemo- or radiotherapy, resulting in disease recurrence following tumor resection. There are great implications if the CSC hypothesis is true and there exists a rare population of cells that are refractory to standard treatments. While standard therapies can effectively target the bulk of the tumor, therapies targeting the CSC population specifically may be necessary for effective elimination of the tumor and the prevention of tumor relapse (Clarke et al., 2006). Therefore, it is crucial to study the mechanisms of CSC survival and maintenance. However, this has not been straightforward and controversies have been raised regarding the validity of the CSC hypothesis.

Controversies involving CSC are manifold and reasons include, but are not limited to methods of isolation, assays for measuring activity, confusion regarding the definition of CSC and whether or not it must be derived from transformed tissue stem cell. Recently, the controversy of CSC was fueled by a study showing that a very high frequency (1 in 4) of tumor-initiating cells were actually present in melanomas when more severely immunocompromised recipient animals were utilized (Quintana et al., 2008). This is contrary to the notion that only a rare population of cells possesses the capability for tumor-initiation. This would argue that the
xenograft transplantation assays have been underestimating the frequency of human CSC when, in fact, a much larger proportion of cells have the tumorigenic potential when the appropriate environment is provided. This highlights the concerns and caveats regarding the use of xenograft transplantation assays as the gold standard for measuring functional CSC activity. Syngeneic transplantation assays carried out in mouse models of B and T-cell lymphomas, driven by c-myc and N-ras expression by the Eu enhancer also concluded that the tumor-initiating population is not as rare as initially expected (>10%) (Kelly et al., 2007). However, in other tumor models of leukemia and breast cancer that examined CSC activity with the syngeneic transplantation of the prospectively isolated tumor stem cells, the results were consistent with the xenograft studies, identifying the tumor-propagating population as a rare population (Guo et al., 2008; Zhang et al., 2008). These studies demonstrate the variability that occurs depending on the experimental context, or alternatively, may be reflecting the biological variability in the frequency that occurs between different tumor types or even between individual tumors of the same type. In fact, the frequency of leukemia initiating cells can vary up to 500 fold between patients (Bonnet and Dick, 1997).

Current methods of CSC isolation are largely based on FACS isolation with cell surface markers. But further complexities in the characterization and the interpretation of CSC populations may arise if the CSC are not a stable population, but demonstrate a phenotypic plasticity allowing for interconvertibility between CSC and non-CSC (Gupta et al., 2009). If CSC are maintained in a stable state with defined properties and pathway dependencies, targeting CSC specifically may be a feasible strategy. However if CSC demonstrate “plasticity” during the progression of tumorigenesis or during therapeutic challenge, this will have important implications for treatment strategies (Jordan, 2009). For example, if dedifferentiation of non-
stem cancer cells can also lead to the generation of a CSC population, this necessitates the need for targeting both the bulk and the stem cell compartment.

Other controversies have arisen due to confusions regarding the term cancer “stem cell”, which have led to the assumption about the cellular origin of these cells, the name suggesting that the precursors of CSC are normal tissue stem cells. While it is true that in some cases of leukemia, the cell of origin is a transformed stem cell, the assays used to identify CSC are purely based on functional tests for tumor-initiation and not intended to imply that they are derived from normal stem cells (Jordan, 2009). Despite the many controversies, the CSC hypothesis has remained a topic of immense interest and efforts continue to further validate and characterize the population of CSC in various tumor types.

**Brain tumor stem cells**

As previously described, mouse and human NSC when cultured as neurospheres in the presence of bFGF and EGF have been shown to maintain the characteristics of clonogenic self-renewal *in vitro* and engraftment and multipotent differentiation *in vitro* and *in vivo* (Reynolds *et al.*, 1992). These methods for studying normal NSC have been employed for the initial identification and isolation of human brain tumor stem cells in astrocytomas, glioblastomas and medulloblastomas (Singh *et al.*, 2004; Hemmati *et al.*, 2003). Culturing human brain tumors as neurospheres in serum-free culture has been shown to better retain and recapitulate the characteristics of the primary tumor (Lee *et al.*, 2006), further supporting the neurosphere culture as an important method for the characterization and isolation of potential brain tumor stem cells, especially in the absence of cell surface markers allowing for the prospective isolation from primary tumors.
Prospective isolation of tumor cells using NSC markers, such as CD133, has also been successfully utilized for the isolation of brain tumor stem cell activity. Specifically, in medulloblastoma, as low as 100 CD133-positive cells was shown to initiate a tumor upon xenograft transplantation and both classic and desmoplastic histologies have been recapitulated, while CD133-negative cells lacked this activity (Singh et al., 2004). Furthermore, nestin\textsuperscript{+}/CD133\textsuperscript{+} brain CSC have been identified in the perivascular niche, interacting with the endothelial cells for maintenance of their stem cell state (Calabrese et al., 2007). A recent lineage-tracing study marking nestin\textsuperscript{+}-expressing NSC in a glioblastoma model demonstrated the ability of these NSC to initiate tumors and importantly, reinitiate tumor formation following chemotherapeutic treatment (Chen et al., 2012). An endogenous population of medulloblastoma stem cells has yet to be examined with lineage tracing studies. While an embryonic stem (ES) cell gene expression profile is enriched in the high grade tumors, which have poor prognoses (Ben-Porath et al., 2008), the correlation between the presence of endogenous stem cell populations in brain tumors and overall survival has also not been studied.

\textit{Ptch1}^{LacZ/+};\textit{Trp53}^{-/-} mouse model of disseminated medulloblastoma with self-renewing, tumor-initiating cells

Despite the recent advances in the development of subtype-specific tumors, few models have examined the phenotypes of dissemination or the population of CSC specifically. This is important given that dissemination/metastases is an indicator for poor prognosis and there is evidence suggesting CSC can exhibit metastatic capabilities (Hermann et al., 2007). Specifically, in pancreatic cancers, the subpopulation of CD133\textsuperscript{+} cells co-expressing CXCR4 (C-X-C chemokine receptor type 4) were located at the invasive front of the tumors and exhibited
migratory and metastatic characteristics (Hermann et al., 2007). In all tumor subtypes except the WNT tumors, which have an overall high rate of survival, in general, patients exhibiting dissemination have worse overall survival compared to those without disseminated tumors (Kool et al., 2012). A relatively small proportion of patients with SHH tumors exhibit metastases (13% in SHH tumors), however, it will be valuable to have models that represent the metastatic phenotype given the poor survival of patients with metastases. Although the SHH tumor models are well established, the smaller subset of SHH tumors with the metastatic phenotype may not be captured in these models and may not uncover the underlying genetic pathways important in dissemination and treatment resistance. In one activated Smo model, a homozygous SmoA1 mutation was shown to result in highly aggressive tumors with leptomeningeal dissemination to the brain and spine and the ability to form secondary tumors transplantation, suggestive of a tumor-initiating population (Hatton et al., 2008).

In other models of medulloblastoma-initiating cells, consistent with the identification of human CSC in the perivascular niche, a Nestin-positive, radioresistant stem cell population was also observed in the perivascular niche in mice (Hambardzumyan et al., 2008). Furthermore, the survival of these stem cells following radiation was dependent on activation of the Akt pathway, suggesting the inhibition of this pathway as a potential avenue for treatment. Recently, postnatal self-renewing CbSC overexpressing c-myc (Pei et al., 2012) or with inactivating mutations of Rb and Trp53 (Sutter et al., 2010) have been shown to initiate tumors upon transplantation, suggesting the potential role for CbSC transformation for medulloblastoma tumorigenesis.

\( \text{Ptch1}^{LacZ/+; Trp53^{-/-}} \) mouse model of medulloblastoma

In mice, \textit{Ptch1} homozygosity results in embryonic lethality at around E9.0-E10.5, but heterozygous \textit{Ptch1} mutants develop medulloblastomas histologically similar to human
medulloblastomas (Goodrich et al., 1997). The combination of Trp53\(^{-/-}\) with the Ptch1\(^{LacZ/+}\) mutation results in a more malignant tumor, accelerating medulloblastoma formation from 10 months (in Ptch1\(^{LacZ/+}\) mice) to 12 weeks and increasing tumor penetrance from 14% to greater than 95% (Wetmore et al., 2001). Histological differences are also observed, as the Ptch1\(^{LacZ/+}\) genotype represents a more benign and focal tumor with no dissemination and the Ptch1\(^{LacZ/+};\) Trp53\(^{-/-}\) tumors are more diffuse (C.Lin thesis). Recently, Sleeping Beauty transposon mutagenesis in the Ptch1 heterozygous background accelerated tumorigenesis and also led to tumors exhibiting leptomeningeal dissemination (Wu et al., 2013), suggestive that additional mutations are required for dissemination in the Ptch1 model.

Our lab further determined that there was a difference in the endogenous stem cell activity between the Ptch1\(^{LacZ/+}\) and Ptch1\(^{LacZ/+};\) Trp53\(^{-/-}\) tumors using the serum-free in vitro neurosphere assay for self-renewal. Ptch1\(^{LacZ/+};\) Trp53\(^{-/-}\) tumor cells have been reported to undergo changes during adherent, serum-enriched tissue culture, such as downregulation of SHH signaling, highlighting concerns that serum-cultured cells in vitro cells may be not representative of the original tumors (Sasai et al., 2006). Thus, our lab sought to culture the tumor cells in neurosphere conditions to better preserve the in vivo characteristics of the Ptch1\(^{LacZ/+};\) Trp53\(^{-/-}\) medulloblastomas, including the potential stem cell population, as the addition of serum leads to differentiation or NSC. As described above, this neurosphere culture method is commonly utilized for the enrichment of brain tumor stem-like cells. While the prospective isolation of tumor stem cells directly from the primary tumor is crucial for further characterization of this population, additional markers may need to be identified for the isolation of Ptch1\(^{LacZ/+};\) Trp53\(^{-/-}\) tumors stem cells. In the Ptch1 heterozygous mouse model, CD133, the most commonly used marker for brain tumors, does not enrich for tumor-initiating capability (Read et al., 2009). One
additional marker, CD15, a marker of embryonic and NSC, was previously shown to fractionate the cells with tumor-propagating capability (Read et al., 2009; Ward et al., 2009).

Ptch1LacZ+/Trp53−/− tumors display robust neurosphere formation at a frequency of approximately 1/50 in clonal growth conditions (C.Lin thesis). In contrast, Ptch1LacZ+ tumors only displayed sporadic, if any, self-renewal activity. In addition, the long term culture of the Ptch1LacZ+/Trp53−/− medulloblastoma neurospheres (MBNS) led to the enrichment of self-renewing cells, with high expression of NSC markers, Sox2 and nestin. Furthermore, tumor-propagation capability of these Ptch1LacZ+/Trp53−/− MBNS was demonstrated by injections of both bulk tumor and neurosphere lines into the cerebella of nude mice (n=5), all of which developed cerebellar tumors. Tumor-initiation occurred more rapidly in the MBNS and their clonally derived subclones compared to the bulk tumors, suggestive of an enrichment for tumor-initiation activity. The transplanted tumors displayed dissemination within the brain and migration to the olfactory bulb and to the spinal cord. Together, these observations demonstrated that a self-renewing, tumor-propagating population can be enriched with in vitro neurosphere culture in the disseminated Ptch1LacZ+/Trp53−/− medulloblastoma model.

The Ptch1LacZ+/Trp53−/− model suggests that there may be an alternate cell of origin for the tumor-initiating cells within SHH-type tumors (C.Lin thesis), distinct from the granule cell progenitors, which have been characterized as the cell of origin in this subtype (Schüller et al., 2008; Yang et al., 2008b). In the Ptch1LacZ+/Trp53−/− animals, self-renewal activity was also present at 3 weeks (at a frequency of approximately 1/100), which is beyond the normal developmental window for self-renewal, as evident by the lack of neurosphere formation in wild-type (WT) 3 week animals. These aberrant CbSC, persisting beyond the stages of normal cerebellar development in the mutant p53 background, may also result in a tumor-initiating cell
population. While normal NSC depend on bFGF and EGF for the maintenance of proliferation and self-renewal, the growth factor responsiveness and pathway dependencies of the MBNS identified in the $Ptch1^{LacZ+/+};Trp53^{-/-}$ model have not been characterized. Data from our lab, however, suggest differences in the growth factor dependencies between the MBNS and the aberrant CBSC. When the growth factors bFGF and EGF were withdrawn from 3 week old $Ptch1^{LacZ+/+};Trp53^{-/-}$ aberrant CBSC cultures, the expression of the NSC marker Sox2 was reduced. The MBNS, however, are not dependent on exogenous bFGF and EGF, and short-term growth factor withdrawal did not affect the expression of Sox2. These data indicate that further elucidation of pathways involved in the maintenance of the MBNS enriched from the $Ptch1^{LacZ+/+};Trp53^{-/-}$ tumors is necessary. In addition, pathways allowing for the aberrant persistence of self-renewing, premalignant cells in 3 week $Ptch1^{LacZ+/+};Trp53^{-/-}$ animals will shed light on the early progression of the tumors.

**Research Objectives**

In my dissertation, we sought to ask about the mechanisms of stem cell regulation and the pathways dependencies of medulloblastoma neurospheres and premalignant tissue stem cells in the $Ptch1^{LacZ+/+};Trp53^{-/-}$ model. The discovery of reprogramming mechanisms for converting somatic cells to a pluripotent embryonic state demonstrated that directed de-differentiation can occur through ectopic expression of the transcription factors, $Oct4$, $Sox2$, $c-myc$, and $Klf4$ (Takahashi and Yamanaka, 2006); the latter two being notable oncogenes expressed in many types of human cancer (Rowland and Peeper, 2006). The intrinsic genetic program of NSC can be reprogrammed to an embryonic state with the induction of a single transcription factor, $Oct4$ (Kim et al., 2009), possibility because of endogenous expression of $Sox2$, $c-myc$ and $Klf4$ (Kim
et al., 2008b), as well as reprogramming markers SSEA-1 (CD15) and alkaline phosphatase (Kim et al., 2009). In Chapter 2, we show that MBNS are able to rapidly adapt to embryonic stem cell culture selection in an in vitro assay for reprogramming. This led to the characterization of pluripotency gene *Klf4* as a crucial factor in MBNS plasticity and self-renewal, which was regulated in a *Stat3*-independent manner during clonogenic self-renewal.

While the culture-enriched *Pch1*^{LacZ/+};*Trp53^+/−* MBNS exhibit properties of CSC, including as long term, clonal self-renewal in vitro and robust tumor-propagation in vivo, the lack of a prospective marker for isolation of the tumor-initiating activity precludes us from terming these cells as definitive CSC endogenously present in the primary tumors. In Chapter 3, we sought to isolate *Sox2*-expressing cells and characterize *Sox2* as a potential marker for the prospective isolation tumor stem cells in the *Pch1*^{LacZ/+};*Trp53^+/−* model. We prospectively isolated the aberrant tissue stem cell population from the *Pch1*^{LacZ/+};*Trp53^+/−* animals using a fluorescent reporter allele of *Sox2*, a NSC marker, with the goal of characterizing pathways involved in the developmental persistence of these cells during tumorigenesis.
Chapter 2: *Klf4* maintains the plasticity and self-renewal of medulloblastoma neurospheres in a *Stat3*-independent manner

Ronnie Yoo\(^1,2,3,5\), ChieYu Lin\(^1,2,3,5\), Suhu Liu\(^4\), Leah Liu\(^3\), David Frank\(^4\), Mark D. Fleming\(^1\) and Laurie Jackson-Grusby\(^1,2\)

\(^1\)Pathology Department and \(^2\)Kirby Center for Neuroscience, Boston Children’s Hospital, \(^3\)Biological and Biomedical Sciences Graduate Program, Harvard University, \(^4\)Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115
\(^5\)These authors contributed equally

**Author Contributions**

RY acquired and analyzed results, wrote the manuscript and prepared figures. CYL contributed to the development of the methodology and acquired results for Figure 2-1. SL and DF contributed to the conception and design of experiments. LL contributed to the preparation of reagents. MDF contributed to the analyses of the histopathology. LJG contributed to the conception and design of experiments, analyzed results, wrote the manuscript and supervised the study.
Introduction

The cancer stem cell hypothesis suggests that only a small subpopulation of stem-like cells within a tumor have the capability for tumor-initiation and self-renewal. This population of cells is associated with greater resistance to conventional therapy, resulting in disease recurrence following tumor resection (Clarke et al., 2006). Indeed, brain tumor-initiating cells displaying self-renewal and secondary tumor initiation in orthotopic xenografts have been identified in high grade human medulloblastomas and glioblastomas (Singh et al., 2003; Galli et al., 2004; Hemmati et al., 2003). In mouse medulloblastoma models, while rational pathway inhibitors are able to slow tumor growth, they are unable to completely eliminate tumor cells, resulting in tumor regrowth (Lau et al., 2012). Consistent with a role for tumor-initiating cells in disease relapse, a small population of stem-like cells resistant to radiotherapy has been identified in the cerebellar perivascular niche in primary human medulloblastomas (Calabrese et al., 2007) and medulloblastoma-prone mice (Hambardzumyan et al., 2008). Therefore, characterization of the mechanisms and pathways involved in the maintenance and survival of the population of medulloblastoma-initiating cells is critical for the development of effective targeted therapeutics.

Examination of the common genetic programs and signaling pathways utilized in stem cells and cancer cells provide important insights into mechanisms governing cancer stem cells (CSC) (Krizhanovsky and Lowe, 2009). For example, in AML, high expression of hematopoietic stem cell signatures directly predicts patient survival (Eppert et al., 2011). A study by Kho et al. comparing human medulloblastoma gene profiles with expression signatures from the developing mouse cerebella observed a high correlation between metastatic human medulloblastomas and the postnatal day 5 through day 7 mouse cerebella (Kho et al., 2004), a developmental timepoint when the cerebellum is largely undifferentiated and cerebellar stem
cells (CbSC) are the most abundant (Lee et al., 2005). Selection for prominin 1 (also known as CD133) enriches for a CbSC population co-expressing pluripotency genes Oct4, Nanog, and Sox2 and the NSC factors nestin and Bmi1 (Po et al., 2010). Notably, the comparison of gene expression profiles of cancers and embryonic stem (ES) cells have also revealed correlations between ES cells and poorly differentiated, high-grade human tumors (Wong et al., 2008; Ben-Porath et al., 2008), including brain tumors (Ben-Porath et al., 2008; Holmberg et al., 2011). Together, these studies reveal coordinated patterns of expression of pluripotency factors in CbSC and cancers; however the extent to which medulloblastoma-initiating cells rely upon these pathways has not been determined.

Oncogenic reprogramming and dedifferentiation of tumor cells has been proposed as a mechanism for generating and maintaining CSC (Krizhanovsky and Lowe, 2009; Hanahan and Weinberg, 2011). We were interested to test whether medulloblastoma neurospheres (MBNS) from metastatic medulloblastomas exhibit signs of endogenous reprogramming and dependency on these pathways. To approach this question, we studied the highly malignant

$Pch1^{LacZ/+};Trp53^{-/-}$ mouse medulloblastoma model (Wetmore et al., 2001). $Pch1^{+/-}$ medulloblastoma cells have previously been shown to undergo reprogramming following somatic nuclear transfer into mouse oocytes (Li et al., 2003), showing that the cancer genomes can be epigenetically reprogrammed by the oocyte to reverse the tumorigenic activity and restore normal early development. Self-renewing, tumor-initiating neurospheres enriched from $Pch1^{LacZ/+};Trp53^{-/-}$ tumors were used in an in vitro assay for reprogramming to assess adaptation to embryonic stem cell culture conditions, which would not normally be expected to support NSC growth in the absence of ectopic reprogramming factors, due to the differentiation factors present in serum (Reynolds et al., 1992). The $Pch1^{LacZ/+};Trp53^{-/-}$ MBNS demonstrated
plasticity and maintained growth and self-renewal in ES culture conditions. Furthermore, given the crucial function Klf4 plays in somatic reprogramming (Yang et al., 2010b) and mouse ES cell self-renewal (Zhang et al., 2010), we examined the role of Klf4 in maintaining the plasticity and self-renewal of the Ptch1\textsuperscript{LacZ+/;Trp53-/-} MBNS. We observed that Klf4 is critical in maintaining both the plasticity of the Ptch1\textsuperscript{LacZ+/;Trp53-/-} MBNS in ES culture conditions and clonogenic growth as self-renewing neurospheres. In addition, Klf4, a known Stat3-target, was regulated in a Stat3-independent manner during clonogenic growth.

**Results**

**Neurosphere culture-enriched Ptch1\textsuperscript{LacZ+/;Trp53-/-} medulloblastoma line exhibits characteristics of self-renewal and tumor-propagation**

CSC are functionally defined as a cell within a tumor with the capability for indefinite self-renewal and tumor initiation and recapitulation of the primary tumor upon secondary transplantation (Clarke et al., 2006). We first sought to functionally assess if stem-like cells cultured from a primary Ptch1\textsuperscript{LacZ+/;Trp53-/-} mouse medulloblastoma exhibit properties of CSC. Self-renewing cells were enriched from primary tumors using neurosphere cultures in serum-free media containing bFGF and EGF (Reynolds and Weiss, 1996), as this approach has been previously utilized for culturing human brain tumor stem cells (Hemmati et al., 2003; Galli et al., 2004; Singh et al., 2003) and has been shown to preserve the genotype, gene expression and histopathology of tumor-propagating cells from human brain tumors (Lee et al., 2006). In addition, traditional serum-based cell cultures of Ptch1\textsuperscript{LacZ+/;Trp53-/-} mouse medulloblastomas have been reported to alter the properties of the original tumor and suppress the Shh pathway activity (Sasai et al., 2006) and serum leads to the terminal differentiation of NSC (Reynolds et
al., 1992; Gage et al., 1995). *Ptc*1<sup>LacZ/+;Trp53<sup>−/−</sup> mouse medulloblastoma neurosphere lines were maintained by dissociating and serially passaging in bulk cultures for more than 50 passages or clonally expanded as subclones. The long-term cultured *Ptc*1<sup>LacZ/+;Trp53<sup>−/−</sup> MBNS were enriched for self-renewal activity ten-fold, compared to the primary tumor neurospheres and maintained elevated expression of Shh pathway target genes *Gli1* and *Gli2* (C.Lin thesis). As NSC surface markers CD15 and CD133 have been shown to mark tumor-propagating cells in mouse *Ptc*1<sup>LacZ/+</sup> tumors (Read et al., 2009) and human medulloblastomas (Singh et al., 2004) respectively, we carried out flow cytometry to assess expression of these markers in a primary tumor and the neurosphere culture-enriched *Ptc*1<sup>LacZ/+;Trp53<sup>−/−</sup> cells. CD15 expression in the MBNS overlapped with the highest expressing cells within the heterogeneous primary tumor, whereas CD133 levels were elevated in the MBNS (Figure 2-1). The *Ptc*1<sup>LacZ/+;Trp53<sup>−/−</sup> MBNS were also enriched in the expression of NSC markers nestin and Sox2, as shown by immunostaining of neurospheres (C. Lin thesis).

![Figure 2-1](image-url)  

**Figure 2-1** A *Ptc*1<sup>LacZ/+;Trp53<sup>−/−</sup> medulloblastoma-derived neurosphere line is enriched for NSC cell marker expression in comparison to the primary tumor

FACS analyses of cell surface markers CD15 and CD133 in primary tumors and a *Ptc*1<sup>LacZ/+;Trp53<sup>−/−</sup> medulloblastoma neurosphere (MBNS) line show an enrichment of the expression of these markers in the culture-enriched line.
To determine if these self-renewing MBNS were capable of tumor-initiation \textit{in vivo}, intracerebellar injections were carried out using $10^4$, $3 \times 10^4$ and $10^5$ cells (n= 2, 3, 3 respectively). Injected animals were sacrificed upon manifestation of neurological symptoms such as hydrocephaly, ataxia, or motor dysfunction and tumors that caused morbidity were observed within six weeks in all animals. X-Gal staining to detect $Ptch1^{LacZ}$ expression in a primary tumor (Figure 2-2a) and the allograft tumors (Figure 2-2d) confirmed tumor engraftment in the cerebella. Upon cerebellar transplantation of the MBNS, dissemination to the olfactory bulb was also observed 60\% of the time (C. Lin thesis). A comparative histological analyses of a primary $Ptch1^{LacZ/+};Trp53^{-/-}$ medulloblastoma (Figure 2-2b, c) and a secondary tumor initiated with the injection of 10,000 MBNS cells (Figure 2-2e, f) demonstrated consistent architecture in the primary and secondary tumors, which were typified by dense cells with angulated nuclei and little cytoplasm. The secondary tumors, however, appeared to have a higher mitotic rate and were marked by less differentiated cells with prominent nucleoli and minimal cytoplasm. Furthermore, our lab has observed that when the same number of primary $Ptch1^{LacZ/+};Trp53^{-/-}$ medulloblastoma cells and culture-enriched MBNS were injected, the MBNS-injected animals display accelerated tumor formation (C. Lin thesis). Together, these results show that $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS exhibit properties of self-renewal and secondary tumor propagation.
Figure 2-2 A neurosphere line derived from a primary $Ptch1^{LacZ/+};Trp53^{-/-}$ medulloblastoma is able to propagate secondary tumors recapitulating the primary tumor

(a) X-gal stained sagittal section of a primary $Ptch1^{LacZ/+};Trp53^{-/-}$ medulloblastoma. (b-c) Hematoxylin and eosin (H&E) stained section of the primary tumor. (d) X-gal stained sagittal section of a secondary tumor formed 4 weeks after intracranially injecting 10,000 $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS into nude mice. (e-f) H&E stained sections of the secondary tumor show that the $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS can propagate a tumor recapitulating the histology of the primary tumor. Scale bars in (b) and (e) are 500um; (c) and (f) are 100um. The white boxes in (b) and (e) indicate the sections enlarged in (c) and (f), respectively.

Phenotypic conversion of $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS grown in ES cell culture conditions

We established an in vitro reprogramming assay that would test the responsiveness of MBNS to fetal bovine serum (FBS) by growth under clonal culture conditions established for ES cells. NSC differentiate upon exposure to FBS (Reynolds et al., 1992; Gage et al., 1995), whereas embryonic stem (ES) cells maintain pluripotency in media containing FBS and leukemia inhibitory factor (LIF). To examine reprogramming activity in $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS, we plated the MBNS in ES culture conditions and monitored ES-like colony formation morphologically and quantified colonies expressing the ES cell marker alkaline phosphatase (AP) (Figure 2-3a).
Figure 2-3 MBNS exhibit growth as alkaline phosphatase-positive colonies in ES cell culture conditions.

(a) Schematic of the in vitro assay for plasticity, in which $P{\text{t}}ch1^{LacZ/+};Trp53^{-/-}$ MBNS cells were plated in low density (1500 cell/ml) in ES cell culture conditions containing serum, mouse embryonic fibroblast (MEF) feeders, and leukemia inhibitory factor (LIF). Control conversion experiments were carried out with primary cerebellar neurospheres (NS) enriched from postnatal day 5 (P5) and day 7 (P7) wild-type (WT) and P5 $P{\text{t}}ch1^{LacZ/+};Trp53^{-/-}$ (Ptc-/-; p53-/-) cerebella. (b) Phase-contrast image of a $P{\text{t}}ch1^{LacZ/+};Trp53^{-/-}$ MBNS grown in suspension culture. (c) Phase-contrast image of adherent MBNS colony formation in ES culture conditions, 6 days post-plating. (d) Adherent MBNS colonies in ES culture conditions stained for ES cell marker, alkaline phosphatase (AP). (e) Homogenously AP-positive clones were identified and quantitated from five independent conversion experiments with the $P{\text{t}}ch1^{LacZ/+};Trp53^{-/-}$ MBNS line. There was no observable colony formation with the cerebellar neurospheres.
The \( Ptc\ell^{LacZ/+};Trp53^{-/-} \) MBNS, which are maintained in media containing bFGF and EGF (Figure 2-3b) were dissociated and plated at low-density (1500 cells/ml) in ES cell culture conditions. Within 6 days, colonies with an ES cell-like morphology were observed and AP-positive staining was observed at a frequency of 2.3±3.2% (Figure 2-3c, d). By contrast, control CbSC also enriched by NS culture from wild-type (WT) postnatal day 5 and day 7 mice or postnatal day 7 \( Ptc\ell^{LacZ/+};Trp53^{-/-} \) mice yielded no colonies in this assay (Figure 2-3e), suggesting a tumor-specific plasticity and resistance to differentiation allowing for the growth and maintenance of self-renewal in ES conditions.

The MBNS colonies from this conversion assay were clonally expanded and generated subclones that retained ES colony morphology and maintained stable AP expression for more than 15 passages (passage 7 subclone is shown in Figure 2-4a). The AP\(^+\) MBNS also showed strong X-Gal staining from the \( Ptc\ell^{LacZ} \) allele (Figure 2-4a), likely due to the loss of heterozygosity of the WT \( Ptc\ell \) allele (C. Lin thesis). To further determine if the phenotypic plasticity of the \( Ptc\ell^{LacZ/+};Trp53^{-/-} \) MBNS, as exhibited by the conversion of MBNS into AP\(^+\) colonies in ES culture conditions \textit{in vitro}, expanded the developmental potency of these cells, we examined the gene expression of pluripotency and reprogramming genes \textit{Oct4} and \textit{Nanog}. Stochastic expression of \textit{Oct4} was observed in one AP\(^+\) MBNS subclone and \textit{Nanog} expression was present in the parental MBNS and maintained in the AP\(^+\) MBNS (Figure 2-4b). In contrast, the \( Ptc\ell^{LacZ/+};Trp53^{-/-} \) tumors had undetectable or relatively lower levels of \textit{Oct4} and \textit{Nanog}, respectively.

To test if the phenotypic conversion in ES conditions and stochastic \textit{Oct4} expression led to an expanded developmental potency of the MBNS \textit{in vivo}, teratoma assays were carried out by
Figure 2-4 AP⁺ MBNS subclones maintain ES-like morphology and exhibit stochastic expression of pluripotency genes

(a) AP and X-Gal stain of $Ptch1^{LacZ/}^{+};Trp53^{−/−}$ ES cells and AP⁺ MBNS subclone (passage 7). (b) RT-PCR of bulk $Ptch1^{LacZ/}^{+};Trp53^{−/−}$ tumors, MBNS, and AP⁺ MBNS shows sporadic expression of pluripotency factor Oct4 in the AP⁺ MBNS. Nanog expression is present in the parental MBNS line and maintained in the AP⁺ MBNS. NuBP (Nucleotide binding protein) is shown as a loading control.

the injection of $10^6$ $Ptch1^{LacZ/}^{+};Trp53^{−/−}$ MBNS and AP⁺ MBNS cells into the flanks of nude mice and monitored for tumor formation, using $Ptch1^{LacZ/}^{+};Trp53^{−/−}$ ES cells as a control. While intracerebellar injections of $10^4$ $Ptch1^{LacZ/}^{+};Trp53^{−/−}$ MBNS led to robust tumor formation causing morbidity by six weeks, the subcutaneous injection of $10^6$ MBNS and AP⁺ MBNS cells resulted in small tumors, all of which were significantly smaller than the ES-derived teratomas (Figure 2-5).

Histological analyses showed that the $Ptch1^{LacZ/}^{+};Trp53^{−/−}$ ES cell-derived teratomas (n=3) were predominantly composed of immature neuroectodermal cells and marked by neuroblasts, but displayed no evidence for endoderm or mesodermal cell types. Nonetheless, the ES-derived tumors exhibited the greatest cell type-diversity between the three cell types injected (Figure 2-6). Tumors formed by subcutaneous injection of the MBNS (n=5) were also neuroblastic in nature, but was comprised of more mature, intermediate-sized cells with vacuoles
Figure 2-5 \( \text{AP}^+ \) MBNS cells do not form teratomas as robustly as ES cells

(a) X-gal stained tumors dissected from the flanks of nude mice subcutaneously injected with \(10^6\) MBNS, \( \text{AP}^+ \) MBNS, or \( P\text{tch}^{1\text{lacZ}+/}, Trp53^{-/-}\) ES cells. Tumors were isolated 3 weeks post-injection. (b) \( P\text{tch}^{1\text{lacZ}+/}, Trp53^{-/-}\) ES-derived tumors were significantly larger than the MBNS and \( \text{AP}^+ \) MBNS tumors (p<0.01 by one-way ANOVA with a Bonferroni post test). (c) After measuring the length (mm) and width (mm) of the tumors, tumor volume (mm\(^3\)) was calculated by length x width x width. The volumes of the ES-derived tumors were significantly higher than the MBNS tumors (p<0.01) and \( \text{AP}^+ \) MBNS tumors (p<0.05 by one-way ANOVA with a Bonferroni post test). Average weight and volume of isolated tumors are represented as mean±sem.

(Figure 2-6). Interestingly, the \( \text{AP}^+ \) MBNS-derived tumors (n=5) displayed an intermediate histology, with a predominance of immature hyperchromatic, nucleolated cells with scant cytoplasm that form sheets and rests. Interspersed between this major cell population, however, were more mature regions resembling the cells predominantly present in the MBNS-derived
tumors. While there is no evidence of acquired pluripotency in the AP⁺ MBNS, which display a phenotypic adaptation in the ES culture conditions, these results suggest that the AP⁺ MBNS are able to exhibit a cellular plasticity to initiate distinct tumors less differentiated than the MBNS-derived tumors.

Figure 2-6 AP⁺ MBNS-derived teratomas are histologically distinct from the parental MBNS-derived tumors

Representative images of H&E stained sections of tumors isolated from the teratoma assay, carried out by injecting $10^6$ MBNS (n=5), AP⁺ MBNS (n=5) or $\text{Ptc}h^1\text{LacZ}^+;\text{Trp}53^−$ ES cells (n=3) into the flanks of nude mice and monitored for tumor formation for 3 weeks, are shown. Mature, intermediate sized cells with cytoplasmic vacuoles are indicated with the yellow arrowheads in both the MBNS and AP⁺ MBNS teratomas. The major cell type in the AP⁺ MBNS teratomas, which are the hyperchromatic cells with scant cytoplasm are observed in the left half of the represented AP⁺ MBNS image and cells in the right half are more histologically similar to the MBNS-derived tumors. A neuroectodermal structure is indicated with the black arrow in the ES teratoma. Scale bars are 100um.
**Klf4 mediates MBNS plasticity during conversion into ES culture conditions**

Since the MBNS were converted in ES culture conditions without the induction of exogenous genes, we wanted to determine if epigenetic changes were involved in mediating the MBNS plasticity. We analyzed DNA methylation in the promoters and 5' regulatory regions of pluripotency genes Oct4, Nanog, Klf4, Sox2, c-myc and Stat3 with a quantitative, bisulfite-based mass spectrometry methylation assay. In cancers, methylation alternations have been reported to occur specifically in CpG island shores, located up to 2kb upstream of the promoter CpG islands and are associated with aberrant gene expression (Irizarry et al., 2009). The average methylation frequency across the CpGs in the regions assayed was significantly different between the MBNS and AP+ MBNS in the Klf4 and Sox2 CpG island shores. The most significant differential methylation was observed in the Klf4 CpG island shore, with 70.7% methylation in the MBNS and a reduction to 34.2% in the AP+ MBNS (Figure 2-7). Reduced methylation was observed in each individual CpG in this Klf4 regulatory region in the AP+ MBNS (Figure 2-8). CpG methylation in the Sox2 CpG island shore was also reduced in the AP+ MBNS compared to the MBNS, to a lesser degree (40.9% in the MBNS vs. 30.7% in the AP+ MBNS). The CpG islands directly upstream of the transcriptional start site (TSS) in the Klf4 and Sox2 promoters were not analyzed by the methylation assay. The average methylation remained unchanged in the other pluripotency genes, as the promoters of c-myc and Stat3 remained hypomethylated and Nanog remained hypermethylated. The levels of CpG methylation in the Oct4 promoter also remained similar between the MBNS and the AP+ MBNS. These results suggest a plasticity in the epigenetic regulation of the CpG island shores of the pluripotency genes Klf4 and Sox2 during the conversion of MBNS into ES culture conditions.
Figure 2-7 CpGs in the 5’ regulatory regions of Klf4 and Sox2 are differentially methylated between the MBNS and AP+ MBNS

(a) Methylation analyses of the CpGs in the promoters and 5’ regulatory regions of pluripotency genes were carried out by quantitative mass spectrometry, in the parental MBNS line and three AP+ MBNS subclones. Average methylation frequencies across the regions analyzed are plotted as mean±sem. Differential methylation is observed in the 5’ regulatory regions between the MBNS and the AP+ MBNS in Klf4 (p<0.0001) and Sox2 (p<0.01), as determined by two-way ANOVA with a Bonferroni multiple comparisons test. In the right panel, a schematic of the promoter and upstream regions of the pluripotency genes indicating the locations of the CpGs analyzed (vertical hash marks) is represented. The methylation analyses for Klf4 and Sox2 only included the CpGs in the 5’ regulatory regions (CpG island shores), as indicated by the black bars.
Figure 2-8 Quantitative methylation analyses of individual CpGs in the 5’ regulatory regions and promoters of pluripotency genes in MBNS and AP+ MBNS show differential methylation in Klf4 and Sox2

The frequency of methylation at each CpG analyzed is denoted by circles (MBNS) or open squares (AP+ MBNS). Genomic coordinates are indicated on the x-axis. Vertical hashes in the Klf4 and Sox2 promoters indicate CpGs that were not analyzed in the methylation array.
Figure 2-9 Klf4 mediates MBNS plasticity for conversion into ES culture conditions

(a) Expression analyses of Klf4 and Sox2 by gel-based RT-PCR. (b) Schematic of the lentiviral vector pSicoR (Ventura et al., 2004), which was modified for puromycin selection (Puro\textsuperscript{R}) and shRNA expression driven by a ubiquitin (Ub) promoter. (c) Klf4 knockdown (kd) MBNS were converted into ES cell culture conditions and monitored for AP\textsuperscript{+} colony formation, as described in Figure 2-3a. (d) Significant reduction in AP\textsuperscript{+} colony formation is observed in the shKlf4 MBNS (p=0.018 by unpaired t-test). Representative images of AP\textsuperscript{+} colonies formed are shown.

Klf4 expression is reported to abrogate the requirement for LIF to maintain mouse ES cells in an undifferentiated state (Zhang et al., 2010) and gel-based RT-PCR confirmed the expression of Klf4 transcript in the AP\textsuperscript{+} MBNS, as well as the parental MBNS (Figure 2-9a). Although not quantitative, Klf4 was also further examined because Sox2 expression appeared to be reduced in the AP\textsuperscript{+} MBNS (Figure 2-9a). Therefore, we next asked if exogenous LIF in the ES media was required for the initiation and the maintenance of the AP\textsuperscript{+} MBNS colony formation. To determine if exogenous LIF was required for the initiation of the conversion in the ES culture condition, we carried out the in vitro reprogramming assay in the presence and
absence of LIF with an AP⁺ MBNS subclone and observed no significant difference in the AP⁺ colony formation (Figure 2-10a, b). However, in the absence of MEFs, which is known to provide soluble factors including LIF, while clusters of cells were present, no AP⁺ colony formation was observed. To test if exogenous LIF was necessary for the maintenance of self-renewal and colony formation, a clonogenic plating efficiency assay was carried out in the presence and absence of exogenous LIF. AP⁺ colony formation was not affected by the removal of exogenous LIF (Figure 2-10c,d). When we further eliminate a potential source of LIF by

![Image](image_url)

**Figure 2-10 Exogenous LIF is not required for the conversion or maintenance of MBNS in ES cell conditions**

(a) The conversion of MBNS into ES cell culture conditions was carried out in the presence and absence of both LIF and MEFs. (b) Quantification of AP⁺ colony formation shows no observable colony formation in the absence of MEFs. With MEFs, no significant difference is observed in the AP⁺ colony formation with or without LIF. (c) A stable AP⁺ MBNS subclone line was assayed for clonogenic plating efficiency in the absence and presence LIF and/or MEFs. (d) AP-positive colonies were quantitated by ImageJ analyses, which show no significant difference in colony formation in the absence of LIF.
carrying out the plating efficiency assay in the absence of MEFs, although the overall frequency of colony formation was reduced, no significant difference was observed in the frequency of colony formation in the absence of LIF (Figure 2-10c, d).

To test if the expression of Klf4 (Figure 2-9a) was functionally involved in the plasticity of the MBNS during the conversion into ES culture conditions, we knocked down Klf4 with a lentivirally-encoded shRNA against Klf4 (Figure 2-9b; Table 1) and 3 days post-infection, the in vitro reprogramming assay was carried out (Figure 2-9c). AP+ MBNS colony formation was significantly reduced with the Klf4 knockdown (kd) (Figure 2-9d), suggesting that Klf4 was functionally important in mediating MBNS plasticity and colony formation in ES culture conditions.

Table 1. Hairpin sequences of shKlf4

<table>
<thead>
<tr>
<th>Position</th>
<th>Sequence</th>
<th>DSIR score</th>
<th>Oligomaker Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>shKlf4 #1 839</td>
<td>GCAGCTTGCAGCAGTAACA</td>
<td>NA</td>
<td>7</td>
</tr>
<tr>
<td>shKlf4 #2 2797</td>
<td>GGTTCAGATGTGCAATAA</td>
<td>100.3</td>
<td>7</td>
</tr>
</tbody>
</table>

Position indicates the first nucleotide position site where the shRNA binds in the target sequence. Scores as determined by two rule-based design algorithms, DSIR (http://biodev.extra.cea.fr/DSIR/) and pSicoOligomaker 1.5 (http://web.mit.edu/jacks-lab/protocols/pSico.html). The predicated efficacy threshold value is set at 90 in DSIR. A Oligomaker score of greater than 6 is reported to have ~90% chance of silencing the target (Reynolds et al., 2004).

Klf4 is important for the self-renewal of MBNS

As Klf4 expression is also observed in the parental MBNS prior to conversion into ES conditions (Figure 2-9a), we next examined the role of Klf4 directly in the MBNS. Quantitative RT-PCR shows that Klf4 expression is significantly increased in the MBNS compared to WT cerebellum (Cb), Ptch1LacZ/+ , and Ptch1LacZ/+;Trp53−/− tumors, with a 2.3 fold enrichment compared to the WT Cb (Figure 2-11a). To directly test the functional role of Klf4 in the MBNS, we knocked down Klf4 with two independent hairpins (Table 1), to levels 20-40% of the control levels (Figure 2-11b) and carried out a clonal density NS formation assay, in which shKlf4
Figure 2-11 Klf4 kd leads to a reduction in MBNS self-renewal

(a) Expression of Klf4 mRNA is significantly upregulated in the MBNS compared to wild-type cerebellum (WT Cb), Ptc1LmZI+ tumors (Ptc Tu), and Ptc1LmZI+/Trp53−/− (Ptc:p53 Tu), as measured by quantitative RT-PCR (p<0.05 by one-way ANOVA with a Bonferroni post test). (b) Expression analyses of Klf4, Stat3 in the d3 post-infection shKlf4 MBNS by quantitative RT-PCR confirm kd of Klf4 with two independent hairpins (n=3; p<0.001 by one-way ANOVA with a Dunnett post test). shKlf4#1 does not affect the expression of Stat3 but shKlf4#2 reduces Stat3 expression by about 25% (p<0.01 by two-way ANOVA with a Dunnett post test). (c) Klf4 kd resulted in the significant reduction of self-renewal in the clonal density (100 cell/ml) 6-well NS formation assay. The efficiency of NS formation was expressed relative to the vector control. (n=3; 6 wells quantified per shRNA per experiment; p<0.001 by one-way ANOVA with a Dunnett post test). Representative images of wells from the NS formation assay quantitated by ImageJ are shown. (d) Clonogenic limiting dilution assays (Tropepe et al., 1999) were carried out and self-renewal indexes of the shKlf4 MBNS were determined by extreme limiting dilution analysis (ELDA) (Hu and Smyth, 2009). 95% confidence intervals (CI) are indicated by the dotted lines. P-values are determined by tests for pair-wise differences between the vector control and each of the shRNAs by ELDA. All values are represented as mean±s.e.m.
Figure 2-11 (Continued)

(a) Klf4

Fold change in expression (relative to WT Cb)

<table>
<thead>
<tr>
<th></th>
<th>Cb</th>
<th>Tu</th>
<th>Tu MBNS</th>
<th>WT</th>
<th>Ptc</th>
<th>Ptc; p53</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genes</td>
<td></td>
<td></td>
<td></td>
<td>n=4</td>
<td>n=5</td>
<td>n=5</td>
</tr>
</tbody>
</table>

(b) Relative Expression (% of control)

<table>
<thead>
<tr>
<th></th>
<th>Empty</th>
<th>#1 shKlf4</th>
<th>#2 shKlf4</th>
<th>Empty</th>
<th>#1 shKlf4</th>
<th>#2 shKlf4</th>
</tr>
</thead>
</table>

(c) 100 cells/ml

Efficiency of NS formation (%)

<table>
<thead>
<tr>
<th></th>
<th>Empty</th>
<th>#1</th>
<th>#2</th>
<th>shKlf4</th>
<th>#1</th>
<th>#2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(d) Limiting Dilution

log fraction nonresponding

dose (number of cells/well)

Empty = 1/7.6
shKlf4 #2 = 1/16.9 (p=6.2e-12)
shKlf4 #1 = 1/29.4 (p=2.8e-28)
MBNS were plated at a cell density of 100 cells/ml, a density ten-fold lower than what is required to ensure a clonal event (Coles-Takabe et al., 2008). When NS formation was quantified 5 days later, *Klf4* kd resulted in a 50-65% reduction in the efficiency of NS formation in the MBNS (Figure 2-11c). The role of *Klf4* in MBNS self-renewal was further confirmed with a limiting dilution assay, where 0.3, 1, 3, 10, and 30 cells were plated per well and assayed for NS formation to determine the frequency of self-renewing cells in the sh*Klf4* MBNS (Tropepe et al., 1999). Extreme limiting dilution analyses (ELDA) (Hu and Smyth, 2009), determined that the self-renewal index was significantly decreased, from 1 in 7.6 cells in the control vector to 1 in 29.4 cells with sh*Klf4* #1 and 1 in 16.9 cells with sh*Klf4* #2 (Figure 2-11d; Table 1). Together, these results support the crucial role of *Klf4* in the mediating MBNS plasticity during conversion into ES culture conditions and in the maintenance of clonogenic self-renewal as neurospheres.

**Stat3 signaling is endogenously activated in MBNS**

To further gain an understanding of the upstream pathways activating *Klf4* expression in the MBNS, we asked if the Stat3 pathway was involved, as *Klf4* is a known downstream target of Stat3 (Niwa et al., 2009; Bourillot et al., 2009; Hall et al., 2009). Furthermore, given that exogenous LIF was not required for the initiation and maintenance of the AP+ MBNS (Figure 2-10), we also hypothesized that downstream Stat3 signaling may be endogenously activated or deregulated in the MBNS and subsequently mediating the expression of *Klf4* downstream. Stat3 pathway activation is also known to maintain the self-renewal of ES cells (Niwa et al., 1998) and the survival of NSC (Androutsellis-Theotokis et al., 2006; Yoshimatsu et al., 2006).

Since *Stat3* expression is modulated by an autoregulatory loop (Ichiba et al., 1998) and increased levels of *Stat3* mRNA reflect Stat3 pathway activity, we first compared *Stat3* mRNA
expression among tissues and stem cells from WT or Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} mice using quantitative RT-PCR. Stat3 expression in the MBNS was greater than 20-fold higher than the WT Cb and significantly higher compared to Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} ES cells and tumors (Figure 2-12a). Stat3 mRNA levels also showed a 15-fold increase in WT P7 CbSC compared to the WT P7 cerebella, consistent with the known developmental role of Stat3 in NSC. The expression levels between the WT P7 CbSC and MBNS, however, were not significantly different, suggesting that Stat3 upregulation alone is not sufficient for AP\textsuperscript{+} colony formation in ES conditions.

![Graph showing Stat3 expression](image)

**Figure 2-12 Stat3 is endogenously activated in MBNS**

(a) Expression of Stat3 mRNA in Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} (Ptc;p53) ES (n=3) cells, MBNS (n=8), WT P7 cerebellar stem cells (WT P7 1\textsuperscript{°}NS) (n=5), and Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} (Ptc;p53) tumors (n=5) compared to wild-type cerebellum (WT Cb) (n=4), as measured by quantitative RT-PCR. All samples are represented as fold change in expression relative to the WT Cb, which is normalized to 1. Significant upregulation of Stat3 is observed in the MBNS compared to Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} ES cells (p<0.01), WT Cb (p<0.001), Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} tumor (p<0.001). Stat3 is upregulated in the WT P7 1\textsuperscript{°}NS compared to the WT cerebellum (p<0.05), Ptc1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} tumor (p<0.05). Statistical significance was determined by one-way ANOVA with a Bonferroni post test. (b) Western blot of protein lysates from MBNS in NS media, AP\textsuperscript{+} MBNS in ES culture conditions, tissues from WT Cb, and Ptc;p53 tumors with pSer727, pTyr705, and total Stat3-specific antibodies. ES cells were used as a positive control for Stat3 activation.
Stat3 pathway activation is directly governed by phosphorylation states, such as in NSC, where pSer727 is essential for survival and pTyr705 leads to differentiation (Androutsellis-Theotokis et al., 2006). To address whether alterations in Stat3 phosphorylation might account for the relative contribution of these mechanisms in MBNS, we performed western blotting with phospho-specific Stat3 antibodies. The results showed activation of both phosphorylated forms of Stat3 in the MBNS cultured in NS media and ES conditions, with robust activation of pSer727 Stat3 (Figure 2-12b). WT Cb and PtcΔ1LacZ;Trp53-/- tumors, however, showed relatively lower levels of pSer727 and total Stat3. These results show that the Stat3 signaling pathway is constitutively activated in the MBNS, as indicated by both transcriptional upregulation and activation of Stat3 by phosphorylation, especially at pSer727.

To assess the signaling pathways involved in the constitutive Stat3 pathway activation, we treated MBNS with kinase inhibitors with targets implicated in medulloblastoma stem cells (Hambardzumyan et al., 2008), the activation of Stat3 signaling in cortical NSC (Androutsellis-Theotokis et al., 2006), as well as Stat3 phosphorylation in other cellular contexts (Stephens et al., 1998; Yokogami et al., 2000; Wierenga et al., 2003) (Figure 2-13). Activation of PI3K/Akt/mTOR signaling confers radioresistance and survival to medulloblastoma cells in the perivascular niche (Hambardzumyan et al., 2008). In cortical NSC, Notch signaling also converges on Akt/mTOR pathway activation for subsequent phosphorylation of Ser727 Stat3 and NSC survival (Androutsellis-Theotokis et al., 2006). Human medulloblastomas have constitutive activation of Stat3 signaling (Schaefer et al., 2002), as well as autocrine production of LIF, a major activator of the Jak/Stat signaling pathway (Liu et al., 1999). While Mek1/2 inhibition has been observed to inhibit the migration of a medulloblastoma cell line in vitro (MacDonald et al., 2001), the involvement of Stat3 has not been examined.
Figure 2.13 Pathways of Stat3 activation and kinase inhibitors used for the treatment of MBNS

Schematic showing the differential roles of phospho-Ser727 Stat3 in survival and phospho-Tyr705 Stat3 in the differentiation of NSC, adapted from Androutsellis-Theotokis, Leker et al. (2006). MBNS were treated with small molecule inhibitors of kinases implicated in the activation of pStat3.

Consistent with canonical Stat3 activation, Jak inhibition robustly reduced pTyr705 Stat3 activation without affecting pSer727 Stat3 levels (Figure 2.14a, b). By contrast, Mek1/2 inhibition, validated by monitoring pErk1/2 levels (Figure 2.14a), caused a modest but significant and reproducible 30% decrease in pSer727 Stat3 levels (Figure 2.14a, b). Inhibitors of PI3K or mTOR did not significantly alter either pSer727 or pTyr705 levels. Analysis of Stat3 target gene expression confirmed these results, with Jak inhibition showing reduced Socs3 and Stat3 levels within 20 hours (Figure 2.14c). Socs3, a direct target of Stat3, is a key response gene in Stat3 signaling (Auernhammer et al., 1999) and Stat3 regulates its own expression (Ichiba et al., 1998). At 20 hours, however, expression levels of the downstream target Klf4 (Hall et al., 2009; Bourillot et al., 2009) were not affected. These results suggest distinct roles for Jak and Mek signaling pathways during Stat3 activation in MBNS.
Figure 2-14 pTyr705 and pSer727 Stat3 are differentially regulated by Jak and Mek signaling in the MBNS

(a) Western blot of protein lysates from MBNS treated with inhibitors of PI3K (10uM LY294002), Mek1/2 (10uM U0126), mTOR (50nM Rapamycin) and Jak (1uM Jak inhibitor 1) for 3 hours. A representative western blot from three experiments is shown. (b) Quantification of three independent western blots by densitometry analyses with ImageJ shows significant reduction of pSer727 Stat3 with Mek inhibition (p<0.0001) and pTyr705 Stat3 with Jak inhibition (p<0.01). (c) Expression analyses of Stat3 and downstream targets Socs3 and Klf4, by quantitative RT-PCR, 20 hours post-inhibitor treatment show that Stat3 expression is significantly increased with mTOR inhibition (p<0.01) and decreased with Jak inhibition (p<0.05). Socs3 expression is significantly decreased with Jak inhibition (p<0.01). Klf4 expression is not significantly altered with the treatment of any inhibitors. Statistical significance was determined by one-way ANOVA with a Dunnett post test

Combination Jak and Mek inhibition leads to the reduction of MBNS survival

To further inhibit both phosphorylated forms of Stat3, we treated the MBNS with both the Jak inhibitor and Mek inhibitor (U0126), which we have shown to modulate Tyr705 and pSer727 Stat3 phosphorylation, respectively. Combination Mek and Jak inhibitor treatment for 20 hours resulted in the downregulation of both phosphorylated forms of Stat3 (Figure 2-15a). When the functional impact of the inhibition of the Mek and Jak pathways was assessed with the clonal neurosphere formation assay, we observed that individually, Mek or Jak pathway
inhibition did not affect neurosphere formation of the MBNS (Figure 2-15b, c). However, the combinatory inhibition of Mek and Jak inhibitors significantly reduced neurosphere formation and the size of neurospheres formed (Figure 2-15c, d). Together these data reveal that modulation of both phosphorylated forms of Stat3 using a combinatoric treatment of Mek and Jak inhibitors inhibits MBNS formation.

Figure 2-15 Combinatory treatment of Jak and Mek inhibitors leads to a synergistic reduction in MBNS self-renewal and size

(a) Western blot of MBNS protein lysates after Mek, Jak, and Mek+Jak inhibitor treatment for 3 hours. (b) Clonal neurosphere formation assays were carried out in the presence of inhibitors of Mek (10uM U0126), Jak (1uM Jak inhibitor 1), or both Mek and Jak (10uM U0126 and 1uM Jak inhibitor 1) for 7 days, with drug supplementation on day 3. (c) Significant reduction of NS formation is observed with the combination treatment of Mek and Jak inhibitors (p<0.001 by one-way ANOVA with a Bonferroni post test). (d) Combination drug treatment also resulted in smaller NS. NS diameters were measured from 60 NS per treatment condition.
MBNS self-renewal is, in part, mediated by Stat3, but less significant than the role of Klf4

As the kinase inhibitors are not specific to Stat3 and likely affecting many other pathways, to examine the functional role of Stat3 upregulation in MBNS in a more specific manner, we constructed lentiviral vectors encoding two independent shRNAs (Reynolds et al., 2004) against Stat3 (Table 2). Western blotting validated Stat3 kd at the protein level by day 8 (d8) post-infection (Figure 2-16a) and time course analysis of Stat3 mRNA expression also showed a stable kd throughout day 3 (d3) to day 15 (d15) post-infection. Kd was maintained at about 20% of control levels in the Stat3 kd bulk cultures, which are seeded at a density of 2-3x10^5 cell/ml (Figure 2-16b). The downstream effect on Stat3 target, Klf4, was observed by day 8 (d8). However, we also noted that Klf4 mRNA expression rebounded to WT levels by d15 post-infection. To determine the functional role of Stat3 in MBNS self-renewal, on d3 following lentiviral infections, MBNS were plated at clonal density (100 cells/ml) in vitro and we observed about a 50% reduction in neurosphere formation compared to the vector control (Figure 2-16c).

Similar to the shKlf4 MBNS, limiting dilution assays were carried out to determine the frequency of self-renewing cells in shStat3 MBNS and extreme limiting dilution analyses (ELDA) showed that self-renewing indexes decreased from 1 in 5.1 cells in the control to 1 in 10.5 and 1 in 7.3 in the shStat3 #1 and #2 MBNS, respectively (Figure 2-16d). However, the effect on Stat3 kd on MBNS self-renewal was less significant than the Klf4 kd. These effects are more apparent when the ELDA was carried out by combining the data from limiting dilution assays from both Stat3 and Klf4 kd MBNS (Table 3). These results show that MBNS self-renewal depends, in part, on Stat3, an upstream activator of Klf4.
**Figure 2-16 Stat3 kd leads to a reduction in MBNS self-renewal**

(a) Western blot of protein lysates from d8 post-infection shStat3 MBNS with total and pSer Stat3 antibodies confirmed Stat3 kd with 2 independent shRNA hairpins. (b) A time course-dependent effect on Stat3 kd and downstream target Klf4 was measured by quantitative RT-PCR in d3, d8, and d15 post-infection shStat3 bulk cultures. (c) Stat3 kd resulted in significant reduction of self-renewal in the clonal density (100 cell/ml) 6-well NS formation assay. The efficiency of NS formation was expressed relative the vector control. (n=4 for shStat3 #1, n=3 for shStat3 #2; 6 wells quantified per shRNA per experiment; p<0.001 by one-way ANOVA with a Dunnett post test). Representative images of wells from the NS formation assay quantitated by ImageJ are shown. (d) A clonogenic limiting dilution assay (Tropepe et al. 1999) was carried out and self-renewal indexes of the shStat3 MBNS were determined by extreme limiting dilution analysis (ELDA) (Hu and Smyth, 2009). P-values are determined by tests for pair-wise differences between the vector control and each of the shRNAs by ELDA. 95% confidence intervals are indicated by the dotted lines. All values are represented as mean±s.e.m.
Table 2. Hairpin sequences of shStat3

<table>
<thead>
<tr>
<th>Position</th>
<th>Sequence</th>
<th>DSIR score</th>
<th>Oligomaker score</th>
</tr>
</thead>
<tbody>
<tr>
<td>shStat3 #1</td>
<td>GCAGGATCTAGAAGACAGAAA</td>
<td>99.4</td>
<td>7</td>
</tr>
<tr>
<td>shStat3 #2</td>
<td>GGAGCTGTTCAGAAGACTTA</td>
<td>101</td>
<td>7</td>
</tr>
</tbody>
</table>

Position indicates the first nucleotide position site where the shRNA binds in the target sequence. Scores as determined by two rule-based design algorithms, DSIR (http://biodev.extra.cea.fr/DSIR/) and pSicoOligomaker 1.5 (http://web.mit.edu/jacks-lab/protocols/pSico.html). The predicted efficacy threshold value is set at 90 in DSIR. A Oligomaker score of greater than 6 is reported to have ~90% chance of silencing the target (Reynolds et al., 2004).

Table 3. Statistical analyses of extreme limiting dilution analyses (ELDA) of Stat3 and Klf4 kd MBNS self-renewal

<table>
<thead>
<tr>
<th>Number of cells/well</th>
<th>Number of positive well/total wells plated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Empty</td>
</tr>
<tr>
<td>30</td>
<td>191/192</td>
</tr>
<tr>
<td>10</td>
<td>156/192</td>
</tr>
<tr>
<td>3</td>
<td>72/192</td>
</tr>
<tr>
<td>1</td>
<td>36/192</td>
</tr>
<tr>
<td>0.3</td>
<td>17/192</td>
</tr>
</tbody>
</table>

NS formation frequency (95% CI) (1/6.97-1/5.60) (1/12.32-1/8.97) (1/9.26-1/5.83) (1/35.7-1/24.2) (1/19.97-1/14.26)

Overall test for differences in stem cell frequencies

P value 7.66E-58

Pairwise test for differences in stem cell frequencies

| Empty vs. shStat3 #1 | Pr (>Chisq) | 8.27E-08 |
| Empty vs. shStat3 #2 | Pr (>Chisq) | 0.241 |
| Empty vs. shKlf4 #1  | Pr (>Chisq) | 6.84E-53 |
| Empty vs. shKlf4 #2  | Pr (>Chisq) | 4.54E-25 |

Stem cell frequencies, 95% confidence intervals, and statistical tests for significance between stem cell frequencies were determined by the ELDA webtool (http://bioinf.wehi.edu.au/software/elda/).

Klf4 levels rebound in a Stat3-independent manner in clonally derived shStat3 MBNS

The partial inhibition of MBNS self-renewal in Stat3 kd cells suggested the potential for a Stat3-independent, compensatory mechanism for the maintenance of self-renewal in clonal cultures. To rule out the possibility that the surviving d8 Stat3 kd MBNS in the clonal neurosphere formation assay was not due to loss of expression of the Stat3 hairpins or another RNAi escape mechanism, we examined Stat3 expression in shStat3 MBNS that emerged from the clonal NS formation assay (Figure 2-17a). Stat3 kd was maintained at levels significantly lower than the controls in both the clonally derived shStat3 NS and the higher-density bulk cultures at d8 (Figure 2-17b). However, supporting the role for Klf4 in self-renewal as described above, we observed Klf4 expression rebounding to levels greater than WT levels in the surviving shStat3 NS derived from the clonal density cultures, but remained decreased as a secondary
effect of Stat3 kd in the high-density bulk cultures (Figure 2-17b). The clonogenic neurosphere assay assesses the cell-intrinsic ability for self-renewal and survival under stringent, clonogenic conditions. In contrast, higher-density bulk cultures may contain a heterogeneous population of cells, including differentiating cells remaining in NS as a result of cell aggregation that may not require Klf4 expression for survival. Furthermore, cell-to-cell contact or secretion of other paracrine growth factors by a heterogeneous population of cells may also be involved in supporting the growth or self-renewal of cells in the bulk cultures. In fact, in adult hippocampus NSC, bFGF alone does not support the mitogenic activity in low density cultures; high density cultures are required for the sufficient production of a necessary autocrine/paracrine cofactor (Taupin et al., 2000). These results suggest that a Stat3-independent upregulation of Klf4 is associated with the maintenance of clonogenic MBNS self-renewal.

Figure 2-17 Klf4 expression rebounds in Stat3-independent manner in clonal density

(a) Experimental timeline of the Stat3 kd in the MBNS and the distinct clonal and bulk shStat3 cultures obtained for analyses. Following antibiotic selection of lentivirally infected MBNS, shStat3 MBNS were assayed for Stat3 knockdown, self-renewal in clonal density (100 cells/ml) cultures, or passaged for maintenance in bulk culture (2-3 x 10^5 cells/ml) on d3 post-infection. (b) Expression analyses of Stat3 and Klf4 in self-renewing NS derived from the d8 post-infection shStat3 bulk (2-3 x 10^5 cells/ml) and clonal density (100 cells/ml) cultures show a significant upregulation of Klf4 in the low-density cultures (p<0.001 for shStat3 #1; p<0.0001 for shStat3 #2), while Stat3 kd is maintained at significant low levels (p<0.0001). Statistical significance was determined by a one-way ANOVA with a Dunnett post test.
**Stat3 and Klf4 independently regulate the expression of Stat3-target survival genes**

As a survival mechanism for cancer cells, *Klf4* has been reported to suppress the apoptotic response of cancer cells following DNA damage (Ghaleb *et al.*, 2007). Stat3 also has known roles in survival by directly regulating the expression of anti-apoptotic target genes including survivin (Gritsko *et al.*, 2006), *Bcl-x* (Catlett-Falcone *et al.*, 1999), *Mcl1* (Epling-Burnette *et al.*, 2001), all of which have been reported to be aberrantly expressed or activated and involved in conferring resistance to apoptosis in various tumor types (Ambrosini *et al.*, 1997; Hazan-Halevy *et al.*, 2010). When we examined the promoter regions of the Stat3-target survival genes, as expected, Genomatix promoter analyses identified Stat3-binding motifs (Figure 2-18a, b, c) within the promoter regions of survivin, *Bcl-x* and *Mcl1* (Figure 2-18c, 19, 20).

Interestingly, we also observed predicted Klf4-binding sites (Figure 2-18b) in close proximity to the Stat3-binding sites, further validated by analyzing ChIP-Seq datasets from published studies (Figure 2-18c).

![Figure 2-18 Binding site motifs of Stat3 and Klf4 and overview of binding sites in the Stat3-target survival gene promoters as determined by Genomatix](image)

(a-b) The binding motifs have been identified by Genomatix by weight matrices containing 375 binding sites for Stat3 and 355 binding sites for Klf4 from ChIP-Seq data from Chen *et al.* 2008. (c) Schematic of the survivin, *Bcl-x*, and *Mcl1* promoters with locations of predicted Stat3 and Klf4-binding sites. The binding positions indicate the position of anchor sequence (center position) of the predicted binding sites in relation to the transcriptional start site (+1). Analyses of ChIP-Seq data by TRANSFAC showed Klf4 binding to the survival gene promoters in ES cells.
Mcl-1 Promoter

-500 TAACCTTTAA GCAATCAAT GTGAATATT CTTTGTGTA TGAGACTGGA GATGCCCTCC
-440 CTGGTTTGCT CTTCAGGGGT ATTAACCTCA GCACTCCACT GGAGGCAGGC ACACAACCC

Stat3 binding site

-380 AAATACCACCA AACAAAAAAA GTGTTTGAAG CTGGTGTATT TATAAAAACAC AGCAAGTATT
-320 GCAACAGAAG AGGCTAAAGC AGGACTGCTT AAGGTGAGGA CCAGCTGGGC ATATACAGAG

Stat3 binding site

-260 TTCAGGGGGA CTTTTTAAT CAAAACAGCA CACGATACAG CAGGGTGTTCC GAGACAGGAA

Survivin Promoter

-645 CTCAGCAGGC AACAGATGCA CCAAGGAGAC ATGATTTTTA TTTGCTTACT GGACTCTTT
-585 GCCGTTGATG GCCTGCTTCC TTTGCTGAGA GCCAGGCGGA TGCTCTGAGA ATAGACACC
-525 CATGACTTTC ATTTTTTCAAC GCTGGGACAG ACAGACACGG CTTCTACCC AGGGTGTCTA
-465 TAGAAAGGAT GCCGGCTGCT GCAGGAGGAGGGTGCTTCT GCATTTCAAG GCCGCCCCCCCT
-405 CACCGAGCCTG TGCGGCGCTGC CCATCCGTG CATTCCGAT ATCTAGCTG GCCAATCTTG
-345 CAACCTTGA GGCAAGAAAG AACTGGACAG ACATGGGACA TGGAGCAAGA CATGCTTTAA
-285 AGAGGTGGCC CAGGGCGGTC CAGGCCCCCTC GCGGCCCCCT CCAGGTCTCT GTGCTCTCTG
-225 TGCCGAGAGT TGCAATGAGA AGAAGGGAGC AGAAGGGGAC AAGACTTCAA AACTCCAGGC
-165 ATGGGCTGG CGCCCCACGGC CCCACAAGGGC AGGGCAAGAT GGGGCGGGGC GGGGACTTTTC

Klf4 binding site

-105 CCGGCTGAGG TGGGCGCGGT CACTCAGGGA AGGCGAGGGG GGAGGGGGGTG GGGGGGGGGG

Klf4 binding site

-45 TCTCCCGCCA TGCTCTGCGG CCGGCCTGCG CGGCGGAGGT TGGAATTCTCT GTGGTTGAAGT

TSS (+1)

16 GTCTTGGCGG AGGTGTGTTG GACGCATCAG TGGGAGCTCC GGGCGTGGCC CAGATCTGGC
76 AGCGTACCT CAGCGACTAC CGGCGCCGGA CCTCAAGACA CTGGCCCCCCCTCGAGACT
136 GCCGCTGGAGA C

STAT3 binding site

Figure 2-19 Mcl1 and survivin promoter analyses identify predicted Klf4 binding sites in close proximity to predicted Stat3-bindersites. 

Genomic sequence of promoters of Stat3-target survival genes survivin and Mcl1 and predicted Stat3 (blue) and Klf4 (red)-binding sites by MatInspector (Genomatix Software Suite). Analyses of ChIP-Seq data (from Chen et al. 2008) by TRANSFAC showed Klf4 binding to the survival gene promoters in ES cells. Binding fragments are indicated by the pink blocks.
Bcl-x Promoter

-557 AAAAGATCTA CTCACTCAGT CACTCACTCT CACTCAGACT CAGGGAAACT CTGTTTTCAC GGTCAATATC
-497 CAAATGTCAG GATTTTTTTT TCCAAAGCAT TTAGATGACT TATTGTGGTG TATTTTCTTA
-437 GTTGTTGCTG TCCACCCTGA AGGTATAAAG CTCATATAAA AAGAGACAGT TGCTCTGCTT
-377 TGTTGCTTCA ACAAACAAA CTAAGGGTTT CTATTTCTTC AGGTCCTTTTA AGTATGCACC
-317 GATACACAGT CAACTGAGGA TCAATATGCG TGCTCTTTTT AAGTGGAGG GGGGAATAC
-257 CAAATGTCAG GAACTGCTTG GATGTGGGAC ACCGATCGC AAGGAAAAAA GCATTTCCTT
-197 GTTAGATGAC AAAGGAGCAG GAATGAGACT GAAAGAAGTT GAAAGAATGT GAACCATAAA
-137 CGTTCCAGGC CCTGGAACATG CCTCAATGCG CTGGCCAGGG CTGGCCGTCTC TGGGATGCT
-77 CGATGCACTG CCGTCTTGGT CCGCGACTCC TTTGCTGCT CCGGCTCGCG CGCGCTCGCG
-17 CGGCACCGGAAGTTGCTGCG TCTGCAAGTT CCCCGCTTCT CTTCAGGGAGA AACTGAGGCG

Figure 2-20 Bcl-x promoter analysis identifies predicted Klf4-binding sites in close proximity to predicted Stat3 binding sites.

Genomic sequence of promoters of Stat3-target survival gene Bcl-x and Stat3 (blue) and Klf4 (red) binding sites predicted by MatInspector (Genomatix Software Suite). Two promoter regions are identified for Bcl-x, as indicated by the boxed regions. Analyses of ChIP-Seq data (from Chen *et al.* 2008) by TRANSFAC showed Klf4 binding to the Bcl-x gene promoters in ES cells. Binding fragments are indicated by the pink blocks.

Therefore, we next asked if Stat3 and Klf4 kd affected expression of the survival genes in the MBNS. When Stat3 or Klf4 were individually knocked down at d3 post-infection, the expression of Bcl-x and Mcl1 remained at levels unchanged relative to the control, although survivin expression was reduced in the Klf4 kd (Figure 2-21a). By d8 post-infection in shStat3 bulk cultures, when Stat3 and Klf4 levels were both reduced to 20% and 40% of control levels,
respectively (Figure 2-17b), coordinate downregulation of \textit{Bcl-x} and \textit{Mcl1} expression was observed (Figure 2-21b). However, in the d8 shStat3 clonal cultures, when \textit{Klf4} levels rebounded (Figure 2-17b), survival gene expression was maintained at WT levels, suggesting that \textit{Stat3} and \textit{Klf4} can compensate for each other in maintaining the expression of the target survival genes. The observations in the bulk culture may also reflect the heterogeneity in this high cell-density culture, as suggested by the cells present in the bulk culture with both \textit{Stat3} and \textit{Klf4} levels reduced, which may be representing non-stem cells that do not require \textit{Klf4} and target survival genes for their self-renewal or are dependent on other mechanisms or pathways for survival.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure21.png}
\caption{Stat3 or Klf4 expression is sufficient for the maintenance of Stat3-target survival gene expression}
\end{figure}

(a) Independent \textit{Stat3} and \textit{Klf4} kd does not affect survival gene expression in MBNS, as measured by quantitative RT-PCR in the d3 post-infection shKlf4 and shStat3 MBNS bulk cultures. The expression of \textit{Bcl-x}, and \textit{Mcl1} are not affected by the kd of \textit{Klf4} or \textit{Stat3}. Survivin expression is reduced in the \textit{Klf4} kd MBNS (P<0.01). (b) In d8 post-infection shStat3 MBNS, a compensatory upregulation of \textit{Klf4} in the clonal cultures is associated with the maintenance of survival gene expression. In the d8 shStat3 bulk cultures, when both \textit{Stat3} and \textit{Klf4} levels are reduced, there is a significant reduction in the expression of \textit{Bcl-x} and \textit{Mcl1} (p<0.0001). Statistical analyses were carried out by one-way ANOVA with a Dunnett post test. Expression values are normalized to the vector control and represented as mean±SEM.
**BCL-X and CD133 expression in human medulloblastoma is associated with poor survival**

When the expression of the STAT3 and KLF4 target survival genes was further analyzed in a human medulloblastoma expression dataset (Kool *et al.*, 2012), significant upregulation of *BCL-X*, but not *MCL1* and *BIRC5* (Survivin) was observed in the Group 3 tumors, which have the worst overall survival probability (Northcott *et al.*, 2011b) (Figure 2-22, 23). Furthermore, expression of PROM1 (CD133), a NSC marker enriched in the MBNS (Figure 2-1) was also elevated in Group 3 tumors (Figure 2-23), which have modeled by the *ex vivo* transformation of CD133-enriched ChSC (Pei *et al.*, 2012), suggesting the potential utility for NSC and survival gene markers as prognostic indicators. In conclusion, by asking about plasticity mechanisms within the *Ptch1LacZ/+;Trp53−/−* MBNS, this led us to the identification of *Klf4*, a reprogramming factor, as a gene also crucial for the clonogenic self-renewal of the MBNS. During the clonogenic self-renewal of MBNS, *Klf4* was upregulated in a Stat3-independent manner and this was further associated with the expression of survival genes.

![Figure 2-22](image1.png)

*Figure 2-22 BCL-X and PROM1 expression is associated with human medulloblastomas with the poorest prognosis*

Expression analyses of *BCL-X* (*BCL2L1*) and *PROM1* (*CD133*) in the human medulloblastomas from the Northcott *et al.* (2011) dataset indicate significant upregulation of these genes in Group 3, the class with the worst overall median survival. All values are represented as mean±s.e.m.
Figure 2-23 BCL-X and CD133 are elevated in Group 3 human tumors

*BCL2L1* (*BCL-X*) expression is significantly higher in Group 3 tumors compared to WNT (p<0.001), SHH (p<0.0001) and Group 4 (p<0.0001). *PROM1* (*CD133*) is also elevated in Group 3 compared to SHH (p<0.01) and Group 4 (p<0.001) tumors. The expression of *BIRC5* (*Survivin*), *MCL1* and *GAPDH*, however, are not significantly (n.s.) different between the tumor classes. Expression values are plotted as mean±s.e.m and statistical analyses was carried out by one-way ANOVA with a Bonferroni post test. The number of human tumors analyzed are as follows WNT=8, SHH=33, Group 3=27; Group 4=35.
Discussion

While efforts to model different subtypes of human medulloblastoma have led to several targeted therapies (Lau et al., 2012), the molecular and genetic pathways involved in relapsing tumors or tumor stem cells are not well understood. In particular, $Ptch1^{LacZ^+};Trp53^{-/-}$ mouse medulloblastomas provide a tractable model for studying the potential role of self-renewing, stem-like cells in these tumors. $Ptch1^{LacZ^+}$ tumors have been characterized as granule neuron progenitor (GCP)-driven tumors, which develop as a focal mass and do not exhibit properties of self-renewal in neurosphere culture conditions (C. Lin thesis). In contrast, $Ptch1^{LacZ^+};Trp53^{-/-}$ tumors are more diffuse and exhibit stem cells characteristics, including high expression of NSC markers such as CD15 and CD184, in comparison to the $Ptch1^{LacZ^+}$ tumors, and exhibit self-renewing neurosphere formation. These $Ptch1^{LacZ^+};Trp53^{-/-}$ MBNS are enriched in stem cell marker expression and are able to initiate tumors upon transplantation in vivo. As shown in this chapter, we also observed that these MBNS also displayed plasticity and growth in ES cell culture conditions as self-renewing, AP$^+$ colonies, despite the presence of differentiating factors in serum. We further discovered that $Klf4$, a reprogramming factor, was crucial for $Ptch1^{LacZ^+};Trp53^{-/-}$ MBNS plasticity and self-renewal and $Klf4$ expression was upregulated in a LIF/Stat3-independent manner during clonogenic growth. Our work suggests that the $Ptch1^{LacZ^+};Trp53^{-/-}$ MBNS are able to utilize endogenously activated components of the pluripotency transcription factor network to sustain expression of genes important for growth in clonal conditions in both ES culture conditions in the in vitro reprogramming assay and in neurosphere culture conditions.
**Tumor-initiating, self-renewing Ptch1\(^{LacZ^+/+}\);Trp53\(^{-/-}\) medulloblastoma cells**

Ptch1\(^{LacZ^+/+}\);Trp53\(^{-/-}\) tumors are able to be propagated as self-renewing neurospheres, display enriched expression of stem cell markers including CD15, CD133 (Figure 1-1), nestin, Sox2 (C. Lin thesis) and are capable of secondary tumor initiation when transplanted into the cerebella of immunocompromised mice. Serum-free neurosphere culture with growth factors EGF and bFGF was initially developed for the isolation of multipotent NSC (Reynolds et al., 1992), but has been extensively utilized for the enrichment of human brain tumor stem cells *in vitro* (Singh et al., 2003; Hemmati et al., 2003; Galli et al., 2004; Dirks, 2008). Neurosphere cultures have been shown to select for cells with tumor-initiating ability that reliably maintain the characteristics of the primary tumor (Lee et al., 2006), whereas non-sphere-forming cells were unable to initiate tumor-formation *in vivo* (Yuan et al., 2004). Postnatal CbSC have also been isolated and characterized as a Math1-negative, bFGF-responsive, CD133-positive population, which grow as self-renewing, Sox2 and nestin-positive neurospheres *in vitro* and exhibit multipotent differentiation *in vitro* and *in vivo* (Lee et al., 2005). This is in contrast to Math1-positive GCP of the cerebellum, which cannot proliferate in response to bFGF (Lee et al., 2005), consistent with the observation that bFGF inhibits GCP proliferation and induces differentiation in Ptch1\(^{LacZ^+/+}\) tumor cells (Fogarty et al., 2007). The presence of bFGF-responsive Ptch1\(^{LacZ^+/+}\);Trp53\(^{-/-}\) cerebellar stem-like cells in the tumors and in 3 week old animals (C. Lin thesis), suggests an aberrantly persistent population of CbSC. Alternatively, the possibility of GCPs to develop a resistance to bFGF-induced differentiation or acquire a more dedifferentiated state cannot be excluded. To differentiate between these two possibilities, lineage-tracing studies following the prospectively labeled CbSC and GCP populations would be necessary.
Although the aforementioned characteristics of the $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS is suggestive of the enrichment of a tumor-propagating cell from the primary tumors with neurosphere culture, the possibility of clonal selection of cells or tissue culture-induced changes promoting increased proliferation and survival must be considered. To ascertain the role of bona fide cancer stem cells in these tumors, prospective isolation of an endogenous cell population with a stem cell marker that can isolate the self-renewal and tumor-initiating activity is necessary and will be further addressed in Chapter 3. In the absence of a validated prospective marker, in acute myeloid leukemia (AML), for example, where CSC were first identified, injections of ten-fold limiting dilution series of unfractionated AML cells were carried out for the quantification of AML-initiating cells (Bonnet and Dick, 1997). To further bolster the role of stem cells in the $Ptch1^{LacZ/+};Trp53^{-/-}$ medulloblastomas, neurosphere differentiation assays to determine multipotency and quantitative serial transplantation assays will also need to be carried out. Nonetheless, it is important to understand the role of these $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS, as they are responsive to culture conditions validated for the enrichment of NSC and other brain tumor stem cells (Dirks, 2008) and demonstrate robust self-renewal and tumor-initiating capability.

**Phenotypic conversion of MBNS**

Phenotypic conversion of MBNS in an in vitro reprogramming assay suggests that pathways shared with the pluripotency network of ES cells can be utilized as a plasticity mechanism by MBNS. The reprogramming of somatic cells to pluripotency involves directed dedifferentiation through ectopic expression of the transcription factors, Oct4, Sox2, c-myc, and Klf4 (Takahashi and Yamanaka, 2006). These same reprogramming genes are normally expressed in CD133-enriched WT cerebellar cells and neurospheres (Po et al., 2010), suggesting
that the pluripotency networks are mostly conserved in NSC. However, our control experiments with developmental CbSC did not provide evidence for colony formation in the \textit{in vitro} reprogramming assay when dissociated neurosphere cells were plated in ES culture conditions. While cortical NSC require exogenous \textit{Oct4} expression for reprogramming (Kim \textit{et al.}, 2009), the MBNS showed endogenous activity and AP$^+$ colony formation and growth without added factors. Our data suggest that the requirement for exogenous factors may be relieved by tumorigenesis. In human cancers, a c-myc centered transcriptional network contributes to the ES-like signatures observed in cancer, rather than the core ES module defining ES cells (Kim \textit{et al.}, 2010), challenging the notion of the dedifferentiation of cancer cells to an ES-like state. Nonetheless, the molecular underpinnings of the MBNS with ES-like gene signatures led us to predict that these cells may exhibit characteristics of plasticity and respond in ES culture conditions. In fact, histological analyses of the AP$^+$ MBNS-derived teratomas suggest an increased diversity in the cell types generated in comparison to the parental MBNS-derived tumors which are characterized by a more differentiated cell type, although further marker analysis is required to definitively determine the distinct neural cell types present. It should be also noted that the control $\text{Ptch}1^{LacZ^+};\text{Trp53}^{-/-}$ ES cell-derived teratomas only consisted of neuroectodermal cells and did not exhibit the formation of all three germ layers, which may be due to the mutant $\text{Ptch}1^{LacZ^+}$ genotype biasing the differentiation into neural lineages in the teratoma assay. The role of Shh signaling in neural development is well established and neural tube defects and overgrowth in the hindbrain, spinal cord and headfold are observed in $\text{Ptch}1$ null embryos (Goodrich \textit{et al.}, 1997).

Cancer genomes have previously been reported to be epigenetically reprogrammed to pluripotency by nuclear transplantation (Li \textit{et al.}, 2003; Hochedlinger \textit{et al.}, 2004) and through
induction of ectopic pluripotency factors (Lang et al., 2012). The in vitro reprogramming assay may be selecting for those MBNS with tumor-associated epigenetic changes that allow the cells to modulate pluripotency transcription factors and respond to ES culture conditions. Methylation analyses of the regulatory regions of pluripotency genes showed that Oct4 and Nanog remained methylated in the AP+ MBNS and c-myc and Stat3 remained hypomethylated. However, a significant reduction in DNA methylation was observed at the 5’ regulatory regions of Klf4 (and Sox2 to a lesser degree) between the MBNS and AP+ MBNS, which led us to ask if Klf4 may be involved modulating the phenotypic plasticity. We have not, however, quantitatively examined if the differential CpG methylation at the 5’ regulatory regions directly reflects a modulation of gene expression. Nonetheless, Klf4 has a known role for preventing the differentiation of ES cells in the absence of LIF (Zhang et al., 2010) and Klf4 expression is required for epiblast stem cells (EpiSC) with restricted potency to attain the ground state pluripotency of ES cells (Guo et al., 2009). Consistent with this, Klf4 kd resulted in reduction of AP+ colony formation in ES culture conditions. Furthermore, Klf4 was also functionally important in the clonal self-renewal of MBNS. It is unknown, however, if the conversion of MBNS in the reprogramming assay is occurring due to a culture-induced epigenetic adaptation or through the selection of a pre-existing population of cells in the primary tumor. For example, the MBNS culture may contain a more primitive NSC, which has been shown to be present as a LIF-dependent population of cells in the neuroectoderm before the formation of the neural tube (Hitoshi et al., 2004).

The role of the Trp53 mutation during the phenotypic conversion of the MBNS must also be considered and may be exhibiting a two-fold effect. Trp53 is a potent barrier to reprogramming, as Trp53 inhibition accelerates the generation of dedifferentiated stem cells (Utikal et al., 2009; Marión et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li et al.,
In addition, p53 loss also increases the adult stem cell pool in various tissue systems including the CNS (Meletis et al., 2006). Therefore, the acquisition of developmental plasticity and an increase in the stem cell pool by the inactivation of Trp53 may render the $P{tch1}^{LacZ/+};Trp53^{-/-}$ tumor cells more susceptible to tumor-associated reprogramming (Spike and Wahl, 2011).

Oncogenic role of Klf4 in MBNS

$Klf4$ is a zinc finger transcription factor, which has known roles in a wide range of functions including the regulation of cell proliferation, differentiation and apoptosis. $Klf4$ is highly expressed in the intestine, where it was first identified, and in skin epithelial cells (Shields et al., 1996). $Klf4$ has been shown to function as both an inhibitor of cell proliferation and inducer of differentiation. In a colon cancer cell line, $Klf4$ negatively regulates cell proliferation by inhibition of cell cycle progression at G1/S (Chen et al., 2001). The crucial role of $Klf4$ in the induction of differentiation is highlighted in the $Klf4$ knockout mice, which die perinatally due to a defective skin barrier function and dehydration caused by aberrant differentiation of the skin (Segre et al., 1999) and colon epithelia (Katz et al., 2002). In human tumors, $Klf4$ has been reported to display opposing functions, as either a tumor suppressor or an oncogene depending on the context and tumor type. While $Klf4$ is a tumor suppressor gene in colon and gastric cancer, it has oncogenic roles in other cancer cancers such as squamous cell carcinoma and breast cancers (Rowland and Peeper, 2006).

The role of $Klf4$ in medulloblastomas has not been studied extensively, but it has been reported that $Klf4$ expression is silenced by genetic events such as chromosomal deletions and promoter methylation in human medulloblastomas (Nakahara et al., 2010). This study also
showed that overexpression of $Klf4$ in medulloblastoma cell lines led to growth suppression both in vitro and in vivo, suggesting the role of $Klf4$ as a tumor suppressor. Although, one must consider that serum-cultured cell medulloblastoma lines were utilized. However, other studies show an association between tumorigenesis and upregulation of $Klf4$ expression. In $Ptch1^{+/−}$ tumors, $Klf4$ expression was observed to be elevated in comparison to the pre-neoplastic lesions and GCPs (Oliver et al., 2005). And as a STAT3-target, high KLF4 expression has also been observed as part of the genetic signature of human tumors with activated Stat3 signaling (Alvarez et al., 2005). Our results with RNAi and small molecule inhibitors show that in the $Ptch1^{LacZ+};Trp53^{−/−}$ MBNS, $Klf4$ expression is also, in part, regulated by Stat3 and $Klf4$ expression is specifically upregulated in the self-renewing MBNS. Recently, $Klf4$ has been shown to be functionally important in the self-renewal of ES cells and the reprogramming of somatic cells to iPS cells, as one of the original four reprogramming factors (Takahashi and Yamanaka, 2006). As a reprogramming factor, $Klf4$ was characterized to function as a key component of the transcriptional network of pluripotency in ES cells, as an upstream regulator of $Oct4$, $Sox2$, $Nanog$, and c-myc (Kim et al., 2008a). Specifically, in the absence of LIF, $Klf4$ expression prevents ES cell differentiation by regulating Nanog (Li et al., 2005; Zhang et al., 2010). $Klf4$ is also expressed in normal NSC and CbSC (Po et al., 2010; Kim et al., 2009), although the function has not been directly addressed. In a study that examined the role of $Klf4$ in cortical NSC, high levels of $Klf4$ expression was observed in the NSC but was decreased in differentiated neurons and astrocytes (Qin et al., 2011), suggesting its potential role in the maintenance of stem cells. However, overexpression of $Klf4$ resulted in the reduction of proliferation and self-renewal and led to impairment in neural differentiation (Qin et al., 2011). While this shows that precise levels of $Klf4$ are critical for the regulation of normal neurogenesis,
the role of endogenously expressed *Klf4* in NSC still remains unclear. The functional role of *Klf4* in the cerebella or cerebellar stem cells, specifically, has also not yet been described.

In *Ptch1<sup>lacZ/+;Trp53−/−</sup>* MBNS, our results suggest that *Klf4* functions to maintain self-renewal through both Stat3-dependent and independent mechanisms. The compensatory Stat3-independent expression of *Klf4* during clonogenic neurosphere formation supports an oncogenic function with its involvement in the maintenance of MBNS self-renewal. In the context of CSC, a study in breast cancers has shown that *Klf4* kd results in a reduction in the frequency, self-renewal, and *in vivo* tumorigenicity of the breast CSC population (Yu et al., 2011). Also in breast cancer, the upregulation of *Klf4* via miR-29 repression contributes to the expansion of CD44<sup>+</sup>/CK5<sup>+</sup> stem-like tumor-initiating cells and knockdown of *Klf4* leads to the reduction of the frequency of these cells (Cittelly et al., 2013), further providing evidence for an oncogenic role of *Klf4* in certain tumor stem cells.

**Role of constitutive activation of Stat3 in MBNS self-renewal**

Several lines of evidence show aberrantly activated STAT3 signaling to be important in human tumors including medulloblastomas (Yu and Jove, 2004). Tumor-specific activation of pSer727 STAT3 is observed in primary human medulloblastomas (Yang et al., 2008a) and the MBNS also showed elevated *Stat3* expression that was associated with robust pSer727 activation. The elevated expression of *Stat3*, which was also seen in WT CbSC, suggests that overexpression of *Stat3* in MBNS may be reflective of a developmental origin of these tumors. Abundant expression of *Stat3* has, in fact, been observed in cerebellar white matter at P3 and P10 in the postnatal rat brain (Gautron et al., 2006). Recent studies have demonstrated that small molecule drugs can inhibit the proliferation of the Daoy medulloblastoma cell line *via* inhibition
of Stat3 and Akt pathways (Yang et al., 2008a; 2010b). Although it must be noted that Daoy cells are also propagated as adherent serum-adapted cultures, which have been described to alter the characteristics of the original tumors (Lee et al., 2006; Sasai et al., 2006), while we have specifically examined the function of Stat3 activation in the self-renewing MBNS.

The effect of Stat3 pathway inhibitors on MBNS shed some light on the differential function of the two post-translational modifications of Stat3; pTyr705 Stat3 is robustly inhibited by Jak inhibition and Mek inhibition led to a partial, but consistent decrease in pSer72 Stat3. Mek inhibition may be reducing pSer Stat3 by blocking the activity of ERK2, a downstream kinase shown to phosphorylate Stat3 at Ser727 in different contexts (Chung et al., 1997; Turkson et al., 1999). However, pSer727 Stat3 was only partially inhibited and this is likely due to the contribution of other tumor-related MAPK pathway kinases such as JNK, p38, and PKC (Roberts and Der, 2007). The treatment of MBNS with Jak and Mek inhibitors suggest that these pathways independently are not crucial for the maintenance of MBNS self-renewal. The lack of an effect on the clonal self-renewal with the Jak inhibitor despite the robust inhibition of pTyr705 Stat3, the main transcriptional activation signal, suggests that the activation of Stat3 signaling is not crucial for the maintenance of MBNS self-renewal. The inhibition of Mek signaling, which is involved a multitude of functions including transcriptional regulation, proliferation, differentiation limits the use of the Mek inhibitor to query a Stat3-specific effect. However, the robust inhibition of Mek signaling, as measured by the reduction of MAPK phosphorylation shows that Mek inhibition alone also does not significantly affect MBNS self-renewal.

The combination treatment of Jak and Mek inhibitors results in a significant reduction of neurosphere formation, suggesting that the concurrent inhibition of both pathways is important
for the effective reduction in MBNS self-renewal. Similarly, a synergistic effect of Stat3 and Mek pathway reduction has been observed to inhibit the growth of multiple myeloma cells (Nelson et al., 2008). However, the limitations of utilizing kinase inhibitors must be taken into consideration when interpreting the specific roles of Stat3 and Klf4 in the MBNS. While the activation of pStat3 is a major role of Jak kinases, they are also involved in a variety of other functions such as the phosphorylation and activation of other growth factor and cytokine receptors, including the granulocyte macrophage colony-stimulating factor (GM-CSF) and type I interferon receptor (Rane and Reddy, 2000) that may lead to a Stat3-independent effect.

Furthermore, as mentioned above Mek signaling is involved in a variety of cellular processes. Nonetheless, further examination of the mechanism involved in the inhibition of MBNS self-renewal by the combination Jak and Mek inhibitors may reveal novel effectors of survival signaling in the MBNS.

While Stat3 expression may not be necessary for the maintenance of MBNS self-renewal and survival, sustained Stat3 signaling may be aiding the stabilization of the transcriptional circuitry for pluripotency and survival in the MBNS. Stat3 functions in cooperation with the pluripotency factor Oct4 to sustain ES cell self-renewal by inducing Klf4 expression (Hall et al., 2009). Furthermore, Stat3 synergizes with Klf4 and Nanog to reset the transcriptional program to overcome the barrier for reprogramming epiblast stem cells (EpiSC) to pluripotency (Yang et al., 2010b). The role of pTyr705 Stat3 in direct transcriptional regulation of target genes, including Klf4 and c-myc, is well established. In the MBNS, pTyr705 Stat3 inhibition by Jak kinase inhibition reduces the expression of Socs3, Stat3 and secondarily, the expression of Klf4. While pSer727 Stat3 in mice has been reported to be required for maximal transcriptional activity, its role in DNA binding and gene regulation is not well established (Decker and Kovarik, 2000).
However, the human homolog pSer STAT3 has been shown to directly bind DNA and activate the transcription of antiapoptotic genes such as survivin, Mcl1, Bcl-x in CLL in a pTyr705 STAT3-independent manner (Hazan-Halevy et al., 2010). This may reflect a conserved mechanism for regulating survival genes in MBNS, through the collaborative involvement with Klf4.

Role of Stat3-independent regulation of Klf4 during clonogenic self-renewal

Despite the MBNS exhibiting significantly elevated levels of Stat3 mRNA expression and phospho-Stat3 activation, Stat3 kd by RNAi and kinase inhibitors led to a moderate decrease in the formation of self-renewing neurospheres and the Stat3 kd was not as functionally significant as the role of Klf4, especially apparent in the limiting dilution neurosphere formation assay. We have observed two discreet phenomena of Klf4 regulation that occur in a cell density-dependent manner. The upregulation of Klf4 expression in MBNS with sustained Stat3 kd suggests that MBNS can, in part, escape and self-renew if Klf4 expression is selectively upregulated during clonogenic growth. At higher cell densities, the compensatory mechanism of Klf4 expression does not take effect, suggesting that there may be cell non-autonomous signals at higher cell densities, which relieve the necessity for Klf4 expression. This leads us to hypothesize that gene expression networks may be relaxed if not necessary, but under environmental challenges such as clonal growth, the consolidation of gene expression necessary for MBNS survival occurs, either by the selection of cells expressing Klf4 or by inducing cells to rapidly upregulate Klf4. Additionally, this suggests that the major mode of Klf4 regulation during MBNS clonogenic growth can occur through a mechanism independent of the canonical LIF/STAT3 pathway, for which Klf4 is direct downstream target.
While the partial effect of the Stat3kd on MBNS self-renewal may be attributable to the downregulation of Klf4 downstream of Stat3, the inhibition of Stat3 signaling alone is not sufficient because Stat3-independent activators of Klf4 can compensate. These activating signals of Klf4 remain to be determined, but Shh signaling may be involved in a Stat3-independent mechanism for Klf4 activation via the network of pluripotency factors, as Shh has been reported to be upstream of transcriptional activation of Klf4 (Sengupta et al., 2007; Moon et al., 2011). Furthermore, the MBNS we describe are driven by loss of the Ptch1 tumor suppressor that governs Shh signaling. Overexpression of Gli1, a downstream activator of Shh signaling, has also been shown to enhance clonogenic NSC, which was associated with the concurrent upregulation of pluripotency genes including Nanog, Sox2, Klf4, and CD133 (Stecca and Ruiz i Altaba, 2009), of which Nanog and Sox2 have been shown to be directly regulated by Gli1/2 binding (Po et al., 2010; Takanaga et al., 2009). It will be important to further elucidate the multiple modes of activation of Klf4 expression for the effective inhibition of MBNS survival and self-renewal for therapeutic applications. In conclusion, our work suggests that Ptch1<sup>LacZ</sup>+/Trp53<sup>−/−</sup> MBNS are able to utilize the endogenously active components of the pluripotency transcription factor network, specifically Klf4, which is functioning partially via the Stat3 signaling pathway, as a factor critical for both MBNS plasticity and clonal self-renewal.

Methods

Neurosphere culture of MBNS line

A primary Ptch1<sup>LacZ</sup>+/Trp53<sup>−/−</sup> medulloblastoma was isolated, minced with razor blades and homogenized in Accutase (Chemicon) and was maintained in suspension culture as neurospheres in DMEM:F12 containing B27 Supplement (Invitrogen), 20ng/ml bFGF (Invitrogen), 20ng/ml
EGF (Invitrogen), and 100U/ml penicillin/streptomycin (Invitrogen) by weekly serial passaging. Neurosphere cultures were passaged by dissociation and trituration with Accutase, centrifugation, and followed by resuspension of the cells in fresh NS media. For isolation of CbSC, postnatal d5 or d7 cerebella were dissected, mechanically dissociated and homogenized with Accutase (Chemicon) and cultured in neurosphere media. After 7 days of culture, primary neurospheres were dissociated and plated in the in vitro reprogramming assay.

**Flow cytometry for cell surface marker expression analyses**

A primary $Ptch1^{LacZ^{+};Trp53^{-/-}}$ medulloblastoma and neurosphere culture-enriched MBNS line was isolated and dissociated as described above and resuspended in Phosphate-buffered saline (PBS) with 2mM EDTA and 0.5% BSA. The samples were incubated with PE-conjugated CD15 (R&D Systems), PE-conjugated CD133/Prominin (Miltenyi), or anti-mouse isotype control antibodies for 30 minutes, washed with PBS, then analyzed on the BD LSRII (BD Biosciences). Analyses for PE staining were carried out on FlowJo software (Tree Star).

**Intracerebellar transplantation assays**

4-6 week old NCr nude ($CrTac:NCr-Foxn1^{nu}$) mice were anesthetized with ketamine/xylazine and placed into a stereotaxic frame (Stoelting). A 1 cm incision was made in the scalp and a hole was drilled approximately 1mm lateral and 3mm posterior to lambda. 10000, 30000 or 100,000 cells in 2ul of PBS were drawn into a glass needle and injected into the cerebellum 3mm below the surface using a PicoPump (World Precision Instruments). Animals were monitored for the development disease symptoms on a daily basis. Mice were maintained in pathogen-free
conditions at Boston Children’s Hospital and procedures were performed following approval by the Institutional Animal Care and Use Committee (IACUC).

*In vitro assay for reprogramming*

For the *in vitro* reprogramming experiments, 3000 MBNS or CbSC were plated per well of a 6-well plate on irradiated mouse embryonic fibroblasts (MEF) in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) containing 15% FCS (Millipore), 2mM L-Glutamine (Invitrogen), 100U/ml penicillin/streptomycin, 100uM non-essential amino acids (Invitrogen) and 1000U/ml leukemia inhibitory factor (Millipore). Six days post-plating, cells were fixed with 2% paraformaldehyde (Electron Microscopy Sciences) and stained for alkaline phosphatase (Vector Laboratories). The frequency of AP-positive ES-like colony formation was determined by counting the homogenously AP-positive colonies. Stable AP⁺ MBNS subclones were maintained in standard ES cell culture conditions. Plating efficiency assays to determine LIF-dependency were performed by plating 3000 AP⁺ MBNS per well of a 6-well plate in technical triplicates, on gelatin or MEF in ES media with or without LIF. Six days post-plating, colonies were fixed, stained for AP, and quantified by ImageJ. Briefly, images of wells were photographed, converted to a grayscale image and thresholded to highlight the colonies, which were counted by the “measure nuclei” macro under the analyze particles function menu.

*Teratoma assays*

The flanks of 4-6 week of NCr nude (*CrTac:NCr-Foxn1nu*) mice were subcutaneously injected with $10^6$ *P* *t* *c* *h* 1$\text{LacZ}^+;Trp53^{-/-}$ ES cells (n=3), MBNS (n=5), and AP⁺ MBNS (n=5) resuspended in 100ul of PBS. Animals were monitored daily for the development disease symptoms, sacrificed
3 week post-injection and tumors were dissected and embedded in OCT (Tissue-Tek) for cryosectioning for H&E staining for histological analyses.

Bisulfite-based mass spectrometry methylation analyses

Genomic DNA (gDNA) from the parental MBNS and three AP⁺ MBNS subclone lines were isolated with the AllPrep DNA/RNA kit (Qiagen). The MassArray EpiTYPER platform (Sequenom, San Diego, CA, USA) was utilized for quantitative analyses of CpG methylation at promoter regions and 5’ regulatory regions ~2kb upstream of the TSS for pluripotency genes Oct4, Nanog, Klf4, Sox2 and Stat3. Briefly, sodium bisulfite-treated gDNA is PCR-amplified with gene-specific primers and followed by in vitro RNA transcription and base-specific cleavage. Cleavage products are subsequently analyzed by MALDI-TOF mass spectrometry to distinguish between the methylated and unmethylated gDNA.

Gel-based and Quantitative RT-PCR

Total RNA (1ug) isolated from WT adult cerebella, Ptch1LacZ+/+;Trp53−/− primary tumors, WT and Ptch1LacZ+/+;Trp53−/− ES cells, WT P7 CbSC, and Ptch1LacZ+/+;Trp53−/− MBNS lines with the RNeasy Kit (Qiagen) was used for cDNA synthesis with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gel-based RT-PCR was carried out by amplifying Oct4 and Nanog for 31 cycles, Sox2 and Klf4 for 28 cycles, NuBP for 26 cycles and Gapdh for 23 cycles. Quantitative RT-PCR was carried out in technical triplicates using the SYBR Green PCR Master Mix (Applied Biosystems) using cDNA dilutions determined by prior primer optimization experiments. Stat3, Socs3, Klf4, survivin, Bcl-x and Mcl1 expression was normalized to GAPDH and changes in gene expression were determined by the ddCT method
and represented as expression levels relative to the WT cerebella control, vehicle-treated or vector control.

Primers:
Gapdh: 5’ GTTGTCCTCCTGCGACTTCA 3’; 5’ TGGTCCAGGGTTTCTTACTC 3’
STAT3: 5’ TGAGAGTCAAGACTGGGCATA 3’; 5’ ACTCTTGCAGGAATCGGCTA 3’
Socs3: 5’ GTTCTGGATCAGTATGATGC 3’; 5’ CGCTTGCAAAAGGTATTGTCC 3’
Klf4: 5’ CCCGGCGGGAAGGGAAAGTGGGGGAAGT 3’
survivin: 5’ CTACCGAGAACGAGCCTGAT 3’; 5’ GGGAGTGCTTTCTATGCTCCT 3’
Bcl-x: 5’ GGTGAGTCCGATTCAAGTT 3’; 5’ TGGTCCCCTAGAGATCCACA 3’
Mcl1: 5’ GTAAGGACGAAACGGGACTG 3’; 5’ CGCCTTCTAGGTCTCTGTACG 3’

Western Blot Analyses
MBNS grown in suspension culture were harvested and centrifuged for protein isolation. For isolation of protein lysates from adherent ES cells or AP+ MBNS grown in ES conditions, MEFs were removed by spot-plating on gelatin-coated plates. Cell pellets were lysed in RIPA buffer (Upstate) containing phosphatase and protease inhibitors (Pierce) on ice for 30 minutes, with vortexing every 10 minutes. After determination of protein concentration by the Dc-Protein Assay (Bio-Rad), 30ug of protein was fractionated on a 8% polyacrylamide gel, transferred to nitrocellulose membranes and probed with rabbit anti-pSer727 Stat3 (1:10,000, gift from D.Frank (Kim et al., 2008a)), rabbit anti-pTyr705 Stat3 (1:10,000, Cell Signaling), rabbit anti-Stat3 (1:10,000, Santa Cruz), rabbit anti-pErk1/2 (1:10,000, Cell Signaling), mouse anti-actin (1:5000, Abcam). Anti-mouse and rabbit HRP-conjugated secondary antibodies (1:10,000,
Jackson ImmunoResearch) were incubated on the blots and detected with the Western Lightning ECL Reagent (Perkin Elmer).

Pathway inhibitor treatment of MBNS

Dissociated MBNS were treated with 10uM PI3K inhibitor LY294002 (Cell Signaling), 10uM Mek1/2 inhibitor U0126 (Cell Signaling), 250nM mTOR inhibitor Rapamycin (Gift from D. Sabatini), and 1uM Jak inhibitor (Calbiochem), or combination Mek and Jak inhibitor. Treated MBNS were harvested for protein and RNA isolation or plated in the neurosphere self-renewal assay (see below) with additional inhibitor media supplementation 4 days post-plating. Neurosphere formation and size was quantified 7 days post-plating.

Generation of shRNA and lentiviral vectors

shRNA against Stat3 and Klf4 were generated with two rule-based shRNA design software, DSIR (http://biodev.extra.cea.fr/DSIR/) and pSicoOligomaker 1.5 (http://web.mit.edu/jacks-lab/protocols/pSico.html). Oligos were ligated into a pSicoR vector modified from the original vector (Ventura et al., 2004) to express the puromycin resistance cassette under the control of the Ubiquitin promoter. Transformed bacterial colonies were picked for colony PCR to screen for shRNA insertion and further validated by sequencing.

Lentiviral infection of the MBNS lines

Viral supernatant was produced by transient calcium chloride transfection of human embryonic kidney cells (HEK293) cells with 10ug PAX lentiviral packaging vector and 5ug VSV envelope vectors and 15ug pSicoR-puro-shRNA vectors. Sixteen hours following transfection, the media
was changed to fresh media. Viral supernatant was collected 48 hours after transfection, supplemented with Polybrene (8ug/ml) and passed through a 0.45um filter. Dissociated MBNS (~10^6) were resuspended with the filtered viral supernatant and centrifuged for 45 minutes at 2500 rpm for lentiviral transduction. Puromycin selection (2ug/ml) was applied 1d post-infection for 48 hours and on d3 post-infection, the lentivirally-infected MBNS were collected for RNA isolation, plated in self-renewal assays, or passaged for maintenance as bulk cultures.

In vitro neurosphere self-renewal assay and limiting dilution assay

At d3 post-infection, shStat3, shKlf4, and vector control MBNS were dissociated and plated at 200 cells per well of 6-well plate in neurosphere media. Neurosphere formation was quantified 5 days post-plating by ImageJ. The neurospheres that emerged from these clonal density assays were collected for RNA isolation for gene expression analyses of d8 clonal cultures.

For the limiting dilution assays, d3 post-infection shStat3 and shKlf4, vector control MBNS were dissociated and plated at 0.3, 1, 3, 10 cells per well of a 96 microwell plate in neurosphere media with 48 wells for each cell concentration. Five days post-plating, each well was scored for positive or negative neurosphere formation. The self-renewal index, which is the number of cells required for the formation of one neurosphere, was determined with the extreme limiting dilution assay (ELDA) webtool (http://bioinf.wehi.edu.au/software/elda/).

Analyses of human medulloblastoma gene expression datasets

Human medulloblastoma gene expression datasets from Northcott et al. (2011) were accessed from the Gene Expression Omnibus (GEO) database and the 103 tumor samples were sorted based on the annotated subclasses (Shh=33 tumors, Wnt=8 tumors, Class 3=27 tumors, Class
4=35 tumors). Expression values were obtained from corresponding gene probes for STAT3 (3757840), KLF4 (3219215), MYC (311504), BIRC5 (3736290), BCL2L (3902489), MCL1 (2434438).

*In silico promoter analyses*

Promoters of *survivin, Mcl1, Bcl-x* were retrieved from the Genomatix ElDorado genome database. Promoters in Genomatix are defined as regions 500bp upstream and 100bp downstream of the transcriptional start site (TSS). Binding site identification was carried out for promoters defined by “gold” transcripts, which are those verified by mapping of 5’ full length cDNAs or at least 4 CAGE (cap analyses gene expression) by Genomatix MatInspector and further analyzed for transcription factor binding sites for STAT3 and GKLF (Klf4).
Chapter 3 : Mechanisms of aberrant persistence of cerebellar stem cells during medulloblastoma development

ChieYu Lin$^{1,2,4}$, Ronnie Yoo$^{1,2,4}$, Juliana Brown$^{1,2}$, Abby Sarkar$^3$, Katrin Arnold$^3$, Christopher Kanner$^2$, Konrad Hochedlinger$^3$, and Laurie Jackson-Grusby$^{1,2}$

$^1$Pathology Department and Kirby Center for Neuroscience, Children’s Hospital Boston, $^2$Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, $^3$Massachusetts General Hospital Boston, MA, Department of Stem Cell and Regenerative Medicine, Harvard University Cambridge, MA

$^4$These authors contributed equally

Author Contributions
CYL contributed to the conception and design of experiments, acquired and analyzed results, prepared figures. RY acquired and analyzed results, wrote the manuscript and prepared figures. JB acquired results. AS, KA, KH contributed to the development of the methodology and reagents. LIG contributed to the conception and design of experiments, analyzed results and supervised the study.
**Introduction**

The cell of origin of the SHH subtype of medulloblastomas has been established and well-characterized to be a granule cell progenitor (Yang et al., 2008b; Schüller et al., 2008). Following the identification of self-renewing, tumor-initiating cells in human primary medulloblastomas (Singh et al., 2004), recent studies have examined the potential roles of non-GCP stem cell populations as the cell of origin in medulloblastoma tumorigenesis. As such, it has been shown that a cerebellar stem cell population (Lee et al., 2005), upon transformation with an oncogene, can lead to the formation of malignant medulloblastomas (Sutter et al., 2010; Pei et al., 2012). Furthermore, *Ptch1*<sub>LacZ/+;Trp53</sub>-/- medulloblastomas have been characterized to contain a population of self-renewing cells expressing NSC markers with the ability for potent tumor-initiation upon secondary transplantation (C. Lin thesis).

The stem cell population of particular interest in the *Ptch1*<sub>LacZ/+;Trp53</sub>-/- model is the aberrantly self-renewing, premalignant cells in the 3 week cerebella. In WT animals, self-renewal activity is decreased by 3 weeks of age (C. Lin thesis). The persistence of self-renewing cells beyond the normal developmental window may be expanding the pool of potential targets for malignant transformation, leading to the establishment of a tumor-initiating stem cell population. This may be analogous to the abnormal proliferative rests of granule cell progenitors in the *Ptch1*<sub>LacZ/+</sub> model, which are predisposed for progression to tumor formation upon the acquisition of additional oncogenic mutations (Kim et al., 2003). A comprehensive comparison of the gene expression profiles between the *Ptch1*<sub>LacZ/+;Trp53</sub>-/- aberrant tissue stem cells and developmental stem cells in both P7 WT and *Ptch1*<sub>LacZ/+;Trp53</sub>-/- animals will allow for the
elucidation of mechanisms and pathways that are allowing the stem cells to persist developmentally and contribute to tumorigenesis in the $Ptch1^{LacZ^+/+};Trp53^{-/-}$ model.

The strategy described in the previous chapter for studying the self-renewing, tumor-initiating cell population in $Ptch1^{LacZ^+/+};Trp53^{-/-}$ tumors relied on the enrichment of these cells by \textit{in vitro} neurosphere culture and the use of heterogeneously expressed markers. $Ptch1^{LacZ^+/+};Trp53^{-/-}$ tumor cells have been reported to undergo changes during adherent, serum-enriched \textit{in vitro} tissue culture, such as downregulation of Shh signaling, highlighting concerns that \textit{in vitro} cell lines may not be representative of the original tumor (Sasai \textit{et al.}, 2006). While the serum-free neurosphere culture conditions employed may better preserve the \textit{in vivo} characteristics of the $Ptch1^{LacZ^+/+};Trp53^{-/-}$ medulloblastoma cells, we cannot exclude the possibility of the medulloblastoma neurospheres (MBNS) undergoing genetic and/or epigenetic changes or clonal selection during the long term passaging of NS cultures. Furthermore, an alteration of cell character due to the absence of the normal developmental environment and niche signals may inaccurately represent what is occurring \textit{in vivo}. Therefore, a validated prospective marker, allowing for the enrichment directly from the brain would greatly facilitate the investigation of these endogenous cell populations.

CD133 (also known as prominin 1) is widely accepted as a cell surface marker for the isolation of NSC and tumor-initiating cells in brain cancers (Lee \textit{et al.}, 2005; Singh \textit{et al.}, 2004), as well as a variety of different solid tumors (Visvader and Lindeman, 2008). While CD133 has been extensively used as an established marker for NSC, it has been shown to be heterogeneously expressed in NSC and in addition, CD133-negative fractions also contain self-renewing, multipotent stem cells (Sun \textit{et al.}, 2009). As a CSC marker, the validity of CD133 as a definitive marker for fractionating cells with cancer-initiating ability has also been challenged in
multiple studies (Beier et al., 2007; Joo et al., 2008; Wang et al., 2006; Chen et al., 2010). This must be considered when using CD133 for the isolation of either NSC or CSC and necessitates the identification and characterization of other definitive markers. Furthermore, in the MBNS lines derived from the \(Ptch^LacZ^+;Trp53^-\) tumors, CD133 expression occurs in an exceedingly heterogeneous fashion, as clonal lines derived from a highly self-renewing MBNS line showed considerable variability in the cell surface expression of CD133, as well as CD15 and CD184, other commonly used markers of NSC (C. Lin thesis).

While markers such as CD133 have been crucial in advancing our understanding of CSC in various tumors types, there are limitations of using such cell surface markers. Cell surface markers do not necessarily encompass functional significance and, as such, are not reflective of the underlying biology of the tissue stem cell that regulates the development of the organ (Clevers, 2011). For the same reason, while cancer stem cells hold promise as a potential target for therapeutic intervention, the currently employed markers are not functional drug targets that will affect CSC survival.

\(Sox2\), a SRY family transcription factor, is important for the maintenance of pluripotency and self-renewal in various stem cells including ES cells (Avilion et al., 2003, Takahashi and Yamanaka, 2006), embryonic and adult NSC (Ellis et al., 2004; Suh et al., 2007), and other tissue stem cells of the stomach, testes, lens, and teeth (Arnold et al., 2011; Juuri et al., 2012). In the brain, \(Sox2\) expression is restricted to neural progenitors (neuroepithelial cells of the neural plate and early neural tube) in the mouse embryo and maintained in the neurogenic regions such as the dentate gyrus of the hippocampus and the subventricular zone surrounding the lateral ventricles in adults (Ellis et al., 2004). Subsequent fate mapping studies have shown that \(Sox2\)-expressing cells are, in fact, multipotent NSC that can differentiate into multiple lineages \textit{in vivo}
(Suh et al., 2007). Functionally, hypomorphic Sox2 alleles and Sox2 knockout studies in the brain have further confirmed the crucial role of Sox2-expressing cells in the neural stem and progenitor cell population during neurogenesis (Cavallaro et al., 2008; Ferri et al., 2004; Favaro et al., 2009). In the cerebellum, Sox2 expression has been observed in the white matter at P7 (Sutter et al., 2010), consistent with the presence of prominin+ CbSC in the white matter. In addition, Sox2 is also observed in the Bergmann glia, both at P7 (Sutter et al., 2010) and in adult mice and humans (Sottile et al., 2006; Alcock et al., 2009). It has been suggested that these Sox2-expressing Bergmann glia may also represent a novel population of multipotent stem cells, but this has not been directly examined.

The observation of high Sox2 expression in the 3 week Ptc1LacZ+/+;Trp53−/− cells cultured in neurosphere conditions (C. Lin thesis) and the known role of Sox2 in NSC prompted us to examine Sox2 as a potential prospective marker in our medulloblastoma model. Preliminary results from our lab characterized Sox2 as a marker for the prospective isolation of CbSC in WT P7 animals using a Sox2-GFP reporter allele (C. Lin thesis). Isolation of Sox2-expressing cells at P7 leads to the fractionation of self-renewal activity and these cells exhibit enriched expression of the stem cell gene Hes1 and downregulation of the granule progenitor marker Math1. As cerebellar development progresses, the frequency of Sox2-expressing cells diminishes, consistent with the reduction of self-renewal activity by 3 weeks of age. Here, I expand and confirm these observations and further examine the role of the Sox2-expressing cells in the Ptc1LacZ+/+;Trp53−/− animals and show that Sox2 also marks the aberrantly self-renewing stem cells in 3 week old Ptc1LacZ+/+;Trp53−/− animals. The establishment of Sox2 as a marker for the prospective isolation of CbSC and the aberrant tissue stem cells during medulloblastoma tumorigenesis will be
valuable for examining the endogenous mechanisms and pathways that go awry during medulloblastoma tumorigenesis.

**Results**

**Sox2-expression marks the self-renewing stem cells in the postnatal day 7 cerebella**

To examine if Sox2 can be used as a prospective marker of CbSC, we first analyzed the cerebella of WT Sox2-GFP reporter mice. The reporter allele utilized is designed to target the endogenous Sox2-locus and replace the Sox2 open reading frame with an *EGFP-loxP-neo<sup>R</sup>-loxP* cassette, while maintaining the upstream regulatory domains (Ellis *et al.*, 2004). This allele has been demonstrated to recapitulate the WT Sox2 expression during embryonic and postnatal neural development (Ellis *et al.*, 2004). To determine the frequency of Sox2-expressing cells during cerebellar development, we dissociated the cerebella from WT animals at P7 and 3 weeks and analyzed the Sox2-GFP expressing cells by FACS. At P7, there was a clearly separable population of GFP-expressing cells comprising approximately 11% of total cells (Figure 3-1). In contrast, there was a greater than 100-fold reduction of GFP-expressing cells by 3 weeks age (Figure 3-1), the time-point when cerebellar development has been completed and self-renewal activity is undetectable (C. Lin thesis).

Functionally, to determine if the Sox2-expressing cells can isolate the normal self-renewing CbSC at P7, we sorted WT Sox2-GFP negative and positive cells into a clonal density neurosphere formation assay. Neurosphere formation was only observed in the GFP-positive sorted wells, at a frequency of about 4%, and all neurospheres formed expressed GFP (C. Lin
thesis, Figure 3-2). These data show that Sox2 can be utilized as a functional marker for the prospective isolation of self-renewing stem cells in the P7 cerebella.

![Figure 3-1 The frequency of Sox2-GFP positive cells is significantly reduced during cerebellar development in wild-type animals](image)

(a) Representative FACS analyses of Sox2-GFP-positive cells in the cerebella of postnatal day 7 and 3 week old, control and Sox2-GFP knock-in reporter colony mice. (b) The frequency of Sox2-GFP-positive cells is significantly decreased during development from P7 to 3 weeks (data shown as mean±s.d; p=0.0008 by an unpaired t-test). The results represent a compilation of experiments performed by C. Lin and R.Yoo.
**Figure 3-2 Sox2 expression fractionates the self-renewal activity of CbSC in wild-type P7 animals**

(a) Unfractionated, *Sox2-GFP*-negative, and *Sox2-GFP*-positive cells were sorted into a low-density neurosphere formation assay (2000 cells per well of a 6-well plate). As observed in the fluorescent and bright field images, NS were only observed in the *Sox2-GFP*-positive wells and all NS are GFP-positive. (b) Quantification of self-renewal was carried out by counting the number of neurospheres by ImageJ analyses. C. Lin carried out these experiments and published figures in Ph.D thesis.

**Enrichment of stem cell gene expression in Sox2-GFP positive CbSC**

The isolation of the self-renewing cells by *Sox2*-expression led us to ask if other commonly used NSC markers were co-expressed with *Sox2*. The *Sox2-GFP* positive fraction had a higher frequency of cells expressing CD133 and CD15 compared to the GFP-negative cells (C. Lin thesis, Figure 3-3a). High levels of *Stat3* expression in the MBNS and CbSC (Chapter 2), suggest that MBNS self-renewal and survival mechanisms utilize conserved pathways present in developmental NSC and CbSC. Indeed, expression of *Stat3* and target genes *Klf4* and *c-myc* were highly upregulated in the *Sox2-GFP* positive cells (Figure 3-3b). The enrichment of NSC markers and genes functionally important in MBNS self-renewal, in particular *Klf4*, in the *Sox2*-positive fraction further supports the validation of *Sox2* as a marker for self-renewing CbSC.
Figure 3-3 Expression of stem cell genes are enriched in WT P7 Sox2-GFP positive cells

(a) Cell surface marker CD15 and CD133 expression measured by FACS in Sox2-GFP-negative and positive fractions. C. Lin carried out these experiments and published figures in Ph.D thesis. (b) Quantitative RT-PCR analyses of Sox2-GFP-negative and positive fractions from wild-type postnatal day 7 cerebella (n=3) show elevated levels of genes functionally involved MBNS self-renewal in the GFP positive fractions (Stat3, p=0.0024; Klf4, p=0.0342; c-myc, p=0.0578 by unpaired t-test).

Characterization of Sox2-GFP positive cells in Ptch1LacZ/+;Trp53−/− chimeras

Following the validation of the preliminary observations in the lab, we next wanted to analyze the role of the Sox2-expressing cells in the Ptch1LacZ/+;Trp53−/− animals during medulloblastoma progression. The Sox2-GFP reporter (Ellis et al., 2004) was knocked into the endogenous Sox2 locus in Ptch1LacZ/+;Trp53−/− ES cells for the generation of chimeric animals. Analyses of Ptch1LacZ/+;Trp53−/− chimeras have shown that the Ptch1LacZ/+;Trp53−/− ES cells preferentially colonize the cerebella and these chimeras develop medulloblastomas which recapitulate the tumor characteristics and kinetics of colony (germline-mutant) mice (C. Lin thesis). Quantitative
analyses by qPCR have indicated that following blastocyst injection, Ptch1 mutant ES cells have a competitive growth advantage over the host cells in the developing cerebellum, leading to increased ES cell contribution in the cerebellum observed as early P7 in these chimeric mice. Therefore, we used this system to generate larger cohorts of Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−};Sox2-GFP compound mutant animals, genotypes which are obtained at low frequency by breeding, as both Ptch1 null (Goodrich et al., 1997) and Sox2 null (Avilion et al., 2003) mutations are embryonic lethal. We carried out the analyses in the P7 and 3 week Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−};Sox2-GFP chimeras, while concurrently breeding the Sox2-GFP allele into the Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−} mouse colony for analyses of non-mosaic animals.

In the Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−} P7 chimeras, the Sox2-GFP positive cells compose a distinguishable population and were consistently present at a higher frequency than WT P7 mice, with 26% in the Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−} vs. 11% in the WT (Figure 3-4b, Figure 3-1b). In addition, the population of Sox2-GFP positive cells remains present in the 3 week old Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−} animals at a frequency of about 5%, 50-fold higher than in the WT 3 week animals (Figure 3-4b). The GFP-expressing cells in the P7 WT and Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−} cerebella are present as a distinct cluster of cells based on forward and side scatter analyses by FACS, as shown by backgating analyses of the GFP-positive populations (Figure 3-5a). The GFP-positive cells observed in the 3 week Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−} chimeras also appear to reside in the same distinct cluster of cells, a population of cells which is largely diminished by 3 weeks in the WT animals (Figure 3-5b). These observations suggest that the Sox2-expressing cells in the Ptch1\textsuperscript{LacZ+/+};Trp53\textsuperscript{−/−} animals are a developmentally persistent cell population, existing beyond the normal developmental window.
Figure 3-4 An identifiable population of Sox2-GFP expressing cells is maintained at 3 weeks in Ptch1\textsuperscript{lacZ/+};Trp53\textsuperscript{-/-} animals

(a) Representative FACS analyses of Sox2-GFP-positive cells in the cerebella of P7 and 3 week old, control and Ptch1\textsuperscript{lacZ/+};Trp53\textsuperscript{-/-};Sox2-GFP knock-in reporter chimeric mouse. Sox2-GFP positive cells persist at 3 weeks in the Ptch1\textsuperscript{lacZ/+};Trp53\textsuperscript{-/-} animals. (b) The frequency of Sox2-GFP cells is decreased during development from P7 to 3 weeks in Ptch1\textsuperscript{lacZ/+};Trp53\textsuperscript{-/-} animals (data shown as mean±s.d; p<0.0001 by an unpaired t-test. Open triangles represent chimeras and closed triangles denote colony (germline mutant animals).
Figure 3-5 Backgating analyses of Sox2-GFP positive cells in WT and Ptc1LacZ+/+;Trp53+/− P7 and 3 week animals suggest that the Sox2-positive cell population in the 3 week Ptc1LacZ+/+;Trp53−/− is a developmentally persistent population.

(a) Backgating analyses of the GFP-positive population show that the Sox2-expressing cells comprise a cell population that is distinguishable by the FSC and SSC profiles in the WT and Ptc1LacZ+/+;Trp53−/− P7 cerebella. (b) Sox2-expressing cells in 3 week Ptc1LacZ+/+;Trp53−/− animals are also present as a distinct cell population, as recognizable by FSC and SSC profiles. This population is absent in 3 week WT animals.
Figure 3-5 (Continued)

a

WT

P7

Ptc; p53

b

WT

3 Week

Ptc; p53
Sox2-expression isolates the self-renewing cells in 3 week $Ptch1^{LacZ/+};Trp53^{-/-}$ cerebella

We next asked if the Sox2-expressing cells persisting at 3 weeks in the $Ptch1^{LacZ/+};Trp53^{-/-}$ animals are functionally associated with the aberrantly self-renewing population by sorting the GFP-negative and GFP-positive cells from $Ptch1^{LacZ/+};Trp53^{-/-}$ colony mice directly into the clonal-density, neurosphere formation assay. (As further described in the discussion, $Ptch1^{LacZ/+};Trp53^{-/-}$ chimeras were not analyzed for self-renewal activity due to confounding factors of host cell contribution). As observed in the WT CbSC, neurosphere formation only occurred in the GFP-positive fraction and all NS formed were GFP-positive (Figure 3-6). While the number of animals analyzed was limited due to low frequency of deriving the $Ptch1^{LacZ/+};Trp53^{-/-};Sox2-GFP$ compound mutants by breeding, the results suggest that Sox2-GFP expression also exclusively marks the aberrantly self-renewing cells in the $Ptch1^{LacZ/+};Trp53^{-/-}$ animals at 3 weeks. Furthermore, the GFP-positive population is significantly higher in the $Ptch1^{LacZ/+};Trp53^{-/-}$ animals at both P7 and 3 weeks, suggesting that deregulation of the stem cell population may be occurring in early postnatal development.

**Figure 3-6 Sox2-expressing cells mark the self-renewing cells in the 3 week $Ptch1^{LacZ/+};Trp53^{-/-}$ cerebella**

(a) $Ptch1^{LacZ/+};Trp53^{-/-}$; Sox2-GFP positive and negative cells were sorted into the clonal-density NS formation assay (2000 cells per well of a 6-well plate). Enrichment of self-renewal activity was observed in the Sox2-GFP fraction and all NS are GFP positive. (b) Quantification of self-renewal carried out by ImageJ show an average self-renewal of 1.8%. Statistical analyses were carried out by one-way ANOVA with a Bonferroni post test.
Figure 3-7 Summary of the frequency of GFP-expressing cells in P7 and 3 week WT Sox2-GFP and Ptc^LacZ/+;Trp53^-/- Sox2-GFP animals

Comparison of the frequency of GFP-positive cells between the WT and Ptc^LacZ/+;Trp53^-/- Sox2-GFP animals at P7 and 3 weeks shows a significant increase in GFP-positive cells in the Ptc^LacZ/+;Trp53^-/- genotype at both timepoints. Statistical significance was determined by individual t-tests between the two different genotypes.

**Differential gene expression between P7 WT and 3 week Ptc^LacZ/+;Trp53^-/- Sox2-GFP positive cells**

To determine if there are differences in gene expression between the Sox2-expressing and non-expressing cells, we sorted the GFP-negative and positive fractions from P7 WT colony mice and 3 week Ptc^LacZ/+;Trp53^-/- chimeras and colony mice for the isolation of RNA. Resorting the GFP-negative and positive fractions further improved the purity of the FACS fractionation, ensuring expression analyses from cells highly enriched for Sox2-expressing and non-expressing cells (Figure 3-8).
Figure 3-8 Sox2-GFP negative and positive cells were re-sorted to increase purity for RNA isolation for gene expression analysis.

Representative examples of FACS plots of GFP expression in P7 WT and 3 Week Ptc; p53⁻/⁻; Sox2-GFP cerebella as analyzed by MoFlo. GFP-negative and positive fractions were collected and each fraction was re-sorted to obtain an increased purity in the fractions.

For validation of the FACS sorts, we examined the expression of the GFP transgene and observed a 50-fold enrichment in the WT P7 Sox2-GFP fractions and about 20-fold enrichment in all of the 3 week Ptc; p53⁻/⁻; Sox2-GFP positive fractions, relative to a P7 WT Sox2-negative control. We next examined the gene expression of a small panel of stem cell, granule cell progenitor, and Shh pathway activation genes in the Sox2-positive fractions, which were all normalized to a P7 WT Sox2-negative sample. In the WT P7 cerebella, enrichment of Sox2 expression and upregulation of Hes1, a gene important in the self-renewal of NSC (Nakamura et al., 2000) was negatively correlated with the expression of Math1, a marker for cerebellar
granule neurons (Figure 3-9a). In contrast, in the 3 week $Ptch1^{LacZ/+};Trp53^{-/-}$ animals, $Sox2$ expression was not associated with a depletion of $Math1$ expression, but showed an increase in $Math1$ in comparison to the WT P7 $Sox2$-negative fraction (Figure 3-9b). In addition, $Gli1$ and $Gli2$ expression was also slightly higher in the 3 week $Ptch1^{LacZ/+};Trp53^{-/-};Sox2$-positive cells. This suggests that while the 3 week $Ptch1^{LacZ/+};Trp53^{-/-};Sox2$-positive cells represent a population of aberrantly self-renewing stem cells, they are also responsive to the differentiation signals of the Shh pathways, which are active during cerebellar development, and may be maintaining characteristics of both cerebellar stem cell and granule cell progenitors.

![Figure 3-9](image)

**Figure 3-9** Differential gene expression of granule cell progenitor markers in the 3 week $Ptch1^{LacZ/+};Trp53^{-/-};Sox2$-GFP positive cerebellar cells

qRT-PCR expression analyses of stem cell markers $Sox2$ and $Hes1$ and granule cell progenitor markers $Math1$, $Gli1$ and $Gli2$ in $Sox2$-positive sorted cells from (a) wild-type P7 colony mice (n=8) and (b) $Ptch1^{LacZ/+};Trp53^{-/-}$ 3 week chimeras (n=4). Fold change in expression is represented relative to P7 WT $Sox2$-negative cell fractions, which is normalized to 1.
Discussion

The $Ptch1^{LacZ+};Trp53^{-/-}$ mouse model of medulloblastoma reveals a population of self-renewing cells from the tumor and at 3 weeks, a developmental time-point when normal cerebellar development is complete and self-renewal activity is largely non-existent (C. Lin thesis). While the MBNS have potent tumor-initiating capability, the aberrantly self-renewing cells from 3-week-old mice have not yet undergone loss of heterozygosity of the $Ptch1$ allele, the tumor-initiating event in the $Ptch1$ model, and do not form tumors (Yang et al., 2008b) (C. Lin thesis). While in vitro enrichment of this pre-malignant tissue stem cell population by serial neurosphere culture has been valuable in uncovering the mechanisms for tumor-initiating events, a prospective marker allowing for isolation of an endogenously occurring, bona fide self-renewing tissue stem cell circumvents concerns about tissue culture-induced changes or enrichment of heterogeneous cell types. Here we show that $Sox2$-$GFP$ expression fractionates the self-renewal activity in both the P7 WT and 3 week $Ptch1^{LacZ+};Trp53^{-/-}$ cerebella, thus validating $Sox2$ as a marker for the prospective isolation of the endogenous self-renewing CbSC as well as the aberrant CbSC. This novel marker will have great utility for further examination of stem cell regulation during medulloblastoma tumorigenesis.

$Sox2$ as a prospective marker for self-renewing normal and aberrantly persistent CbSC

Critical for the validation of CSC markers is the strict correlation between marker expression with bona fide self-renewal activity (Clarke et al., 2006). For example, it has been shown that CD133, a widely used cell surface marker, does not strictly isolate stem cell activity, as CD133-negative cells also demonstrated properties of self-renewal (Sun et al., 2009). Variations in FACS isolation with cell surface marker staining have also been reported to be
subject to inconsistencies due to antibody differences and other technical variations (Visvader and Lindeman, 2012). By using an endogenous reporter for Sox2-expression, we show that the prospective isolation of Sox2-expressing cells fractionated the self-renewing, developmental CbSC at P7. No NS formation was observed in the GFP-negative fraction and all the neurospheres that formed were GFP-positive. By 3 weeks of age, the frequency of Sox2-expressing cells is significantly reduced, consistent with the abolished self-renewal activity at 3 weeks in WT animals. In contrast, although at a significantly lower frequency than the P7 Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} animals, GFP-positive cells were reliably sorted from every 3 week Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} animal. However, the functional significance of the wide variability in the frequency of Sox2-positive cells in the 3 week Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} cerebella is unknown. Nonetheless, Sox2-expression also unambiguously marked the self-renewing cells in the developmentally persistent stem cells in the 3 week Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} cerebella. While the mechanism of developmental persistence is unknown, the absence of GFP-negative NS suggests that the expression of Sox2 may be functionally important in the self-renewal of CbSC, further supporting Sox2 as a robust marker. The functional role of Sox2 in NSC maintenance and neurogenesis is well-established and it’s role in CSC self-renewal, specifically, has also been demonstrated in glioblastoma (Gangemi et al., 2009) and breast cancer (Leis et al., 2011). Alternative to the hypothesis of the persistence of Sox2-positive CbSC during development, we must also consider the possibility of a Sox2-expressing population arising \textit{de novo} during the development of Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} animals, rather than an endogenous Sox2-expressing population persisting from early development. To address this, an inducible Sox2-GFP allele may be utilized to track the Sox2-expression during development. Using the Sox2-
CreER;ROSA26-IsI-EYFP mice, tamoxifen-induced recombination can be carried out to activate the expression of the fluorescent marker then tracked during cerebellar development.

**Analyses of P*tc*h*1^LacZ/++;Trp53^-/-;Sox2-GFP chimeras**

It must be noted that the analyses of the P*tc*h*1^LacZ/++;Trp53^-/-;Sox2-GFP chimeras have caveats. While the complete colonization of the cerebella by the P*tc*h*1^LacZ/++;Trp53^-/- ES cells in chimeric mice has been carefully validated (C. Lin thesis), the effect of the Sox2-GFP reporter allele on this colonization phenotype has not been directly examined. The Sox2-GFP reporter allele is knocked into the endogenous Sox2 promoter and targeting results in the inactivation of one Sox2 allele. While the Sox2 heterozygous animals are viable and display no overt abnormalities (Avilion et al., 2003), given the importance of Sox2 in NSC, the possibility of a haploinsufficient effect of Sox2 heterozygosity on the colonization phenotype cannot be disregarded. The analyses of P7 P*tc*h*1^LacZ/++;Trp53^-/-;Sox2-GFP chimeras demonstrate that this in fact, may be the case; the formation of GFP-negative neurospheres was observed in the Sox2-GFP negative fractions in the low-density neurosphere formation assay, implying that there may be WT host-derived contamination. To circumvent the confounding factors introduced by the contamination of the host cells WT for Sox2, further analyses of P*tc*h*1^LacZ/++;Trp53^-/-;Sox2-GFP animals were only carried out with colony (germline-mutant) animals.

**Differential gene expression between the Sox2-GFP expressing P7 cerebellar stem cells and 3 week aberrant tissue stem cells**

Despite the complications that may arise from the chimeric analyses, as the host cells lack the GFP allele, the Sox2-GFP-positive fractions from the chimeras are all necessarily
derived from ES cells, and thus have been used for analyses of gene expression. In the case of the GFP-negative cells, although wild-type host cells are not expected to express Sox2 at 3 weeks, they do retain both copies of the WT Sox2 allele and may confound the analyses of gene expression in the 3 week Ptch1\textsuperscript{\textit{LacZ/\textplus;Trp53\textsuperscript{-/-}}} Sox2-negative fractions. Therefore, chimera-derived GFP-negative cells from 3 week old mice have not been included in the gene expression analyses; the Sox2-\textit{GFP} negative fractions of the WT Sox2-\textit{GFP} animals derived from the colony were used as controls.

In the WT P7 Sox2-\textit{GFP} positive cells, there was an enrichment for the expression of \textit{Hes1}, a stem cell marker, and Sox2-expression was negatively correlated with \textit{Math1}. This pattern of gene expression is consistent with the Sox2-positive cells representing CbSC and the Sox2-negative cells containing the \textit{Math1} lineage-restricted granule cell progenitors, which are actively proliferating at P7. The maintenance of the \textit{Math1} expression and to a lesser extent \textit{Gli1} and \textit{Gli2} expression in the 3 week Ptch1\textsuperscript{\textit{LacZ/\textplus;Trp53\textsuperscript{-/-}}} Sox2-positive cells suggests that the aberrantly self-renewing cells are responsive to the Shh signaling pathway for granule-lineage determination, but also concurrently exhibit NSC characteristics. Whether this is due to a resistance to differentiation or an ectopic acquisition of stem cell behavior in differentiated granule cell progenitors are both potential mechanisms that may be explored. bFGF, which is present in NS culture conditions, has been shown to abolish Shh-induced proliferation and promote differentiation of the GCP (Fogarty \textit{et al.}, 2007). Neurosphere formation of the \textit{Ptch1\textsuperscript{\textit{LacZ/\textplus;Trp53\textsuperscript{-/-}}} Sox2} positive cells from 3 week old animals suggests that these cells are exhibiting a block in differentiation.
**Future Studies**

Using the Sox2-GFP positive and negative sorted fractions, a genome-wide expression analyses will be carried out. There will be great utility for the genome-wide expression profiles and signatures of the specific subsets of cell populations, such as CSC and premalignant stem cells in the Ptch1^{LacZ/+};Trp53^{-/-} model. Potentially, gene expression profiles specifically identifying the CSC population may have important clinical implications. In fact, in the hematopoietic system, the characterization and comparison of HSC and leukemia stem cell expression profiles have allowed for the accurate prediction of patient outcomes (Eppert *et al.*, 2011). It can be imagined that the identification of a medulloblastoma stem cell-specific expression profile can be used to better predict prognoses and improve risk stratification. Insights into the mechanisms and pathways involved in the persistence of aberrant tissue stem cells will also be important. For example, if the aberrantly persisting stem cells are expanding the pool of targets for oncogenic transformation, reduction or elimination of this population may decrease the frequency of cells acquiring the transforming mutation (Wicha *et al.*, 2006), allowing for earlier therapeutic intervention.

Sox2-positive cells can also be isolated from postnatal day 7 Ptch1^{LacZ/+};Trp53^{-/-} Sox2-positive animals. By comparing this to the WT Sox2-GFP cells, this will allow us to determine if the Ptch1^{LacZ/+};Trp53^{-/-} genotype exhibit aberrant patterns of gene expression early on in cerebellar development.

**Methods**

*ES cell generation*

V6.5 wild-type ES cells were electroporated with the Sox2-GFP targeting vector (Ellis *et al.*, 2004, generous gift from K. Hochedlinger) and selected in neomycin for 7 days. The Sox2-GFP
targeting vector was modified to exchange the neomycin-selection cassette with a puromycin-selection cassette for electroporation into Ptch1<sup>LacZ/+</sup>;Trp53<sup>−/−</sup> ES cells. Neomycin- and puromycin-resistant colonies were picked and expanded for genotyping for targeting by a quantitative qPCR for genomic copy number of the Sox2 allele.

*Generation of mouse chimeras and animal husbandry*

Blastocyst stage embryos were isolated from CD-1 superovulated females crossed to CD-1 males (Charles River) at 2.5dpc and cultured in KSOM-AA overnight. Expanded blastocysts were injected with 5-10 WT Sox2-GFP and Ptch1<sup>LacZ/+</sup>;Trp53<sup>−/−</sup> Sox2-GFP ES cells and transferred to 2.5dpc pseudopregnant CD-1 females. WT Sox2-GFP chimeric males were crossed to Albino/B6 females and germline transmission was confirmed by genotyping F1 pups for the Sox2-GFP allele. Sox2-GFP mice were bred into the Ptch1 and Trp53 mutant background for generation of Ptch1<sup>LacZ/+</sup>;Trp53<sup>−/−</sup> animals. Ptch1<sup>LacZ/+</sup>;Trp53<sup>−/−</sup> Sox2-GFP chimeras were used directly for experiments. Mice were maintained in pathogen-free conditions at Boston Children’s Hospital and procedures were performed following approval by the Institutional Animal Care and Use Committee (IACUC).

*Flow cytometry*

Cerebellar tissues were dissociated into single cell suspension by mincing with a razor blade and followed by trituration in NS media, washed and resuspended in PBS+2mM EDTA+0.5% BSA and run on a BD FACS Aria and Beckman Coulter/Dako MoFlo at the HSCI/Joslin Flow Cytometry Core. Samples were stained with 7-AAD (BD Biosciences) for exclusion of dead cells and gated on the GFP-positive or GFP-negative fractions. For the low-density neurosphere
formation assay, cells were sorted directly into a 6-well plate with neurosphere culture media (DMEM:F12 containing B27 Supplement (Invitrogen), 20ng/ml bFGF (Invitrogen), 20ng/ml EGF (Invitrogen), and 100U/ml penicillin/streptomycin (Invitrogen)).

Expression analyses by quantitative PCR

Sox2-GFP-positive and negative sorted cells were pelleted and resuspended in Trizol Reagent (Invitrogen) for RNA isolation, using RNase-free glycogen (Invitrogen) as a carrier. Isolated RNA was treated with DNaseI (New England Biolabs) and synthesized as cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was carried with the SYBR Green PCR Master Mix (Applied Biosystems) using cDNA dilutions determined by prior primer optimization experiments. GFP, Sox2, Gli1, Gli2, Hes1, and Math1 expression was normalized to Gapdh and changes in gene expression were determined by the ddCT method and represented as expression levels relative to the P7 WT Sox2-GFP negative control.

Primers:
Gapdh: 5’ GTTGTCTCCTGCAGCATCTCAG 3’; 5’ TGGTCCAGGGTTTCTTACTC 3’
GFP: 5’ GAAAGGAGAGGTTAAGG 3’; 5’ CTTGTACAGCTCGTCCATG 3’
Sox2: 5’ CCGAGGAGAGAGCGCTGT 3’; 5’ GCTCGAGACGGCGAAGTG 3’
Gli1: 5’ TCTAAGGGCCATCAGGCTATGCT 3’; 5’ GCTCGAGACGGCGAAGTG 3’
Gli2: 5’ TCGGCTCTGTGAGG 3’; 5’ TCGGCTCTGTGAGG 3’
Hes1: 5’ ATGCCGGGAGCTATCTTTCT 3’; 5’ GCTCGAGACGGCGAAGTG 3’
Math1: 5’ ACAGGTCTGTGCTTGC 3’; 5’ GCTCGAGACGGCGAAGTG 3’
Chapter 4: Conclusions and Future Directions
Prior to the emergence of “medulloblastomics”, medulloblastoma has been largely considered and studied as a single-entity disease but it has become evident that it is, in fact, a heterogeneous collection of tumors comprised of distinct molecular subtypes (Northcott et al., 2012). The generation and examination of subtype-matched mouse models have shed light on discrete mechanisms for disease progression and the cell of origin (Kool et al., 2012). Now with the core four groups of medulloblastoma established, studying the heterogeneity within a subgroup for further subcategorization may also be relevant for the investigation of targeted therapies. As such, it has been shown that within the SHH tumors, pediatric and adult tumors are transcriptionally, genetically, and clinically discrete (Northcott et al., 2011a). Work in our lab has also shown that the $Ptch1^{LacZ/+}$ and $Ptch1^{LacZ/+};Trp53^{-/-}$ genotypes also result in functionally distinct tumors in mice. Notably, the $Ptch1^{LacZ/+};Trp53^{-/-}$ model results in aggressive tumors with a population of self-renewing and tumor-propagating cells (C. Lin thesis). In addition, while the cell of origin in the SHH tumors has been established as the granule cell progenitors (GCP), cerebellar stem cells (CbSC) have been suggested as another potential tumor-initiating cell population (C. Lin thesis). Recent work has also shown that postnatal CbSC transformed with the overexpression of c-myc can lead to tumor-initiation upon transplantation (Kawauchi et al., 2012; Pei et al., 2012). The presence of a self-renewing, tumor-initiating stem cell population in the $Ptch1^{LacZ/+};Trp53^{-/-}$ tumors and the observation of an aberrantly self-renewing, premalignant population of CbSC further substantiated the examination of stem cell regulation in this medulloblastoma model.
In Chapter 2, we wanted to examine the pathway dependencies and plasticity mechanisms of the self-renewing, tumor-initiating cells in the $Ptch1^{LacZ/+};Trp53^{-/-}$ medulloblastomas. Specifically, we asked if an endogenously active pluripotency transcription factor network could be utilized for the survival and maintenance of self-renewal of the $Ptch1^{LacZ/+};Trp53^{-/-}$ MBNS. The observation of phenotypic plasticity and conversion of the tumor-initiating medulloblastoma neurosphere cells in the ES culture conditions in the absence of ectopic factors led us to ask if epigenetic regulation such as DNA methylation alterations could be involved. This subsequently led to the identification of reprogramming factor $Klf4$ as a gene important in the mediating both the MBNS plasticity and self-renewal.

The functional role of pluripotency genes in mediating cancer stem-like phenotypes has been described. For example, $Oct4$ expression induces the dedifferentiation of melanoma cells and leads to the acquisition of CSC characteristics, such as expression of melanoma stem cell markers and multipotent differentiation (Kumar et al., 2012). Furthermore, the induction of pluripotency gene expression in immortalized breast epithelial cells results in the formation of cancer stem-like cells with tumor-initiating ability and interestingly, an increased resistance to chemotherapeutic agents (Nishi et al., 2013). The similarities between the expression profiles of ES cells and high-grade, malignant tumors (Ben-Porath et al., 2008) further provide a rationale for the “oncogenic reprogramming” model for the generation and maintenance of CSC. However, the examination of the role of $c-myc$ in the transcriptional profiles of cancer cells has revealed that the ES gene signature is merely reflective of an activated $c-myc$ signature of tumors (Kim et al., 2010). Functionally, the role of $c-myc$ has been further shown to globally amplify the output of existing transcriptional programs by increased binding at the promoters and enhancers of genes already activated (Lin et al., 2012), shedding light on the mechanism for the diverse
effects of \(c\text{-}myc\) observed in various tumors. If \(c\text{-}myc\) is functioning in a similar manner in the \(Ptch1^{LacZ/+};Trp53^{-/-}\) medulloblastomas, it can be postulated to be playing a role in promoting stem cell-driven tumorigenesis by amplifying the activated stem cell signatures in the aberrant tissue stem cells. Though the potential mechanism of dedifferentiation of GCP or CbSC during \(Ptch1^{LacZ/+};Trp53^{-/-}\) tumor progression has not been directly addressed in this study, the plasticity of tumor cells to alter cellular states and respond to different environmental variations remains an plausible mechanism for tumor stem cell survival, metastases and treatment evasion.

\(Klf4\) overexpression has been shown to abrogate the necessity for exogenous LIF in ES culture media for the maintenance of ES cells in an undifferentiated state (Zhang et al., 2010). \(Klf4\) is also a known direct downstream target of the Stat3 pathway, crucial in ES cells (Niwa et al., 1998), NSC (Yoshimatsu et al., 2006; Androutsellis-Theotokis et al., 2006) and observed to be aberrantly activated in various tumors (Yu and Jove, 2004), including brain tumors (Schaefer et al., 2002; Yang et al., 2008a). Based on the observation of LIF independence and \(Stat3\) overexpression and constitutive activation in the MBNS, we hypothesized that upstream \(Stat3\) signaling may be mediating the function of \(Klf4\). However, \(Stat3\) kd by pharmacological inhibition and RNAi both led to a partial and non-significant effect on the self-renewal of the MBNS, especially in the limiting dilution assay. Furthermore, \(Klf4\) expression levels rebounded in \(Stat3\) kd neurospheres, suggesting that the regulation of \(Klf4\) can occur in a manner independent of the canonical LIF/Stat3 pathway to maintain clonogenic growth. The \(Stat3\)-independent compensatory mechanism remains to be determined, but highlights the importance of uncovering the multiple modes of \(Klf4\) regulation for a more extensive understanding of the transcriptional networks regulating the self-renewal and survival pathways in the tumor-initiating cells.
Through the modulation of Stat3 and Klf4 levels, we observed that the expression of Klf4 is crucial for MBNS plasticity and self-renewal and can be regulated in a Stat3-independent manner. The novel role of Klf4 in maintaining the clonogenic growth of self-renewing cells in a medulloblastoma model provides the rationale to further examine the function of KLF4 in human medulloblastomas, specifically in the class of human tumors with the poorest rates of survival. While KLF4 expression is not enriched in the Class C human medulloblastomas (data not shown), which have the lowest survival rates, if it is functioning in a small subset of self-renewing cells within the bulk tumor, the expression levels may not be reflected in the gene expression analysis of bulk tumors. The expression levels of KLF4 specifically in a population of cells enriched for self-renewal, such as prominin 1 positive cells, may be important and interesting to analyze. Further, the therapeutic potential of KLF4 inhibition can also be considered. A pilot experiment in the MBNS testing the synergy between Klf4 kd and gamma irradiation, a treatment modality used in human medulloblastoma patients, suggests that the kd of Klf4 may sensitize the cells to doses of radiation ineffective in cells with WT levels of Klf4, as measured by a decrease in NS formation frequency with the combination of Klf4 kd and irradiation. Further validation of this experiment must be carried out, but these initial observations provide an additional motivation for studying the role of Klf4 in the survival of the tumor-initiating, self-renewal population in medulloblastomas. In the MBNS, the maintenance of antiapoptotic gene expression was associated with the compensatory upregulation of Klf4. While this is suggestive of an antiapoptotic role of Klf4, which has been reported (Ghaleb et al., 2007), functional apoptosis following Klf4 kd must first be addressed and can be measured by a variety of assays such as TUNEL staining, cleaved Caspase-3 staining in the MBNS. During Ras-mediated transformation, Klf4 has been shown to directly repress the transcription of p53,
leading to resistance to DNA-damage mediated apoptosis (Rowland et al., 2005). Since a mechanism for radiation sensitization by Klf4 inhibition will be a Trp53-independent mechanism if demonstrated in Ptch1LacZ/;Trp53−/−, this will be important, considering that human medulloblastoma patients harboring somatic TP53 mutations exhibit early disease recurrence and lack of long-term survival compared to patients with WT TP53 receiving the same craniospinal irradiation and chemotherapy (Tabori et al., 2010).

The compensatory mechanism of transcription factors in related pathways may be a general mechanism of CSC to exhibit plasticity and survival against the environmental challenges they must overcome, such as irradiation or adaptation to a new niches during metastases. Therefore, it will be important to characterize such mechanisms and determine if multiple pathways must be targeted for effective treatment. In contrast to oncogene addiction, in which tumor cells are dependent on a specific gene for survival, CSC may exhibit flexibility in the regulation of the expression of functionally redundant genes important for its survival and therefore require targeting multiple genes to exert a “synthetic lethality” effect (Luo et al., 2009).

Further expanding on the idea of targeting multiple pathways in CSC, our observations may provide the rationale for the combinatory inhibition of the Shh pathway and pathways important for self-renewal. Since the effect of Stat3 inhibition alone on self-renewal was partial, the inhibition of the Shh pathway in combination with Stat3 inhibition is a potential approach that may be examined. Considerable efforts have been made to target the Stat3 and Shh pathways in medulloblastomas and other tumors, therefore small molecule inhibitors are readily available. Constitutive Stat3 activation is observed in human medulloblastomas (Schaefer et al., 2002; Yang et al., 2008a), with the NSC survival-associated phosphorylation of Ser727 (Androutsellis-Theotokis et al., 2006) occurring as a tumor-specific activation (Schaefer et al., 2002; Yang et
Multikinase inhibitors whose activities are associated with the inhibition of Stat3 phosphorylation (Yang et al., 2008a; 2010a), selective inhibitors of the Jak2/Stat3 pathway (i.e. JSI-124) (Lo et al., 2008), and Stat3 DNA binding site inhibitors (Ball et al., 2011) have all been shown to reduce proliferation and induce apoptosis in multiple medulloblastoma cell lines. Interestingly, JSI-124 treatment was shown to sensitize the medulloblastoma cells to an otherwise ineffective chemotherapeutic, BCNU, and displayed synergy with cisplatin in inhibiting medulloblastoma cell survival (Lo et al., 2008). Importantly, both chemotherapeutics are currently used to treat medulloblastoma patients in the clinic. Specifically in brain tumor stem cell populations, small molecule Stat3 inhibitors (Stattic and STA-21) have been demonstrated to inhibit glioblastoma stem cell neurosphere formation and induce apoptosis (Sherry et al., 2009; Villalva et al., 2011). However, the effect of Stat3 inhibition on the expression of target gene Klf4 has not been examined in these studies and remains to be determined if the therapeutic function of Stat3 inhibitors is mediated by a downstream inhibition of Klf4, as suggested in our work.

Given the well-established role of the SHH pathway in cerebellar and medulloblastoma development, a number of SHH inhibitors, including Cyclopamine and SMO antagonist, HhAntag have been reported to be effective in slowing the growth of SHH tumors (Berman et al., 2002; Romer et al., 2004). In particular, SMO antagonist GDC-0449 has had partial success in the clinic, whereby rapid tumor regression was observed following GDC-0449 treatment in an adult patient with a SHH pathway-activated tumor (Rudin et al., 2009). However, tumor relapse occurred rapidly and widespread dissemination followed. The mechanism of resistance was subsequently identified to be a somatic mutation in the drug binding site in SMO, which did not exist prior to treatment (Yauch et al., 2009). To overcome resistance mechanisms, new inhibitors
effective against the GDC-0449-resistant mutants were identified in a small molecule inhibitor screen, but additional resistance mechanisms occurring downstream of SMO prompted the targeting of an alternative pathway for overcoming resistance (Dijkgraaf et al., 2011). Importantly, GDC-0449-resistant mutants were sensitive to PI3K/Akt inhibition, suggesting this pathway as a potential target in GDC-044-resistant tumors (Dijkgraaf et al., 2011). These observations are consistent with the idea that a unique population of cells within the tumor may possess the ability to utilize multiple compensatory pathways for survival. Therefore, studying the self-renewing cells that specifically exhibit properties of plasticity and survival in varying growth conditions may also present a novel strategy for examining resistance mechanisms.

In Chapter 3, we sought to validate Sox2 as a prospective marker for the isolation of postnatal CbSC and further establish it as a marker for the enrichment of the aberrantly self-renewing, premalignant stem cells in the Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{−/−} animals. Culturing glioblastoma cells as neurospheres in serum-free culture in the presence of bFGF and EGF has been described for the isolation of self-renewing, multipotent, tumor-initiating cells expressing NSC markers (Yuan et al., 2004) and maintenance of the characteristics of the primary tumors (Lee et al., 2006). Only the neurosphere cells, but not the non-sphere-forming cells, were able to initiate tumor-formation \textit{in vivo} (Yuan et al., 2004). Similarly, in the absence of appropriate markers for CSC for the Ptch1\textsuperscript{LacZ/+};Trp53 medulloblastomas, we first utilized the neurosphere culture-based system to isolate and characterize pathways important in self-renewal and survival. The Ptch1\textsuperscript{LacZ/+};Trp53 MBNS exhibit self-renewal, as demonstrated by limiting dilution assays and the derivation of clonal lines, high expression of NSC markers CD133, nestin, and possess potent ability for tumor-initiation \textit{in vivo} (C. Lin thesis). We must note, however, that the multipotent
differentiation capability of these medulloblastoma-initiating neurosphere cells has not been directly addressed. Growth factor withdrawal from the $P{tch1}^{LacZ/+};Trp{53}$ MBNS suggests a block in differentiation as observed by the maintenance of $Sox2$ expression following bFGF and EGF removal. The withdrawal of growth factors from the aberrant $P{tch1}^{LacZ/+};Trp{53}$ tissue stem cells, also enriched by neurospheres cultures, however, exhibited a reduction in $Sox2$ expression. The neurosphere culture method has also been utilized to isolate bFGF and EGF-responsive multipotent CbSC from the postnatal d7 cerebella (Lee et al., 2005). The persistence of a bFGF and EGF-responsive population in 3 week old $P{tch1}^{LacZ/+};Trp{53}$ animals at a time point when cerebellar development is complete, suggests an developmentally persistent population of stem cells. Cerebellar granule progenitor cells proliferate in response to SHH during cerebellar development, but bFGF directly inhibits SHH signaling (Fogarty et al., 2007). The CbSC may have a block in differentiation that allows them to persist as stem cells, however, the possibility of progenitor cells dedifferentiating to stem-like cells with neurosphere-forming capability also cannot be ruled out. To further this question, a marker for the prospective genetic marking of stem cells is necessary, which we have started to address by examining the potential for $Sox2$ as a prospective marker for the aberrant CbSC during medulloblastoma progression.

Using an endogenous $Sox2$-GFP reporter allele, we observed that the prospective isolation of $Sox2$-expressing cells was able to fractionate the self-renewing activity in the WT CbSC and the aberrant tissue stem cells. Preliminary expression analyses with a small subset of genes also show that expression of $Math1$, a marker for GCP, is inversely correlated with $Sox2$ expression in the WT CbSC. However, in the 3 week $P{tch1}^{LacZ/+};Trp{53}^{-/-};Sox2$-GFP cells, the expression of $Math1$, $Gli1$ and $Gli2$ suggest that the responsiveness to the Shh signaling for granule cell differentiation is intact, but stem cell characteristics are also maintained. Genome-
wide transcriptional profiling of these aberrantly self-renewing stem cells will provide further insight into the mechanisms and pathways of developmental persistence and block in differentiation. In addition, comparison of the 3 week aberrant tissue stem cells and the P7 CbSC will allow us to identify pathways or therapeutic targets specific to the aberrant population, which is especially critical given that medulloblastomas are developmental tumors and nonspecific effects of therapeutics may have dire side effects in young patients. Comparison of the WT and \textit{Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-};Sox2-GFP} CbSC at P7 may also provide insight into the early mechanisms of stem cell deregulation.

For future studies, the \textit{Sox2-GFP} reporter can also be utilized to determine the localization of \textit{Sox2}-expressing cells during cerebellar development and malignant progression. At P7, \textit{Sox2} expression is observed in the white matter, coinciding with the location of the CD133-positive CbSC (Lee \textit{et al.}, 2005). With further maturation of the cerebellum, by P25 and in the adult, \textit{Sox2} expression is restricted to the Purkinje cell layer, specifically marking the Bergmann glia (Sottile \textit{et al.}, 2006). The location of the \textit{Sox2}-expressing population in the 3 week \textit{Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-}} cerebella is currently unknown. Based on the current knowledge of \textit{Sox2}-expression during normal cerebellar development, it can be postulated that the \textit{Sox2}-positive cells are marking the subset of CbSC present in the white matter, aberrantly persisting due to a deficiency in differentiation. Alternatively, \textit{Sox2}-expression may be marking an expanded \textit{Sox2}-positive Bergman glial cell population, which has been proposed as a potential NSC population that has yet to be characterized (Sottile \textit{et al.}, 2006). Another possibility is the dedifferentiation of lineage-restricted GCP cells of the EGL, due to an acquisition of stem cell character during progenitor expansion. Histological or immunohistochemical analyses of \textit{Sox2} expression in both WT and \textit{Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-}} tissues will allow for us to determine the location
of the Sox2-expressing cells and further our understanding of the possible cell of origin and mechanisms of \( Ptch1^{LacZ^+}\cdot Trp53^{-} \) medulloblastoma progression. In addition, similar to the recent lineage tracing studies which identified \textit{bona fide} CSC \textit{in vivo}, with an inducible Sox2-GFP reporter, lineage tracing can be carried out to examine the individual contribution of the Sox2-expressing cells during medulloblastoma progression and if the progeny of the Sox2-GFP cells do, in fact, mark the resultant tumor in the \( Ptch1^{LacZ^+}\cdot Trp53^{-} \) animals.

The Sox2-GFP marker may be useful, not only in the developmental context but also as a marker for the MBNS in the endpoint \( Ptch1^{LacZ^+}\cdot Trp53^{-} \) tumors. The analyses of Sox2-expressing cells in the tumors may yield greater insight into the potential role for dedifferentiation or reprogramming-like mechanisms in CSC. The use of long-term passage MBNS lines for the \textit{in vitro} reprogramming assay has made it difficult to address whether or not the cells with the capability for growing in ES culture conditions were a preexisting population in the tumor or a result of long-term culture-induced changes. The direct isolation of the Sox2-GFP population into ES culture conditions in the \textit{in vitro} reprogramming assay will allow us to determine more definitively if a pre-existing, endogenous population of stem cells with the ability for reprogramming is preexisting in the tumor.

In a tentative hypothesis for the aberrant persistence of tissue stem cells in the \( Ptch1^{LacZ^+}\cdot Trp53^{-} \) animals (Figure 4-1), we postulate that a deregulation of stem cell self-renewal and resistance to differentiation may be mediated by collaboration between the loss of \( Trp53 \) function and activated Shh signaling. This is suggested by the increase in basal level of self-renewal in 3 week \( Trp53^{-} \) animals (C. Lin thesis), which is consistent with the role of p53 in the maintenance of NSC populations (Meletis \textit{et al.}, 2006) and dedifferentiation during
somatic reprogramming (Krizhanovsky and Lowe, 2009). Furthermore, a Gli1 and Trp53 negative regulatory loop was described to control NSC numbers (Stecca and Ruiz i Altaba, 2009), whereby Gli1 negatively regulates Trp53 to increase stem cell activity and Trp53 in turn inhibits Gli1 activity, thereby ensuring the control of NSC proliferation. However, in the Ptch1\(^{LacZ^+/+;Trp53^{-/-}}\) genotype, it can be hypothesized that both genetic mutations alter the stem cell activity, as the Ptch1 mutation will lead to an increase in downstream Gli1 expression and the Trp53 null genotype to a deregulation in the inhibitory loop. The activation of the HH-GLI pathway has been reported to maintain the self-renewal of glioma stem cells (Clement \textit{et al.}, 2007) and induce an ES stem-like signature in metastatic colon cancers (Varnat \textit{et al.}, 2010). Furthermore, Gli2 has been reported to bind to the enhancer and activate the transcription of Sox2 in neuroepithelial cells (Takanaga \textit{et al.}, 2009), providing a potential mechanism for the increased Sox2 expression in a Ptch1\(^{LacZ^+/+;Trp53^{-/-}}\) mutants. Stat3 signaling also converges onto Sox2, as the direct regulation of Sox2 by Stat3 has been described in neural precursor cells (Foshay and Gallicano, 2008). Furthermore, the upregulation of both Gli and Sox2 transcription factors in the Ptch1\(^{LacZ^+/+;Trp53^{-/-}}\) mutant background may lead to an increased co-binding of Gli1 and Sox2 to activate the expression of cooperatively regulated target genes, as observed during neural patterning and progenitor specification (Peterson \textit{et al.}, 2012). Transcriptional profiling of the CbSC and aberrant tissue stem cells will allow us to determine if a gene signature specific for CbSC can be identified and if enhanced activation of a subset of genes in the aberrant tissue stem cell are coregulated by Gli1 and Sox2.
Figure 4-1 Tentative hypothesis for the aberrant persistence of Sox2-expressing cerebellar stem cell in the 3 week Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} animals

In the WT CbSC, the Gli1-p53 negative regulatory loop regulating stem cell numbers is intact and CbSC genes are expressed at normal levels. However, in the Ptch1\textsuperscript{LacZ/+};Trp53\textsuperscript{-/-} cerebella, loss of p53 and Ptch1 inactivation may be leading to enhanced Gli1 activation, which in cooperation with Sox2 may be aberrantly maintaining a subset of CbSC genes. Furthermore, high levels of Stat3 expression, which is observed in MBNS, may also be playing a role in maintaining the persistent expression of its target gene Sox2.
Chapter 5: References


Oncogene 26: 2365–2373.


Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391–403.


Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, et al. (2010). Genetic and


Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. *Cancer Cell* **14**: 135–145.


